Sign In

The AASLD Liver Meeting 2017, Washington DC, October 20-24

Sunday, November 15

Poster Session II
8:00 am - 5:00 pm
Presenters in attendance 12:30 pm - 2:00 pm

Advances in Imaging and Noninvasive Markers of Fibrosis
Bile Acids, Cholangiocyte Biology, and Experimental Cholestasis
Donor and Allocation Issues: Living Donor and Split Liver Transplantation and Hepatobiliary Surgery
Experimental Steatohepatitis
HCV Virology and Pathogenesis
Hepatitis C: Therapeutics (Approved Agents)
Immunosuppression, Outcomes, and Complications in Transplant

Advances in Imaging and Noninvasive Markers of Fibrosis

773 High risk of misclassifying liver stiffness using 2D shear-wave and transient elastography during a moderate or high calorie meal
Maria Kjærgaard1, Maja Thiele1, Bjørn S. Madsen1, Christian Jansen2, Jonel Trebicka2, Aleksander Krag1
1Odense University Hospital, 2University of Bonn

774 A Novel Diagnostic Index to Predict Cirrhosis in Patients with Chronic Liver Disease
Zohair Ahmed1, Jinma Ren2, Adam Gonzalez3, Carmen S. Kirkness2, Daniel Martin4, Sherri Yong5, Sonu Dhillon4
1University of Illinois, 2University of Illinois, 3University of Illinois, 4University of Illinois, 5University of Illinois

775 Usefulness of Shear Wave Elastography in the evaluation of liver fibrosis in patients with HCV-related liver disease: a comparison with Transient Elastography
Silvia Tonello2, Paola Bizzotto2, Sara Piovesan3, Antonietta Romano2, Georgios Anastassopoulos3, Alfredo Alberti3, Marta Tonon2, Paolo Angeli2, 1, Giancarlo Bombonato1
1University of Padova, 2University of Padova, 3University of Padova

776 ELF Test Thresholds for disease stratification and prognosis in chronic liver disease.
James W. Day1, William M. Rosenberg1, Julie Parkes1, 2
1University College London, 2University of Southampton

777 Changes in liver stiffness by transient elastography (TE) and serum lysyl oxidase-like-2 (sLOXL2) in patients with cirrhosis treated with ledipasvir/sofosbuvir (LDV/SOF)-based therapy
Marc Bourlière1, Veronique Loustaud-Ratti2, Sophie Metivier3, Vincent Leroy4, Armando Abergel5, Robert P. Myers6, Raul E. Aguilar Schall6, Robert H. Hyland6, Mani Subramanian6, John G. McHutchison6, Lawrence Serfaty7, Victor de Ledinghen8
1Hépato-Gastro-Entérologie, Hôpital Saint Joseph, 2Recherche Clinique et de l’Innovation, CHU de Limoges and Inserm UMR 1092, Université de Limoges, 3Service d’Hépato-Gastro-Entérologie, Hôpital Purpan, 4Hépato-Gastro-Entérologie, CHU de Grenboble, 5Médecine Digestive, CHU Estaing, 6Gilead Sciences, Inc., 7Hépatologie, Hôpital Saint Antoine, 8CHU de Bordeaux

778 A Hepatic Stellate Cell Secreted Protein Signature that Has Potential for use in the Non-invasive Detection of Fibrosis and Fibrogenic Activity in Chronic Liver Diseases
Daniel L. Motola1, Chan Zhou1, Samuel York1, Yujin Hoshida2, Alan Mullen1, Raymond T. Chung1
1MGH, 2, Icahn School of Medicine at Mount Sinai

779 Diagnostic disparity of FIB4, APRI and AAR in predicting liver fibrosis in HDV/HBV co-infected patients.
Varun K. Takyar1, David E. Kleiner2, Kenneth J. Wilkins3, Pallavi Surana1, Ohad Etzion1, Jay H. Hoofnagle1, T. Jake Liang1, Theo Heller1, Christopher Koh1
1NIH, 2NCI, 3NIDDK

780 Collagen maturation measured by true formation of Type III collagen (PRO-C3) provides high diagnostic accuracy in alcoholic liver fibrosis: A prospective biopsy controlled study with 196 patients
Aleksander Krag1, Bjørn S. Madsen1, Diana J. Leeming2, Maja Thiele1, Mette J. Nielsen2, Annette D. Fialla1, Ove B. Schaffalitzky de Muckadell1, Janne F. Hansen1, Linda S. Møller1, Sönke Detlefsen3, Morten A. Karsdal2
1Odense Universityhospital, 2Nordic Bioscience, 3Odense Universityhospital

781 Usefulness of ultrasound elastography in assessing liver fibrosis in patients with chronic hepatitis and the difference of liver stiffness between HBV-related chronic hepatitis and non-HBV-related chronic hepatitis.
Takashi Nishimura2, 1, Chikage Nakano2, 1, Tomoko Aoki3, Kyohei Kishino1, Yoshihiro Shimono1, Kunihiro Hasegawa1, Ryo Takata1, Kazunori Yoh1, Akio Ishii1, Tomoyuki Takashima1, Yoshiyuki Sakai1, Nobuhiro Aizawa1, Naoto Ikeda1, Hiroki Nishikawa1, Yoshinori Iwata1, Seiichi Hirota4, Jiro Fujimoto5, Shuhei Nishiguchi1, Hiroko Iijima2, 1
1Hyogo College of Medicine, 2Hyogo College of Medicine, 3Yoka Hospital, 4Hyogo College of Medicine, 5Hyogo College of Medicine

782 qFibrosis scoring for different animal models with liver fibrosis induced by TAA, CCl4 or BDL
Feng Liu, Long Chen, Huiying Rao, Wei Zhang, Nan Wu, Lai Wei
Peking University People’s Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases

783 Serum Wisteria floribunda agglutinin-positive human Mac-2 binding protein is associated with an increased risk of mortality in patients with liver cirrhosis
Yuki Kugiyama, Kazumi Yamasaki, Yuuki Sonoda, Shigemune Bekki, Satoru Hashimoto, Shinjiro Uchida, Akira Saeki, Shinya Nagaoka, Seigo Abiru, Atsumasa Komori, Hiroshi Yatsuhashi
Nagasaki Medical Center

784 Predicting clinical outcomes in chronic liver disease: The ELF test is superior to histology and simple scores
Katharine Irvine1, Leesa F. Wockner2, Mihir Shanker1, Kevin Fagan1, Leigh Horsfall1, Linda Fletcher3, Jacobus Ungerer4, Carel J. Pretorius4, Gregory Miller1, Andrew D. Clouston1, Guy Lampe4, Elizabeth E. Powell1, 3
1The University of Queensland, 2QIMR Berghorfer Medical Research Institute, 3Princess Alexandra Hospital, 4Pathology Queensland

785 Supersonic Shear Imaging Is More Accurate Than Clinical Scoring Systems for the Assessment of Liver Fibrosis in Patients with Chronic Hepatitis C
Masato Yoneda, Emmanuel Thomas, Tiffannia Grant, Seth N. Sclair, Eugene R. Schiff
University of Miami Miller School of Medicine

786 Comparative 10-Years Prognosis of Fibrotest (FT) and Liver Stiffness Measurement (LSM) by Transient Elastography (TE, Fibroscan) in 9364 Chronic Liver Diseases (CLD) Patients (Pts).
Mona Munteanu1, 2, Yen Ngo2, Hugo Perazzo3, Pascal Lebray3, Helmi Mkada4, Olivier Deckmyn2, Denis Monneret4, Françoise Imbert-Bismut4, Dominique Bonnefont-Rousselot4, Vincent Thibault5, Vlad Ratziu3, Chantal Housset6, Thierry Poynard3
1University Pierre and Marie Curie – Univ Paris 06 UMR_S 938, 2Biopredictive Hepatology Resarch Unit, 3UPMC Liver Center APHP, 4Biochemistry Department, UPMC Liver Center, 5Virology Department, Hôpital Pitié-Salpêtrière, AP-HP, 6Centre de Recherche Saint-Antoine & Institute of Cardiometabolism and Nutrition (ICAN), INSERM & UPMC –Univ Paris 06 UMR_S 938

787 Liver stiffness assessed by SWE strongly correlates with liver dysfunction and clinical signs of portal hypertension in cirrhotic patients.
Renata Senkerikova1, Halima Gottfriedova1, Sona Frankova1, Eva Sticova2, Pavel Trunecka1, Julius Spicak1, Milan Jirsa3, Jan Sperl1
1Institute for Clinical and Experimental medicine, 2Institute for Clinical and Experimental Medicine, 3Institute for Clinical and Experimental Medicine

788 Assessment of biliary fibrosis and disease progression by strain elastography compared to VCTE in patients with PBC
Yohei Koizumi, Masashi Hirooka, Yusuke Imai, Yoshiko Nakamura, Takao Watanabe, Osamu Yoshida, Yoshio Tokumoto, Masanori Abe, Yoichi Hiasa
Ehime University Graduate School of Medicine

789 Differences in Diagnostic Accuracy According to A-Priori Risk: A Biopsy-Controlled Study of Transient Elastography and 2D Shear Wave Elastography for Alcoholic Cirrhosis
Maja Thiele1, 2, Bjørn S. Madsen1, 2, Janne F. Hansen3, Sönke Detlefsen4, Linda S. Møller5, Annette D. Fialla1, 6, Aleksander Krag1
1Odense University Hospital, 2Odense University Hospital, 3Odense University Hospital, 4Odense University Hospital, 5Odense University Hospital Svendborg, 6Esbjerg University Hospital

790 Comparison of noninvasive fibrosis scores and association with mortality in adults with moderate to severe hepatic steatosis and NAFLD
Benjamin D. Renelus1, Fengxia Yan2, Michael C. Flood3
1Morehouse School of Medicine, 2Morehouse School of Medicine, 3Morehouse School of Medicine

791 Effect of inflammation on liver stiffness in active autoimmune liver disease: A simultaneous biopsy-controlled study using Acoustic Radiation Force Impulse (ARFI) elastography
David I. Sherman1, Waleed Fateen1, Minal J Sangwaiya2, Paul Tadrous3, Philip J. Shorvon2
1Central MIddlesex Hospital, London North West Healthcare NHS Trust, 2Central Middlesex Hospital, London North West Healthcare NHS Trust, 3Northwick Park Hospital, London North West Healthcare NHS Trust

792 2D Shear Wave Elastography is not Superior to Transient Elastography in Difficult-to-Scan Patients: A Comparative Feasibility Study
Benjamin Staugaard3, Janne F. Hansen3, Belinda Mössner3, Bjørn S. Madsen1, Aleksander Krag1, Peer B. Christensen3, Maja Thiele1, 2
1Odense University Hospital, 2Odense University Hospital, 3Odense University Hospital

793 ELF™ predicts clinical outcomes in liver disease.
Brian J. Hogan2, James O'Beirne2, 1, David W. Patch1, Dominic Yu3, Ioanna Parisi2, Amar P. Dhillon4, 2, Andrew R. Hall4, Ankur Srivastava2, Paul M. Trembling2, Sudeep Tanwar2, Julie Parkes2, William M. Rosenberg2
1Royal Free London NHS Foundation Trust, 2University College London, 3Royal Free London NHS Foundation Trust, 4Royal Free London NHS Foundation Trust

794 Association of skin capsular distance with accuracy of liver stiffness measurements of the FibroScan XL probe—comparison with virtual touch quantification and the FibroScan M probe
Erina Kumagai1, 3, Keiko Korenaga2, Masaaki Korenaga1, 2, Misuzu Ueyama1, 3, Yoshihiko Aoki2, Yoko Yamagiwa1, Masatoshi Imamura2, Kazumoto Murata1, 2, Tatsuya Kanto1, 2, Naohiko Masaki1, 2, Sumio Watanabe3, Masashi Mizokami1, 2
1National Center for Global Health and Medicine at Kohnodai, 2Kohnodai Hospital, National Center for Global Health and Medicine, 3Juntendo University School of Medicine

795 The liver stiffness evaluation by Transient Elastography in diabetes mellitus and NAFLD patients
Ruxandra G. Mare
University of Medicine and Pharmacy “Victor Babes” Timisoara, Romania

796 Glyco-isomer of Serum Mac-2-Binding Protein is The Most Useful Biomarker for Liver Fibrosis in Patients with Chronic Hepatitis C
Mina Hamano, Masafumi Naito, Toshifumi Ito
Japan Community Healthcare Organization Osaka Hospital

797 Liver fibrosis evaluation using real-time shear wave elastography in chronic hepatitis C and the evaluation of the rapid effect of antiviral treatment on liver stiffness values.
Wim Verlinden1, 2, Stefan Bourgeois1, 3, Luisa Vonghia1, Thomas Vanwolleghem1, Peter P. Michielsen1, 2, Sven M. Francque1, 2
1Antwerp University Hospital, 2University of Antwerp, 3ZNA Stuivenberg Hospital

798 Machine-learned Image Analysis Models for Classifying Liver Fibrosis Stage from Magnetic Resonance Images
Timothy G. St. Pierre1, Michael J. House1, Ajmal Mian2, Sander Bangma3, Gary Burgess6, Richard A. Standish4, Stephen Casey5, Emma Hornsey7, Peter W. Angus5
1University of Western Australia, 2The University of Western Australia, 3Resonance Health Ltd, 4Deakin University, 5Austin Hospital, 6Pfizer Inc, 7Austin Hospital

799 Real-time shear wave elastography is effective for evaluating liver fibrosis in patients with chronic liver diseases
Kaori Muromachi1, Tsutomu Tamai1, Kohei Oda1, Sho Ijuin1, Hiroka Onishi1, Haruka Sakae1, Akihiko Oshige1, Kotaro Kumagai1, Seiichi Mawatari1, Akihiro Moriuchi2, Hirofumi Uto1, 3, Akio Ido1
1Kagoshima University Graduate School of Medical and Dental Sciences, 2Kagoshima University Graduate School of Medical and Dental Sciences, 3Miyazaki Medical Center

800 Role of Acoustic Radiation Force Impulse (ARFI) elastography in non-invasive assessment of fibrosis in active autoimmune liver disease: A simultaneous biopsy-controlled study
David I. Sherman1, Waleed Fateen1, Minal J Sangwaiya2, Paul Tadrous3, Philip J. Shorvon2
1Central MIddlesex Hospital, London North West Healthcare NHS Trust, 2Central Middlesex Hospital, London North West Healthcare NHS Trust, 3Northwick Park Hospital, London North West Healthcare NHS Trust

801 A clustering based fully automated method for collagen proportional area extraction in liver biopsy images
Nikos Giannakeas2, Zoi Tsianou2, Markos Tsipouras2, Alexandros T. Tzallas3, Pinelopi Manousou1, Epameinondas Tsianos2
1Royal Free Hospital and UCL, 21st Division of Internal Medicine and Division of Gastroenterology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 3School of Applied Technology, Department of Computer Engineering, Technological Educational Institute of Epirus

802 Feasibility of three ultrasound shear wave elastographic methods in overweight and obese patients
Ioan Sporea
University of Medicine and Pharmacy Timisoara

803 Fast macromolecular proton fraction (MPF) mapping of the human liver in vivo for quantitative assessment of hepatic fibrosis
Vasily L. Yarnykh1, 2, Erica Tartaglione3, George N. Ioannou3, 4
1University of Washington, 2Tomsk State University, 3Veterans Affairs Puget Sound Health Care System, 4University of Washington
 

Bile Acids, Cholangiocyte Biology, and Experimental Cholestasis

804 A Novel Mitochondrial Pathway to Bile Acids through 24-Hydroxycholesterol in Mouse Liver
Genta Kakiyama3, Dalila M. Marques3, Kuniko Mitamura1, Hajime Takei2, Hiroshi Nittono2, Daniel Rodriguez-Agudo3, Gregorio Gil4, Huiping Zhou3, Phillip B. Hylemon3, William M. Pandak3
1Kinki University, 2Junshin Clinic, Bile Bile Acid Institute, 3Virginia Commonwealth University and McGuire VA Medical Center, 4Virginia Commonwealth University

805 Bile acid induced cholestatic liver injury involves TLR9 initiated inflammatory signals in mouse hepatocytes
Shi-Ying Cai, Xinshou Ouyang, Albert Mennone, Carol J. Soroka, Wajahat Z. Mehal, James L. Boyer
Yale Univ

806 Proteomics analysis of rat canalicular membrane reveals the expression of several P4-ATPases in liver
Pururawa . Chaubey, Bruno Stieger
University Hospital Zurich

807 TGR5 agonists improve pancreatic beta cell mass and function by reprogramming alpha cells to produce GLP-1: a novel mechanism of action of bile acids in diabetes
Divya P. Kumar1, Amon Asgharpour2, Faridoddin Mirshahi2, So Hyun Park3, Sichen Liu3, Yumi Imai3, Jerry L. Nadler3, Karnam S. Murthy1, Arun J. Sanyal2
1Virginia Commonwealth University, 2Virginia Commonwealth University, 3Eastern Virginia Medical School

808 Higher order metabolites of heme increase under conditions of hyperbilirubinemia, trigger cholestasis and impair hepatocellular integrity
Raphael A. Seidel1, 5, Franziska Schleser1, Christoph Sponholz1, Frans Cuperus2, 3, Sandor Nietzsche4, Georg Pohnert5, Michael Bauer1
1Jena University Hospital, 2Medical University of Vienna, 3University of Groningen, 4Jena University Hospital, 5Friedrich Schiller University Jena

809 NF-kB is critically important for the up-regulation of organic solute transporter OSTa/OSTß in cholestasis
Natarajan Balasubramaniyan, Frederick J. Suchy
University of Colorado Denver

810 The Ileal Bile Acid Transporter Inhibitor A4250 Modulates Bile Acid Synthesis and Decreases Serum Bile Acids.
Hanns-Ulrich Marschall1, Per-Göran Gillberg2, Hans Graffner2, Leif Rikner2
1Institute of Medicine, University of Gothenburg , 2Albireo

811 Inhibition of Adenylyl Cyclase 5 reduces cyst growth in mice with polycystic liver disease (ADPKD) caused by defective Polycystin-2
Carlo Spirli1, Ambra Villani1, Valeria Mariotti1, 2, Luca Fabris3, Romina Fiorotto1, Mario Strazzabosco 1, 2
1Yale University, Section of Digestive Diseases, 2University of Milano-Bicocca, 3University of Padova

812 Cholestatic-induced biliary proliferation and fibrosis are decreased in mice lacking mast cells: an innovative study using C-kit knockout mice
Laura Hargrove1, Lindsey Kennedy2, Jennifer Owens2, Heather L. Francis2, 1
1Scott and White Memorial Hospital, 2Central Texas Veterans Health Care System

813 YAP Reduces Liver Parenchymal Damage by Promoting Bile Duct Capacity in Cholestatic Injury
Quy P. Nguyen1, Nan Wu2, Tianhao Zhou2, Haibo Bai1
1BaylorScott&White Hospital, 2Texas A&M University College of Medicine

814 Glutathione depletion is critical for the early pathogenesis of biliary atresia (BA) in the toxin-induced BA model
Xiao Zhao1, Benjamin J. Wilkins2, Kristin Lorent1, John R. Porter3, Rebecca G. Wells1, Michael Pack1
1University of Pennsylvania, 2The Children's Hospital of Philadelphia, 3University of the Sciences

815 The bile acid Ursodeoxycholic acid activates cholangiocyte TMEM16A Cl- channels
Qin Li, Amal K. Dutta, Charles Kresge, Andrew P. Feranchak
University of Texas Southwestern Medical Center

816 The bile-acid receptor TGR5 regulates biliary epithelium permeability.
José Ursic-Bedoya1, 2, Hayat Simerabet1, 2, Isabelle Doignon1, 2, Noémie Péan1, 2, Zahra Tanfin1, 2, Christoph Ullmer3, Lydie Humbert4, 5, Dominique Rainteau4, 5, Doris Cassio1, 2, Thierry Tordjmann1, 2
1INSERM, 2Université Paris sud, 3Roche Innovation Center Basel, 4INSERM , 5UPMC

817 Knockout of the Secretin/Secretin Receptor Axis Delays Regeneration of small and large cholangiocytes by enhanced senescence following 70% partial hepatectomy (PH).
Ying Wan3, Shannon S. Glaser1, Nan Wu4, Fanyin Meng2, Julie Venter4, Romina Mancinelli5, Heather L. Francis2, Antonio Franchitto5, Paolo Onori5, Tina Kyritsi4, Shanika Avila4, Guido Carpino7, Holly A. Standeford6, Gianfranco Alpini2, Eugenio Gaudio5
1Central Texas Veterans Health Care System and Texas A&M HSC College of Medicine, 2Veterans Health Care System and Texas A&M HSC and BaylorScott&White, 3BaylorScott&White, 4Texas A&M University HSC, 5University La Sapienza, 6Central Texas Veterans Health Care System, 7University of Rome "Foro Italico

818 Pre-treatment with TIMP-3 prevents the development of biliary injury in an LPS enhanced ischaemia-reperfusion animal model
Janske Reiling1, 2, Kim Bridle1, 3, Catherine M. Campbell4, Nishreen Santrampurwala1, 3, Laurence J. Britton1, 3, Ari J. Cohen5, Darrell H. Crawford1, 3, Cornelis H. Dejong2, 6, Jonathan Fawcett1, 7
1University of Queensland, 2Maastricht University, 3Gallipoli Medical Reserach Foundation, 4Envoi Specialist Pathologists, 5Institute of Translational Research, Ochsner Clinical Foundation, 6Maastricht University Medical Centre, 7Princess Alexandra Hospital

819 Natural Killer T cells aggravate inflammation in a novel induced murine model of cholangitis
Natalie L. Berntsen1, Bjarte Fosby1, Corey Tan1, Elisabeth Schrumpf1, Tonje Bjoernetroe1, Aksel Foss2, Pål-Dag Line2, Tom H. Karlsen1, Richard S. Blumberg3, Espen Melum1
1Norwegian PSC Research Center, 2Oslo University Hospital, 3Brigham and Women’s Hospital, Harvard Medical School

820 Intraductal papillary neoplasm of bile duct is a heterogeneous disease with respect to its histopathologic similarities to pancreatic intraductal papillary mucinous neoplasm
Yasuni Nakanuma1, Yuko Kakuda1, Katsuhiko Uesaka1, Takashi Miyata1, Yuki Fukumura2, Masaru Takase3
1Shizuoka Cancer Center, 2Juntendo University School of Medicine, 3Koshigawa City Hospital

821 Wnt/ß-catenin cooperates with Yap signaling to promote hepatobiliary repair in a model of chronic liver injury
Kari Nejak-Bowen, Hirohisa Okabe, Satdarshan (Paul) S. Monga
University of Pittsburgh

822 Prolonged usage of H1 or H2 histamine receptor antagonists decreases fibrosis and liver damage in MDR2-/- mice: novel evidence of the therapeutic benefits of anti-histamines
Hannah Jones1, Laura Hargrove1, Lindsey Kennedy2, Jennifer Owens2, Heather L. Francis2, 1
1Scott and White Memorial Hospital, 2Central Texas Veterans Health Care System

823 Hepatic CD4+ lymphocyte responses and initiation of biliary injury in mdr2 knockout mice depend on dendritic cell costimulation
Celine S. Lages1, Tiffany Shi1, Paige Bolcas1, Julia Simmons1, Avery Maddox1, Shiva K. Shanmukhappa2, Alexander G. Miethke1
1Cincinnati Children's Hospital Medical Center, 2Cincinnati Children's Hospital Medical Center

824 Tetrahydroxylated Bile Acids Reduce Cholangiocyte Damage in Abcb4-/- mice
Renxue Wang1, Jonathan Sheps1, Lin Liu1, Victor Ling1, 2
1BC Cancer Research Centre, 2University of British Columbia

825 Role of Cellular Inhibitor of Apoptosis Proteins (cIAP) in Primary Sclerosing Cholangitis (PSC).
Maria Eugenia Guicciardi, Anuradha Krishnan, Steven Bronk , Petra Hirsova, Gregory J. Gores
Mayo Clinic

826 CD39/ENTPD1 is protective in a model of biliary fibrosis and modulates CD8+ T cell gut-homing via a4ß7 integrin.
Sonja Rothweiler, Zhen-Wei Peng, Susan B. Liu, Naoki Ikenaga, Yury Popov, Simon C. Robson
Beth Israel Deaconess Medical Center

827 Feedback regulation of autotaxin in mice: why cholestatic mice don’t scratch
Ruth Bolier1, Dagmar Tolenaars1, Jacqueline Langedijk1, Piter J. Bosma1, Ulrich Beuers 1, 2, Ronald Oude Elferink1
1Academic Medical Center, 2Academic Medical Center

828 Loss of Caspase 8 in liver parenchymal cells protects against experimental obstructive cholestasis
Francisco Javier Cubero, Jin Peng, Maximilian Hatting, Gang Zhao, Miguel Eugenio Zoubek, Ricardo Macías-Rodríguez, Astrid Ruiz-Margáin, Johanna Reissing, Henning W. Zimmermann, Nikolaus Gassler, Tom Luedde, Christian Liedtke, Christian Trautwein
University Hospital Aachen, RWTH Aachen

829 NHERF-1 assembles macromolecular complexes in the liver that are essential for the inflammatory response in cholestasis
Man Li1, Albert Mennone1, Carol J. Soroka1, Lee R. Hagey3, Kathy M. Harry1, Edward J. Weinman2, James L. Boyer1
1Yale University School of Medicine, 2University of Maryland School of Medicine, 3University of California, San Diego

830 Knockdown of a7-Nicotinic Receptor Inhibits Biliary Proliferation and Hepatic Fibrosis during Extrahepatic Cholestasis
Allyson Martinez1, April O'Brien1, Laurent Ehrlich1, David E. Dostal1, Shannon S. Glaser1, 2
1Texas A&M Health Science Center and Central Texas Veterans Health Care System, 2Scott & White Digestive Disease Research Center

831 Keratin 23 represents a novel liver injury marker reflecting the severity of ductular reaction
Nurdan Guldiken1, Gokce Kobazi Ensari1, Pooja Lahiri2, Christian Liedtke1, Henning W. Zimmermann1, Christian Trautwein1, Marianne Ziol3, Pavel Strnad1
1Internal Medicine III , 2Institut für Pathologie, 3Pathology Department

832 RIP3-dependent signalling contributes to necroinflammation in cholestatic liver injury
Marta B. Afonso2, Pedro M. Rodrigues2, André L. Simão2, Helena Cortez-Pinto 3, 4, Dimitry Ofengeim5, Joana D. Amaral1, Rui E. Castro1, Junying Yuan5, Cecília M. Rodrigues1
1Faculty of Pharmacy, University of Lisbon, 2iMed.ULisboa, Faculty of Pharmacy, University of Lisbon, 3Gastrenterology, Hospital de Santa Maria, 4Faculty of Medicine, University of Lisbon, 5Harvard Medical School

833 Gut microbiota contributes to disease in a spontaneous mouse model of chronic cholangitis
Elisabeth Schrumpf1, 2, Martin Kummen1, 2, Kristian Holm1, 2, Tom H. Karlsen1, 2, Johannes R. Hov1, 2, Richard S. Blumberg3, Espen Melum1, 2
1Oslo University Hospital, Rikshospitalet, 2Oslo University Hospital, Rikshospitalet, 3Brigham and Women’s Hospital, Harvard Medical School

834 The secretin receptor antagonist (SCT 5-27) reduces biliary hyperplasia and liver fibrosis in an animal model of primary sclerosing cholangitis.
Nan Wu2, Fanyin Meng1, Ying Wan3, Julie Venter2, Haibo Bai3, Shanika Avila2, Kelly McDaniel3, Holly A. Standeford4, Paolo Onori5, Eugenio Gaudio5, Gianfranco Alpini1, Shannon S. Glaser1
1Central Texas Veterans Health Care System, Scott & White and Texas A & M Health Science Center College of Medicine and Scott White, 2Texas A&M University HSC, 3BaylorScott&White, 4Central Texas Veterans Health Care System, 5University La Sapienza

835 Knockdown of the melatonin receptor, MT1, reduces biliary hyperplasia and liver fibrosis in cholestatic bile duct ligated (BDL) mice.
Nan Wu2, Fanyin Meng1, Ying Wan3, Julie Venter2, Holly A. Standeford4, Heather L. Francis1, Lindsey Kennedy4, Yuyan Han1, 2, Kelly McDaniel3, Antonio Franchitto5, Paolo Onori5, Sharon DeMorrow1, Tami Annable3, Eugenio Gaudio5, Shannon S. Glaser1, Gianfranco Alpini1
1Central Texas Veterans Health Care System, Scott & White and Texas A & M Health Science Center College of Medicine and Scott White, 2Texas A&M University HSC, 3BaylorScott&White, 4Central Texas Veterans Health Care System, 5University La Sapienza

Donor and Allocation Issues: Living Donor and Split Liver Transplantation and Hepatobiliary Surgery

836 Longer Term Efficacy of Simultaneous Liver Transplantation plus Sleeve Gastrectomy versus non-invasive Weight Loss followed by Liver Transplantation
Daniel Zamora-Valdes1, Kymberly D. Watt2, John J. Poterucha2, Charles B. Rosen1, Todd A. Kellogg3, Sara R. Di Cecco2, Nicki M. Francisco Ziller2, Julie Heimbach1
1Mayo Clinic, 2Mayo Clinic, 3Mayo Clinic

837 Preliminary Data Analysis from the Improving DCD Outcomes in Liver Transplantation (IDOL) Consortium
David S. Goldberg1, Seth J. Karp3, Julie Heimbach5, James F. Markmann6, Richard Gilroy4, Roberto Hernandez-Alejandro7, Peter L. Abt2
1Hospital of the University of Pennsylvania, 2University of Pennsylvania, 3Vanderbilt University , 4University of Kansas, 5Mayo Clinic, 6Massachusetts General Hospital, 7London Health Sciences Center

838 A shift to the left: A comparison of the A2ALL experience using left lobe vs. right lobe grafts
Benjamin Samstein1, Abigail Smith9, Talia B. Baker8, Chris Freise12, Jean C. Emond2, Brenda W. Gillespie9, David Grant4, Elizabeth A. Pomfret11, Adrian Cotterell3, Trevor L. Nydam6, Kim M. Olthoff7, Abhinav Humar10, Robert M. Merion5
1Weill Cornell Medical Center, 2Columbia University, 3Virginia Commonwealth University, 4University of Toronto, 5Arbor Research Collaborative for Health and University of Michigan Department of Surgery, 6University of Colorado School of Medicine, 7University of Pennsylvania, 8Northwestern University Feinberg School of Medicine , 9University of Michigan , 10University of Pittsburgh, 11Lahey Hospital and Medical Center, 12University of California, San Francisco

839 Obesity is predictive of NAFLD recurrence in the transplanted liver graft.
Angela Dolganiuc, Vikas Khullar, Virginia C. Clark, Roberto J. Firpi
University of Florida

840 3D Printed Liver Models for Precise Resection of Complex Hepatic Tumors
Maggie H. Samaan, Bijan Eghtesad, Cristiano Quintini, Juliana Kissiedu, Ibrahim A. Hanouneh, Ryan Klatte, Charles M. Miller, Nizar N. Zein
Digestive Disease Institute, C.C.F

841 Physical function predicts length of stay (LOS) after liver transplant (LT): From the Functional Assessment in Liver Transplantation (FrAILT) Study
Jennifer C. Lai, Kenneth E. Covinsky, Iryna Lobach, Sandy Feng
UCSF

842 Low serum testosterone predicts outcome in men with cirrhosis independent of the MELD score
Marie Sinclair1, 2, Adam Shannon2, Mathis Grossmann2, Peter W. Angus1, 2, Rudolf Hoermann2, Paul Gow1, 2
1Austin Hospital, 2The University of Melbourne

843 Tool for efficient and effective Medical Record Review to Identify Safety Risks in Every Living Liver Donor with available Resources at each Program
Blake Platt1, Donna Woods1, Amna Daud1, Elizabeth A. Pomfret2, Mary Ann Simpson2, James V. Guarrera4, Robert A. Fisher3, Anton I. Skaro1, Timothy Curtis1, Ella F. Reyes1, Erin Wymore1, Daniela Ladner1
1Northwestern University, 2Lahey Medical Clinic, 3Virginia Commonwealth University, 4Columbia University

844 Older Liver Transplant (LT) Candidates with Prolonged Wait-Times Have a Low Probability of LT
Connie W. Wang, Jennifer C. Lai
University of California, San Francisco

845 Functional Status Predicts Postoperative Mortality after Liver Transplantation
Natasha Dolgin, Paulo N. Martins, Adel Bozorgzadeh
UMass Medical School

846 Recanalization of complete anastomotic biliary obstruction after liver transplantation by using a through the scope magnet: A case series
Erkan Parlak1, Fahrettin Küçükay2, Aydin Koksal1, Ahmet T. Eminler1, Mustafa I. Uslan1
1Sakarya University, Faculty of Medicine, 2Yüksek Ihtisas Hospital

847 Patient Safety in Living Donor Liver Transplantation – We have a lot to learn
Daniela Ladner1, Elizabeth A. Pomfret2, Mary Ann Simpson2, James V. Guarrera3, Robert A. Fisher4, Anton I. Skaro1, Rebeca Khorzad1, Ella F. Reyes1, Amna Daud1, Erin Wymore1, Andy Hung-Yi Lee1, Donna Woods1
1Northwestern University, 2Lahey Medical Center, 3Columbia Medical Center, 4Virginia Commonwealth University

848 The effect of recipient and donor diabetes on long-term outcomes following liver transplantation, analyzed according to underlying disease etiology.
Oliver J. Duncan, Leon A. Adams, Gerry C. MacQuillan, Gary P. Jeffrey, George Garas
Sir Charles Gairdner Hospital

849 A Failure of the Model of End-stage Liver Disease (MELD) – Significant Mortality among Cirrhotic Patients with a Low (<20) MELD Score
Daniela Ladner1, Kathryn Skibba1, Kathryn Jackson1, Niloufar Safaeinili1, David S. Goldberg2, Lisa B. VanWagner1, Satyender Goel1, Abel Kho1, Amna Daud1, Nazanin Salehitezangi1, Anton I. Skaro1
1Northwestern University , 2University of Pennsylvania

850 Objective Measurement of Karnofsky Performance Status in End Stage Liver Disease Patients
Lisa Louwers, Emmanouil Palaios, Galal El-Gazzaz, Mario Spaggiari, Bijan Eghtesad, Dympna Kelly
Cleveland Clinic

851 PALBI-An Objective Score Based on Platelets, Albumin & Bilirubin Stratifies HCC Patients Undergoing Resection & Ablation Better than Child's Classification
Sasan Roayaie1, Ghalib Jibara2, Sarah Berhane3, Parissa Tabrizian4, Joong-Won Park5, Jijin Yang6, Lunan Yan7, Guohong Han8, Francesco Izzo9, Minshan Chen10, Jean-Frédéric Blanc11, Masatoshi Kudo12, Lewis R. Roberts13, Morris Sherman14, Phillip Johnson3
1North Shore-LIJ, Lenox Hill, 2Brookdales Medical Center, 3University of Liverpool , 4Mount Sinai Medical Center, 5National Cancer Center, 62nd Medical Military University, 7Sichuan University, 84th Medical Military University, 9National Cancer Institute of Naples, 10Sun Yat-sen University Cancer Center, 11Hôpital Saint-André, 12Kinki University, 13Mayo Clinic, 14University of Toronto

852 “Oldest Old” (=80 years) Donors in Liver Transplantation: National U.S. Organ Procurement Organization (OPO) Practices
Suzanne R. Sharpton1, Sandy Feng2, Dorry L. Segev3, Jennifer C. Lai1
1University of California, San Francisco, 2University of California, San Francisco, 3Johns Hopkins

853 External Validation of a US-Derived Living Donor Liver Transplant Risk Score
David S. Goldberg1, Kyung-Suk Suh2, Suk-Won Suh1, Peter L. Abt3, Kim M. Olthoff3, Abraham Shaked3, Shaleen Agarwal4, Subhash Gupta4, Benjamin French3
1Hospital of the University of Pennsylvania, 2Seoul National University Hospital, 3University of Pennsylvania, 4ANG Centre for Liver and Biliary Sciences

854 Outcomes of Patients Undergoing Liver Transplantation using Donors with Confirmed Positive Blood Cultures: A review of the UNOS dataset
Moises Huaman2, Valery Vilchez1, Xiaonan Mei1, Malay B. Shah1, Michael F. Daily1, Roberto Gedaly1
1Univ of Kentucky, 2University of Kentucky

855 Association of Pre-Transplant Body Mass Index (BMI) with the Survival Benefit of Liver Transplantation (LT)
Mohannad Dugum1, 2, Nizar N. Zein3, Alex Dugum4, Rocio Lopez5, Bijan Eghtesad6, Ibrahim A. Hanouneh3
1Cleveland Clinic, 2University of Pittsburgh, 3Cleveland Clinic, 4University of California, San Diego, 5Cleveland Clinic, 6Cleveland Clinic

856 Predicting Futility of Liver Transplantation (LT): A Scoring System Based on LT Survival Benefit
Mohannad Dugum1, 2, Nizar N. Zein3, Alex Dugum4, Rocio Lopez5, Bijan Eghtesad6, Ibrahim A. Hanouneh3
1Cleveland Clinic, 2University of Pittsburgh, 3Cleveland Clinic, 4University of California, San Diego, 5Cleveland Clinic, 6Cleveland Clinic

857 Remnant Liver Ischemia Is Associated With Early Recurrence and Poorer Survival after Liver Resection
Jai Young Cho, Ho Seong Han, YoungRok Choi, Yoo-Seok Yoon, Jae Yool Jang, Hanlim Choi, Jae Seong Jang, Seong Uk Kwon
Seoul National University Bundang Hospital

858 Novel Sonar Guided Technique For Management Of Incarcerated Umbilical Hernia In Cirrhotic Patients Awaiting Liver Transplantation
Abd Elrazek A. Hussein1, Shymaa E. Bilasy2, Hamdy M. Moustafa1, Mohammed Nafady3
1Al Azhar School of Medicine, 2Faculty of Pharmacy, Suez Canal University, 3Al Azhar Faculty of Medicine

859 Safety of live liver donation by individuals with G6PD deficiency: Initial results and comparative study
Mettu S. Reddy, Manoj V. Shrivastav, Ilankumaran Kaliamoorthy, Mohamed Rela
Global health city

860 Living donor liver transplantation for patients with HCC exceeding Milan criteria: results of pilot study.
Josep M. Llovet1, 2, Mihai-Calin Pavel3, Jordi Rimola1, Maria Alba Diaz5, Jordi Colmenero4, 6, Constantino Fondevila3, Josep Fuster1, 4, Pere Gines4, 6, Jordi Bruix1, 6, Juan Carlos García-Valdecasas3
1BCLC, IDIBAPS, CIBEREHD, Universitat de Barcelona, 2Institució Catalana de Recerca i Estudis Avançats, 3Hospital Clinic, University of Barcelona, 4Hospital Clinic, University of Barcelona, 5Hospital Clinic, University of Barcelona, 6Hospital Clinic, University of Barcelona

861 Traveling for a Liver Transplant within the U.S. Is Not Driven by Geographic Disparity of MELD and Does Not Improve Survival
Catherine T. Frenette1, Ann M. Harper2, Angeles Baquerizo1, Randolph L. Schaffer1, Jonathan S. Fisher1, Christopher L. Marsh1
1Scripps Clinic, 2United Network for Organ Sharing

862 Clinical impact of 18F-FDG-PET/CT in living donor liver transplantation for advanced hepatocellular carcinoma
Seung Duk Lee, Eung Chang Lee, Seong Hoon Kim
National Cancer Center, Republic of Korea

863 Living or Deceased Donor Liver Transplantation for Hepatocellular Carcinoma: A Western multicenter, intention to treat, cohort study
Daniel Azoulay
Hopital Mondor APHP

864 Third Liver Transplantation - Utility and Principles to Guide Future Transplants; an Analysis of UNOS data
Vandana Khungar1, David S. Goldberg1, Peter L. Abt2
1University of Pennsylvania , 2University of Pennsylvania

865 Mechanisms of Gender Disparities in Liver Transplantation: An Examination of Organ Offers
Lauren D. Nephew, James D. Lewis, David S. Goldberg, Kimberly A. Forde
Hospital of the University of Pennsylvania

866 Significance of functional hepatic resection rate using 3D fusion image of CT and 99mTc-galactosyl human serum albumin scintigraphy.
Yosuke Tsuruga, Toshiya Kamiyama, Hirofumi Kamachi, Shingo Shimada, Kenji Wakayama, Tatsuya Orimo, Hideki Yokoo, Akinobu Taketomi
Hokkaido University Graduate School of Medicine

867 Auxiliary partial orthotopic liver transplantation (APOLT) for metabolic liver disease- is it still relevant?
Mohamed Rela2, Priya Ramachandran1, Mohamed Safwan2, Naresh P. Shanmugam2, Sanjay Govil2, Mettu S. Reddy2
1CHILDS Trust Hospital, 2Global Hospital & Health City

868 Graft Survival following Domino Liver Transplantation: The U.S. Experience
Ian W. Folkert1, David S. Goldberg2, Matthew H. Levine1, Kim M. Olthoff1, Abraham Shaked1, Peter L. Abt1
1Hospital of the University of Pennsylvania, 2Hospital of the University of Pennsylvania

869 Application of Gadoxetate Disodium-Enhanced MR Imaging in a Rat Model of Acute Partial Liver Congestion
Akira Shimizu, Akira Kobayashi, Takahide Yokoyama, Hiroaki Motoyama, Hiroshi Sakai, Noriyuki Kitagawa, Tsuyoshi Notake, Tomoki Shirota, Kentaro Fukushima, Shinichi Miyagawa
Shinshu University, School of medicine

870 Lack of Radiologic-Pathologic Correlation and Associated Clinical Features of Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation
Amy Tan1, M. Isabel Fiel3, Stephen C. Ward3, Marcelo Facciuto4, Swan N. Thung3, Myron E. Schwartz4, Sander S. Florman4, Thomas D. Schiano2
1Icahn School of Medicine at Mount Sinai, 2Icahn School of Medicine at Mount Sinai, 3Icahn School of Medicine at Mount Sinai, 4Recanati/Miller Transplantation Institute; Icahn School of Medicine at Mount Sinai

871 Using Biomarkers to Predict Progression to End-stage Renal Disease within 6 Months of Liver Transplant
Joseph Bahng, Peter L. Abt, Deirdre Sawinski, Anirban Ganguli, Debra McCorriston, Mary Ann Lim, Kimberly A. Forde
Perelman School of Medicine at the University of Pennsylvania

872 Traveling for a Liver Transplant in the US does not Result in a Lower Match MELD for the Majority of Patients
Catherine T. Frenette1, Ann M. Harper2, Angeles Baquerizo1, Randolph L. Schaffer1, Jonathan S. Fisher1, Christopher L. Marsh1
1Scripps Clinic, 2United Network for Organ Sharing

873 Natural history of liver transplant candidates listed with a low Model for End-stage Liver Disease (MELD) score
Khurram Bari1, Shimul Shah2, Tiffany E. Kaiser1, Brad Ballinger3
1University of Cincinnati, 2University of Cincinnati, 3University of Cincinnati Hospital

874 Coronary Angiography in Patients being evaluated for Orthotopic Liver Transplantation
Feng Li, A. James Hanje, Khalid Mumtaz, Robert B. Kirkpatrick, Douglas M. Levin, Elmahdi Elkhammas, Sylvester Black, Alice Hinton, Anthony Michaels
The Ohio State University Medical Center

875 Long Term Survival Of Liver Grafts From Elderly Donors
Marius Braun1, Eviatar Nesher2, Michal Cohen-Naftaly1, Assaf Issachar1, Amir Shlomai1, Yael Harif1, Sigal Eisner2, Ran Tur-Kaspa1, Eytan Mor1
1Rabin Medical Center, 2Rabin Medical Center

876 Controlled attenuation parameter (CAP) assessment may be clinically useful to screen hepatic steatosis for liver transplant purposes
Youngmi Hong1, Ki Tae Yoon1, Mong Cho1, Daehwan Kang1, Hyungwook Kim1, Cheol Woong Choi1, SuBum Park1, Jeong Heo2, Hyun Young Woo2, Won Lim2
1Pusan National University Yangsan Hospital, 2Pusan National University Hospital

877 Predictors of Retransplantation in Liver Transplant Recipients: An Updated Analysis from UNOS/OPTN Database
Ryan B. Perumpail2, Nathaniel Smith1, Robert J. Wong3, Zobair M. Younossi4, 5, Rachel Beckerman1, Aijaz Ahmed2
1CBPartners, 2Stanford University, 3Alameda Health System, Highland Hospital, 4Center for Liver Diseases, Inova Fairfax Hospital, 5Inova Health System

878 Interactive Effect Of Donor Age And Recipient Meld Score On The Post-Transplant Outcome In Cadaveric Liver Transplantation
Kyota Fukazawa, Alexander A. Vitin, Kenneth Martay, Jorge Reyes
University of Washington

Experimental Steatohepatitis

879 Ethanol-Mediated Lipocalin 2 Induction Selectively Impairs Hepatic Chaperone-Mediated Autophagy and Causes Alcoholic Steatosis in Mice
Xudong Hu1, 2, Jiayou Wang1, 3, Alvin Jogasuria1, Kwangwon Lee1, Jiashin Wu1, Min You1
1Northeast Ohio Medical University (NEOMED), 2Shanghai University of Traditional Chinese Medicine, 3Guangzhou University of Chinese Medicine

880 Hepatocyte-specific depletion of UBXD8 accelerates fibrosis in a mouse non-alcoholic steatohepatitis model
Norihiro Imai1, 2, Yoji Ishizu1, Teiji Kuzuya1, Takashi Honda1, Kazuhiko Hayashi1, Masatoshi Ishigami1, Yoshiki Hirooka1, Toyoshi Fujimoto2, Hidemi Goto1
1Nagoya University Graduate School of Medicine, 2Nagoya University Graduate School of Medicine

881 Regulation of Adaptive Thermogenesis by the Gut Microbiome: Implications for Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis
Tibor I. Krisko1, 2, Hayley T. Nicholls1, Katherine B. Leclair1, Alexander S. Banks1, David E. Cohen1
1Brigham and Women's Hospital, 2VA Medical Center

882 The dual FXR/TGR5 agonist INT-767 counteracts nonalcoholic steatohepatitis in a rabbit model of high fat diet-induced metabolic syndrome
Linda Vignozzi1, Ilaria Cellai1, Sandra Filippi4, Paolo Comeglio1, Erica Sarchielli2, Annamaria Morelli2, Elena Maneschi1, Gabriella Barbara Vannelli2, Luciano Adorini3, Mario Maggi1
1University of Florence, 2University of Florence, 3Intercept Pharmaceuticals, 4University of Florence

883 Lipid-induced Endoplasmic Reticulum Stress But Not Hepatic Steatosis Contributes to Blockage of Autophagosome-Lysosome Fusion
Koichiro Miyagawa, Shinji Oe, Yuichi Honma, Masaru Harada
University of Occupational and Environmental Health

884 CHOP and the Unfolded Protein Response Regulate NF-?B Activity through IRAK2 in the Pathogenesis of Non-Alcoholic Steatohepatitis
Jeffrey A. Willy1, James L. Stevens1, Howard C. Masuoka2, Ronald C. Wek1
1Indiana University School of Medicine, 2Indiana University School of Medicine

885 Deletion of G-protein-coupled bile acid receptor (Gpbar-1, Tgr5) alleviates fasting induced hepatic steatosis by altering hepatic lipid metabolism
Ajay C. Donepudi, Shannon M. Boehme, John Chiang
Northeast Ohio Medical University

886 Hepatic NOD-like receptors, pyrin domain-containing 3 (NLRP3) inflammasome activation is associated with histological severity in patients with nonalcoholic fatty liver disease
Hironori Mitsuyoshi, Kohichiroh Yasui, Tasuku Hara, Hiroyoshi Taketani, Hiroshi Ishiba, Akira Okajima, Yuya Seko, Atsushi Umemura, Taichiro Nishikawa, Kanji Yamaguchi, Michihisa Moriguchi, Yoshio Sumida, Masahito Minami, Yoshito Itoh
Kyoto Prefectural University of Medicine

887 Liver MicroRNA-21 is Overexpressed in Non Alcoholic Steatohepatitis in Patients and Contributes to this Disease In Two Mouse Models by restoring PPARa expression
Xavier Loyer1, Valerie Paradis3, Carole Hénique1, Anne-Clémence Vion1, Nathalie Colnot3, Coralie . Guerin1, Cécile Devue1, Sissi On1, Jérémy Scetbun1, Mélissa Romain1, Jean-Louis Paul4, Marc E. Rothenberg5, Patrick Marcellin2, Francois Durand2, Pierre Bedossa3, Carina Prip-Buus6, Eric Baugé7, Bart Staels7, Chantal Boulanger1, Alain Tedgui1, Pierre-Emmanuel Rautou1, 2
1Paris Cardiovascular Research Center - PARCC@HEGP, 2Hôpital Beaujon, APHP, 3Hôpital Beaujon, APHP, 4Hôpital Européen Georges Pompidou, AP-HP , 5Division of Allergy and Immunology, Department of Pediatrics, 6Université Paris Descartes, Sorbonne Paris Cité, 7University of Lille; and Institut Pasteur de Lille

888 Two different aspects of PD-1 expression on intrahepatic CD4+ and CD8+ T cells in a High Fat High Cholesterol Diet-induced murine NASH.
Kanji Yamaguchi1, Akira Okajima1, Yuya Seko1, Hiroshi Ishiba1, Hiroyoshi Taketani1, Atsushi Umemura1, Taichiro Nishikawa1, Yoshio Sumida1, Hironori Mitsuyoshi1, Kohichiroh Yasui1, Takeshi Okanoue2, Yoshito Itoh1
1Kyoto Prefectural University of Medicine, 2Saiseikai Suita Hospital

889 DNA Methylation Profiles of Fibrosis-Associated Gene in Blood Reflects Liver Fibrosis Severity in Human Nonalcoholic Fatty Liver Disease
Cynthia A. Moylan1, 2, Susan K. Murphy3, Carole Grenier3, Manal F. Abdelmalek1, Anna Mae Diehl1
1Duke University Medical Center, 2Durham Veterans Affairs Medical Center, 3Duke University

890 Blocking of IL-17A signaling attenuate alcohol induced steatohepatitis and liver fibrosis
Jun Xu1, 2, Tian Lan2, 1, Xiao Liu1, 2, David A. Brenner 2, Tatiana Kisseleva1
1UC San Diego, 2UC San Diego

891 Nuclear localization of autophagy marker LC3 is associated with fibrosis in nonalcoholic fatty liver disease (NAFLD)
Aaron B. Koenig2, Rohini Mehta2, Gary Bratthauer2, Fanny Monge1, Zachary D. Goodman1, Zobair M. Younossi2, 1
1Inova Fairfax Hospital, 2Inova Health System

892 Soluble Intercellular Adhesion Molecule-1 is Independently Associated with Increased Collagen Deposition in Patients with Nonalcoholic Steatohepatitis (NASH)
Elzafir Elsheikh1, 2, Mehmet Sayiner2, Zahra Younoszai2, Fanny Monge1, Lakshmi Alaparthi1, Munkhzul Otgonsuren2, Brian P. Lam1, Hussain Allawi2, Dinan Abdelatif2, Zachary D. Goodman1, Zobair M. Younossi1, 2
1Inova Fairfax Hospital, 2Inova Health System

893 Beneficial effects of obeticholic acid on gut vascular barrier permeability and nonalcoholic steatohepatitis in mice fed methionine choline deficient diet
Edina Hot1, Ilaria Spadoni1, Luciano Adorini2, Giuseppe Penna1, Maria Rescigno1
1European Institute of Oncology, 2Intercept Pharmaceuticals

894 Hepatocyte-specific autophagy-deficiency prevents obesity in HFD-fed mice and improves glucose tolerance
Wilhelmus J. Kwanten1, Wim Martinet2, Benedicte Y. De Winter1, Peter P. Michielsen1, 3, Sven M. Francque1, 3
1University of Antwerp, 2University of Antwerp, 3Antwerp University Hospital (UZA)

895 Mixed Lineage Kinase 3 Mediates Release of C-X-C Motif Ligand 10-Enriched Chemotactic Extracellular Vesicles from lipotoxic hepatocytes in NASH
Samar Ibrahim, Petra Hirsova, Kyoko Tomita, Steven Bronk , Gregory J. Gores
Mayo Clinic

896 NADPH oxidase (NADPHox) plays a major role in the pathogenesis of the oxidative phosphorylation (OXPHOS) dysfunction found in mice on a high fat diet.
José A. Solís-Herruzo, Pablo Solis-Munoz, Daniel Fernández-Moreira, Teresa Muñoz-Yagüe, Inmaculada García-Ruiz
Hospital "12 de Octubre"

897 Dual targeting of nuclear receptors ameliorates NAFLD pathogenesis in mice
Pedro M. Rodrigues2, Marta B. Afonso2, André L. Simão2, Marta Caridade2, Catarina C. Carvalho3, Alexandre Trindade3, António Duarte3, Pedro M. Borralho1, Mariana V. Machado4, Helena Cortez-Pinto 4, 5, Cecília M. Rodrigues1, Rui E. Castro1
1Faculty of Pharmacy, University of Lisbon, 2iMed.ULisboa, Faculty of Pharmacy, University of Lisbon, 3Faculty of Veterinary Medicine, University of Lisbon, 4Hospital Santa Maria, 5Faculty of Medicine, University of Lisbon

898 Alteration of Neutrophil-derived Lipocalin 2 in Bone Marrow Cells Modulates Non-alcoholic Steatohepatitis in Mice
Dewei Ye1, 2, Yu Wang2, 1, Karen S. L. Lam1, 2, Aimin Xu1, 2
1The University of Hong Kong, 2The University of Hong Kong

899 Key role of ASMase in the susceptibility of MAT1A deficient mice to choline deficient diet-induced steatohepatitis.
Cristina Alarcón-Vila1, Vicent Ribas1, Susana Nuñez1, Carmen Garcia-Ruiz1, 2, Jose Fernandez-Checa 1, 2
1Instituto Investigaciones Biomedicas Barcelona, CSIC, 2Liver Unit, Hospital Clinic-IDIBAPS

900 Genetic Ablation of Phosphatidylcholine Transfer Protein (PC-TP) in ob/ob Mice Improves Glucose Homeostasis Without Increasing Energy Expenditure: Evidence for the Direct Role for PC-TP in Hepatic Insulin Resistance
Tibor I. Krisko1, 2, Katherine B. Leclair1, David E. Cohen1
1Brigham and Women's Hospital, 2VA Medical Center

901 Aging associated impaired metabolic compensation in adipose tissues promotes diet-induced murine nonalcoholic fatty liver disease.
Hiroyoshi Taketani1, Taichiro Nishikawa1, Hisakazu Nakajima2, Satoru Sugimoto2, Ikuyo Itoh2, Kazuki Koudou2, Atsushi Umemura1, Kanji Yamaguchi1, Michihisa Moriguchi1, Yoshio Sumida1, Hironori Mitsuyoshi1, Kohichiroh Yasui1, Yoshito Itoh1
1Gastroenterology and Hepatology of Kyoto Prefectural University of Medicine, 2 Kyoto Prefectural University of Medicine

902 The dual FXR/TGR5 agonist INT-767reduces visceral fat mass, promoting preadipocyte brown differentiation, mitochondrial function and insulin sensitivity in a rabbit model of high fat diet-induced metabolic syndrome
Linda Vignozzi2, Ilaria Cellai2, Sandra Filippi1, Paolo Comeglio2, Tommaso Mello2, Daniele Bani3, Daniele Guasti3, Erica Sarchielli3, Annamaria Morelli3, Elena Maneschi2, Gabriella Barbara Vannelli3, Luciano Adorini4, Mario Maggi2
1University of Florence, 2University of Florence, 3University of Florence, 4Intercept Pharmaceuticals

903 CXCL1 promotes steatohepatitis and fibrosis in a mouse model of high-fat diet-plus-binge ethanol feeding
Zhou Zhou1, Ming-Jiang Xu1, Binxia Chang1, 2, Yan Cai1, Bin Gao1
1National Institute of Alcohol Abuse and Alcoholism, 2Institute of Alcoholic Liver Disease, Beijing 302 Hospital

904 Vitamin D through Induction of Paneth Cell Defensins Attenuates Gut Dysbiosis and Improves Metabolic Disorders in Animal Models
Yuan-Ping Han1, Danmei Su1, Yuanyang Nie1, Airu Zhu1, Zishuo Chen1, Li Zhang1, Pengfei Wu1, Mei Luo1, Guihui Wu2, Richard Hu3, Aurelia Lugea4, Jun Xu5, Hidekazu Tsukamoto5, Stephen J. Pandol4
1Sichuan University, 2Chengdu Public Health Clinical Center, 3Olive View-UCLA Medical Center, 4Cedars-Sinai Medical Center, 5University of Southern California

905 Fecal Alkaline Phosphatase Is a Determinant Of Metabolic Endotoxemia And Severity Of Nonalcoholic Fatty Liver Disease (NAFLD)
Kalyani Daita1, Lorenzo Mulazzani2, Robert Vincent1, Amon Asgharpour1, Sophie C. Cazanave1, Mohammad S. Siddiqui1, Puneet Puri1, Michael Idowu1, Sherry L. Boyett1, Faridoddin Mirshahi1, Hae-Ki Min1, Robert E. Brown3, Masoumeh Sikaroodi3, Patrick M. Gillevet3, Arun J. Sanyal1
1VCU, 2Università di Bologna, 3George mason university

906 Ectopic expression of N-acetylglucosaminyltransferase V (GnT-V) accelerates hepatic triglyceride synthesis
Yusuke Ebisutani2, Yoshihiro Kamada2, 1, Sachiho KIda2, Kayo Mizutani2, Maaya Akita2, Akiko Yamamoto2, Hironobu Fujii2, Tomoaki Sobajima2, Naoko Terao2, Shinji Takamatsu2, Yuichi Yoshida1, Tetsuo Takehara1, Eiji Miyoshi2
1Osaka University, Graduate School of Medicine, 2Osaka University, Graduate School of Medicine

907 High Milkfat Diet Causes More Severe NASH Compared to High Lard Diet: The Dual FXR-TGR5 Agonist INT-767 Prevents NASH in both Models.
Xiaoxin Wang1, Yuhuan Luo1, David J. Orlicky2, Luciano Adorini3, Moshe Levi1
1Univ Colorado, 2University of Colorado, 3Intercept Pharmaceuticals

908 Ornithine transcarbamylase gene expression and hepatic urea nitrogen handling are reduced in models of NAFLD and recovers with dietary modulation and reducing bacterial translocation: Rationale for ammonia lowering therapy in NASH patients.
Karen Louise Thomsen1, Francesco De Chiara1, Fausto Andreola1, Krista Rombouts1, Jane MacNaughtan1, Jane Grove2, Guruprasad P. Aithal2, Rajeshwar Mookerjee1, Rajiv Jalan 1
1University College London, 2Nottingham University Hospital

909 Regulatory T Cells Prevent Alcohol-Induced Hepatic Steatosis in Mice
Hongwu Wang2, Ting Wu2, Yaqi Wang2, Xiaojing Wang2, Xiaoping Luo1, Qin Ning2
1Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 2Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

910 NOX2 deficiency attenuates ethanol-induced hepatic steatosis by down-regulating CB1R-mediated lipogenesis in mice
Jong-Min Jeong, So Yeon Kim, Won-IL Jeong
KAIST

911 L-Fabp deletion attenuates both hepatic steatosis and fibrosis resulting from hepatic microsomal triglyceride transfer protein (Mttp) deletion.
Elizabeth P. Newberry2, Susan M. Kennedy2, Yan Xie2, Hui Jiang2, Anping Chen1, Daniel S. Ory2, Nicholas O. Davidson2
1St. Louis University, 2Washington University School of Medicine

912 Intrahepatic expression levels of bile acid transporters are inversely correlated with histological progression of non-alcoholic fatty liver disease
Kazuya Okushin1, Takeya Tsutsumi2, Kenichiro Enooku1, Hidetaka Fujinaga1, Akira Kado1, Kyoji Moriya3, Hiroshi Yotsuyanagi2, Kazuhiko Koike1
1The University of Tokyo, 2The University of Tokyo, 3The University of Tokyo

913 Non-invasive quantitative decline in liver fat content on MRI and histologic response in nonalcoholic steatohepatitis: A secondary analysis of MOZART trial
Janki R. Patel1, Ricki Bettencourt2, 3, Jeffrey Y. Cui2, Joanie Salotti4, 2, Jonathan Hooker5, Archana Bhatt2, Carolyn Hernandez2, Phirum Nguyen2, Hamed Aryafar5, William Haufe5, Catherine A. Hooker5, Lisa M. Richards2, 4, Claude B. Sirlin5, Rohit Loomba2, 4
1University of California, San Diego, 2University of California, San Diego, 3University of California, San Diego, 4University of California, San Diego, 5University of California, San Diego

914 Mast Cell Involvement in Non-Alcoholic Fatty Liver Disease in Humans
Anna Christina Dela Cruz1, Mehmet M. Altintas1, Nestor De La Cruz-Munoz2, Gabriel S. Gaidosh4, Leopoldo Arosemena1, Mehrdad Nadji3, Monica Garcia-Buitrago3, Ali Nayer1
1University of Miami Miller School of Medicine, 2University of Miami Miller School of Medicine, 3University of Miami Miller School of Medicine, 4University of Miami Miller School of Medicine

915 Assessment of Donor and Environmental Risk Factors in a Human Physiologically Relevant Model of Nonalcoholic Steatohepatitis (NASH)
Ryan E. Feaver, Mark Lawson, Aaron J. Mackey, David Manka, Brian R. Wamhoff, Ajit Dash, Brett R. Blackman
HemoShear Therapeutics

916 An Intact Fgf15 Signaling Pathway is Necessary for Hepatoprotection after Bariatric Surgery
Andriy Myronovych1, 2, Kenneth D. Setchell3, Brandon Tan4, Rosa-Maria Salazar-Gonzalez2, Wujuan Zhang3, Karen K. Ryan5, Darleen A. Sandoval1, Randy J. Seeley1, Rohit Kohli2
1University of Michigan, 2Cincinnati Children's Hospital Medical Center, 3Cincinnati Children’s Hospital Medical Center, 4University of Cincinnati, 5University of California, Davis

917 L-carnitine ameliorates hepatic steatosis in diabetic KK-Ay mice by facilitating ß-oxidation
Kazuyoshi Kon, Kenichi Ikejima, Hiromi Kusama, Maki Morinaga, Kumiko Arai, Akira Uchiyama, Tomonori Aoyama, Shunhei Yamashina, Sumio Watanabe
Juntendo University School of Medicine

918 Wheat Bran Autolytic Peptides, Containing a Branched-chain Amino Acid, Ameliorate Nonalcoholic Steatohepatitis with Up-regulation of Anti-oxidant Potential in High-fat Diet-fed Mice.
Takumi Kawaguchi4, Takato Ueno1, 3, Yoichi Nogata2, Masako Hayakawa3, Hironori Koga4, 3, Takuji Torimura4, 3
1Asakura Medical Association Hospital, 2NARO Western Region Agricultural Research Center, 3Kurume University, 4Kurume University School of Medicine

919 Hepatic but not Intestinal Specific FXR Deficiency Led to Accelerated Non-alcoholic Steatohepatitis Development
Bo Kong1, Runbin Sun1, 2, Jianliang Shen1, Yang Pan1, Jia He1, Quan Jin1, Justin D. Schumacher1, Le Zhan1, Haoyue Zhou1, Xinjie Qiu1, Yongping Wang3, Jiye Aa2, Jason R. Richardson4, Tracy Anthony3, Grace L. Guo1
1Rutgers University, 2China Pharmaceutical University, 3Rutgers University, 4Robert Wood Johnson Medical School

920 Deletion of orphan nuclear receptor small heterodimer partner prevents development of nonalcoholic steatohepatitis
Chunki Kim, Mikang Lee, Yoonkwang Lee
Northeast Ohio Medical University

921 Differential carbonylation of proteins in human fatty and nonfatty NASH
Colin T. Shearn, David J. Orlicky, Dennis R. Petersen
University of Colorado Anschutz Medical Campus

922 Lysosomal cholesterol in Kupffer cells, particularly when oxidized, contributes to murine steatohepatitis
Sofie Walenbergh1, Tom Houben1, Tim Hendrikx1, Patrick van Gorp1, Mike Jeurissen1, Marie-Hélène Lenders1, Marion J. Gijbels1, Jogchum Plat1, Marten H. Hofker2, Christoph J. Binder3, Dieter Luetjohann4, Fons Verheyen1, Ger H. Koek1, Ronit Shiri-Sverdlov1
1Maastricht University, 2University Medical Center Groningen, 3Research Center for Molecular Medicine of the Austrian Academy of Sciences, 4 Institute of Clinical Chemistry and Clinical Pharmacology

923 Cholesterol crystallization within hepatocyte lipid droplets and its role in NASH
George N. Ioannou2, 1, Savitha Subramanian1, Alan Chait1, Matthew M. Yeh1, W. G. Haigh2, Christopher Savard2, 1
1University of Washington, 2Veterans Affairs Puget Sound Healthcare System

924 Fenofibrate and LXRa agonist combination attenuated intrahepatic inflammation in non-alcoholic fatty liver.
Eun Chul Jang1, Dae Won Jun2, Seung Min Lee3, Yong Kyun Cho4, Sang Bong Ahn5
1Soonchunhyang University Cheonan Hospital, 2Hanyang University College of Medicine, 3Sungshin Women's University, 4Kangbuk Samsung Hospital, Sungkyunkwan University, School of Medicine, 5Eulji University School of Medicine

925 A novel transcriptional repressor Hairy and Enhancer Split 6 mediates hepatic lipid homeostasis through inhibition of Pparg2 expression
Chunki Kim, Mikang Lee, James P. Hardwick, Yoonkwang Lee
Northeastern Ohio Univ. College of Med

926 Effects of Dietary Different Doses of Copper and High Fructose Feeding on Rat fecal Metabolome
Ming Song1, Xiaoli Wei2, Xinmin Yin2, Dale Schuschke3, Imhoi Koo2, Craig J. McClain1, 4, Xiang Zhang2
1University of Louisville, 2University of Louisville, 3University of Louisville, 4Robley Rex VAMC

927 Liver sinusoid endothelial cell derived bone morphogenetic protein binding endothelial regulator (BMPER) induces iron overload of high-fat diet induced non-alcoholic fatty liver mice.
Takumu Hasebe1, Koji Sawada1, Shunsuke Nakajima1, Hiroki Tanaka2, Takaaki Ohtake3, Mikihiro Fujiya1, Yutaka Kohgo3
1Asahikawa Medical University, 2Asahikawa Medical University, 3International University of Health and Welfare Hospital

928 Analysis of T and myeloid cells in patients with NASH and diabetes mellitus
Luisa Vonghia1, Denis Mogilenko2, 3, An Verrijken4, 5, Luc van Gaal4, 5, Bart Staels2, 3, Sven M. Francque1, 5, David Dombrowicz2, 3
1University Hospital, 2Inserm U1011, 3Institut Pasteur, University of Lille , 4University Hospital of Antwerp, 5University of Antwerp

929 Regulation of hepatocellular senescence by melatonin during alcoholic liver injury
Jessica S. Garner1, Yuyan Han3, 2, Tiaohao Zhou3, 2, Kelly McDaniel2, 3, Ying Wan1, 2, Tami Annable2, 1, Nan Wu3, 2, Julie Venter3, 2, Haibo Bai1, 2, Shannon S. Glaser3, 2, Heather L. Francis1, 2, Fanyin Meng2, 1, Gianfranco Alpini3, 2
1Scott & White Hospital, Texas A&M HSC College of Medicine, 2Central Texas Veterans Healthcare System, 3Texas A&M HSC College of Medicine

930 Hypoxia accelerates fatty acid uptake leading to increased fat accumulation and inflammation in mice and in cultured human hepatocyte-derived cells
Agueda Gonzalez-Rodriguez, Gloria Mateo, Ines Soro-Arnaiz, Mar Torres-Capelli, Ainara Elorza, Julian Aragones, Carmelo García-Monzón
University Hospital Santa Cristina

931 Predicted prevalence of NAFLD and NASH in a large population using non-invasive multiparametric MRI.
Catherine Kelly, Rajarshi Banerjee
Perspectum Diagnostics Ltd

932 Akkermansia Muciniphila Is Decreased In Patients With Non-Alcoholic Fatty Liver Disease
Tarkan Karakan1, Ceren Gundogdu2, Meltem Yalinaycirak2, Mehmet Ibis1
1Gazi University, 2Gazi University

933 Leucine synergizes with metformin and sildenafil to treat Non-Alcoholic Fatty Liver Disease (NAFLD) and Steatohepatitis (NASH)
Michael Zemel1, Antje Bruckbauer1, Bingzhong Xue2, Hang Shi2
1NuSirt Biopharma, 2Georgia State University

934 Role of fibroblast growth factor 15 in the development of high fat diet induced NASH
Justin D. Schumacher1, Bo Kong1, Yang Pan2, Le Zhan1, Runbin Sun2, Jiye Aa2, Jason R. Richardson1, Debra Laskin1, Grace L. Guo1
1Rutgers University, 2Chinese Pharmaceutical University

935 Fatty Acid-Stimulated Inflammasome Activation Contributes to Hepatic Stellate Cell Activation in High Fat/Clarrie Diet-Fed Mice
Xue-Jing Liu1, Na-Na Duan1, Ning-Ping Zhang2, 3, Jia Ding1, 4, Jian Wu1, 2
1Fudan University Shanghai Medical College, 2Fudan University Shanghai Medical College, 3Fudan University Affiliated Zhongshan Hospital, 4Shanghai Jing’an District Central Hospital

936 Ancestral starvation-activated caspase-2 promotes obesity, the metabolic syndrome and Nonalcoholic fatty liver disease
Mariana V. Machado1, 2, Gregory A. Michelotti1, Guanhua Xie1, Thiago A. Pereira1, Mark Jewell1, Richard T. Premont1, Anna Mae Diehl1
1Duke University Medical Center, 2Hospital de Santa Maria, CHLN

937 Antihypertensive therapy improves insulin resistance and imbalances of interleukin-6 and -10 in spontaneously hypertensive rats with steatohepatitis
Masaya Kozono1, Hirofumi Uto2, 1, Rie Ibusuki3, 1, Shiho Arima1, Kohei Oda1, Sho Ijuin1, Hiroka Onishi1, Haruka Sakae1, Kaori Muromachi1, Akihiko Oshige1, Seiichi Mawatari1, Tsutomu Tamai1, Akihiro Moriuchi4, Hirohito Tsubouchi5, Akio Ido1
1Kagoshima University Graduate School of Medical and Dental Sciences, 2Miyazaki Medical Center Hospital, 3Kagoshima University Graduate School of Medical and Dental Sciences, 4Kagoshima University Graduate School of Medical and Dental Sciences, 5Kagoshima City Hospital

938 Alterations in NK cell phenotype with disease progression in a murine model of non-alcoholic fatty liver disease (NAFLD).
Rachel McMahan, Cara Porsche, Lucy Golden-Mason, Hugo R. Rosen
University of Colorado

939 Omentectomy prevents nonalcoholic fatty liver disease (NAFLD) by reducing food intake and body weight in rats on a high fat diet.
José A. Solís-Herruzo, Pablo Solis-Munoz, Daniel Fernández-Moreira, Teresa Muñoz-Yagüe, Inmaculada García-Ruiz
Hospital "12 de Octubre"

940 RIP3-dependent hepatocyte necroptosis in human and experimental non-alcoholic steatohepatitis
Marta B. Afonso2, Pedro M. Rodrigues2, Tânia Carvalho3, Marta Caridade2, Paula Borralho Nunes4, Helena Cortez-Pinto 5, 6, Rui E. Castro1, Cecília M. Rodrigues1
1Faculty of Pharmacy, University of Lisbon, 2iMed.ULisboa, Faculty of Pharmacy, University of Lisbon, 3Instituto de Medicina Molecular, 4Instituto de Anatomia Patológica, University of Lisbon, 5Hospital Santa Maria, 6Faculty of Medicine, University of Lisbon

941 Over-expression of HNF4a attenuated lipotoxicity in non-alcoholic fatty liver disease model
Jai Sun Lee1, Dae Won Jun2, Seung Min Lee3, Yong Kyun Cho4, Eun Chul Jang5, Sang Bong Ahn6
1Hanyang University Graduate School of Biomedical Science and Engineering, 2Hanyang University College of Medicine, 3Sungshin Women's University, 4Kangbuk Samsung Hospital, Sungkyunkwan University, School of Medicine, 5Soonchunhyang University Cheonan Hospital, 6Eulji University School of Medicine

942 Thioesterase Superfamily Member 2 (Them2) Reduces Membrane Fluidity and Promotes Endoplasmic Reticulum (ER) Calcium Loss in Response to Saturated Free Fatty Acids: Pathogenic Role in Non-Alcoholic Fatty Liver Disease (NAFLD)
Baran A. Ersoy, Yingxia Li, David E. Cohen
Brigham and Women's Hospital and Harvard Medical School

943 Genetic analysis of NAFLD within a Caribbean Hispanic Population
Devorah Edelman2, Bernice Morrow2, Maria Delio2, Mortadha Abd4, Adam Auton2, Tao Wang3, Allan W. Wolkoff1, 4, Harmit S. Kalia1, 4
1Albert Einstein College of Medicine, 2Albert Einstein College of Medicine, 3Albert Einstein College of Medicine, 4Montefiore Medical Center

944 Inhibitor Of DNA Binding 2 Gene Induced By High Levels Of Insulin Contributes To Adipogenesis And Fatty Liver In A Model Of Type 2 Diabetes Mellitus
Tomoyuki Nemoto, Hidetaka Matsuda, Katsushi Hiramatsu, Yoshihiko Ozaki, Tatsushi Naito, Kazuto Takahashi, Kazuya Ofuji, Masahiro Ohtani, Hiroyuki Suto, Yasunari Nakamoto
University of Fukui

945 Human amniotic epithelial cells reduce liver fibrosis and the incidence of hepatocellular carcinoma in a ‘fast food’ NAFLD model.
Alexander Hodge1, Nathan T. Kuk1, Ying S. Sun1, Kristy Nguyen1, Rebecca Lim2, William Sievert1
1Monash Medical Centre,Monash University, 2Hudson Institute of Medical Research

946 Standard American Diet (SAD) induced-nonalcoholic steatohepatitis (NASH) is mitigated by a pharmacalogical CCR2 inhibitor; in contrast, addition of dietary iron to the SAD made NASH refractory to the salutory effects of the CCR2 inhibitor.
Priya Handa2, Vicki Morgan-Stevenson2, Shenna Washington1, Matthew M. Yeh3, Kris V. Kowdley4
1Benaroya Research Institute, 2Swedish Medical Center, 3University of Washington, 4Swedish Medical Center

947 Adipose tissue-derived stromal cells preventatively suppressed pathological progression of murine non-alcoholic steatohepatitis model.
Masatoshi Yamato1, 2, Yoshio Sakai1, Hatsune Mochida2, Akihiro Seki2, Kosuke Ishida2, Masao Honda2, 1, Shuichi Kaneko2, 1
1Kanazawa University, 2Kanazawa University

948 High and Low Capacity Runner (HCR and LCR) rat lines do not display significant differences in NASH phenotype when fed a fast food diet.
Howard C. Masuoka1, 3, Oscar Cummings2, Naga P. Chalasani1, 3, Lawrence Lumeng1
1Indiana University, 2Indiana University, 3Indiana University

949 High calories intake and particulate matter exposition promote the progression from steatosis to steatohepatitis and create a permissive enviroment for hepatocellular carcinoma development.
Mirko Tarocchi, Giada Marroncini, Simone Polvani, Sara Tempesti, Tommaso Mello, Francesca Zanieri, Elisabetta Ceni, Andrea Galli
University of Florence

950 A Balanced Carbohydrate and Fat Containing Diet Protects Mice from Nutritional NAFLD and Vascular Dysfunction
Yong Ook Kim1, Michael Hausding2, Kyoung-Sook Park1, Andreas Daiber2, Detlef Schuppan1, 3
1Institute of Translational Immunology and Research Center for Immune Therapy (FZI), University Medical Center of the Johannes Gutenberg University Mainz, 2Department of Molecular Cardiology, Med. II, University Medical Center of the Johannes Gutenberg University Mainz, 3Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School

951 Fermented soymilk prevent free fatty acid-induced lipogenesis and production of reactive oxygen species in hepatocellular steatosis model
Sang Bong Ahn1, Byoung Kwan Son1, Dae Won Jun2, Yong Kyun Cho3
1Eulji University, School of Medicine, 2Hanyang University, College of Medicine, 3Kangbuk Samsung Hospital, Sungkyunkwan University, School of Medicine

952 Increased 53-binding protein 1 nuclear focus expression in patients with non-alcoholic steatohepatitis.
Koji Okamoto2, Yuko Akazawa4, Hisamitsu Miyaaki4, Satoshi Miuma4, Naota Taura4, Hisayoshi Kondo3, Masahiro Nakashima1, Kazuhiko Nakao4
1Atomic bomb disease institute , 2Nagasaki University School of Medicine, 3Atomic Bomb Disease Institute, 4Nagasaki University Hospital

953 S-Adenosylmethionine Treatment Corrects Deregulated Lipid Metabolic Pathways and Prevents Progression of Non-Alcoholic Steatohepatitis in Methionine Adenosyltransferase 1a Knockout Mice
David Fernández2, Cristina Alonso1, Sebastiaan van Liempd3, Marta Varela2, Nicolás Navasa3, Ibon Martinez-Arranz1, Patricia Aspichueta4, Ana M. Aransay2, Juan Anguita5, Juan M. Falcon-Perez5, Maria L. Martinez-Chantar2, Shelly C. Lu6, Jose M. Mato2
1OWL, 2CIC bioGUNE, Ciberehd, 3CIC bioGUNE, 4University of the Basque Country, 5CIC bioGUNE, Ikerbasque, 6Cedars-Sinai Medical Center

954 Angiogenesis in the pathogenesis of non-alcoholic fatty liver disease: a differential gene expression study
Savneet Kaur1, Sebastian Vlaic2, Reinhard Guthke2, Rania Dayoub3, Mohsin Hasan4, Hamda Siddiqui1, Thomas S. Weiss3, Shiv K. Sarin4
1Gautam Buddha University, 2Leibniz Institute for Natural Product Research and Infection Biology , 3University children hospital (KUNO), University of Regensburg, 4Institute of liver and biliary sciences

955 Glucagon-like peptide-1 potently attenuates steatohepatitis and liver fibrosis by regulating liver macrophage infiltration, activation and polarization
Xiaoyu Wang1, Shih-Yen Weng1, Yong Ook Kim1, Olena Molokanova1, Thomas Klein2, Detlef Schuppan1, 3
1Institute of Translational Immunology , 2Boehringer Ingelheim Pharma, 3Division of Gastroenterology

956 Hepatic Estrogen Receptor Negatively Correlates with Fibrosis Only in Male Patients with Non-Alcoholic Steatohepatitis (NASH)
Rohini Mehta2, Michael J. Estep2, Gary Bratthauer2, Fanny Monge1, Thomas Jeffers2, Zachary D. Goodman1, Zobair M. Younossi2, 1
1Inova Fairfax Hospital, 2Inova Health Systems

957 Liver-Directed Allosteric Inhibitors of Acetyl-CoA Carboxylase Reduce Hepatic Steatosis and Improve Dyslipidemia in Diet-Induced Obese Rat Models and Reduce Inflammation and Fibrosis in a Cirrhotic Rat Model
Geraldine Harriman1, Danielle K. DePeralta2, Omeed Moaven2, Lan Wei2, Jeremy R. Greenwood3, Sathesh P. Bhat3, Kenneth K. Tanabe2, Bryan C. Fuchs2, William Westlin1, H. James Harwood1, Rosana Kapeller1
1Nimbus Therapeutics , 2Massachusets General Hospital, 3Schrodinger

958 Metformin targets a phosphoSTAT3-miRNAs pathway to inhibit lipid droplets accumulation and intracellular inflammation in vitro and in vivo
Natalia Pediconi1, Silvia Di Cocco3, Silvia Piconese3, Federica Mori4, Laura Belloni2, Abigail D. Nunn2, Tullio Scopigno2, Vincenzo Barnaba3, Giovanni Blandino4, Sabrina Strano4, Massimo Levrero3, 2
1Sapienza University, 2IIT-Sapienza, 3Sapienza University, 4Regina Elena Cancer Institute

959 Exacerbation of non-alcoholic fatty liver disease (NAFLD) in mice with myeloid cell-specific deletion of FXR.
Rachel McMahan1, Cara Porsche1, Moshe Levi2, Hugo R. Rosen1
1University of Colorado, 2University of Colorado

960 miRNA-339-3p is increased in human and experimental models of NAFLD and targeted by TUDCA in insulin-resistant muscle cells
André L. Simão2, Marta B. Afonso2, Pedro M. Rodrigues2, Andreia J. Amaral5, Margarida Gama-Carvalho5, Pedro M. Borralho1, Mariana V. Machado3, Helena Cortez-Pinto 3, 4, Cecília M. Rodrigues1, Rui E. Castro1
1Faculty of Pharmacy, University of Lisbon, 2iMed.ULisboa, Faculty of Pharmacy, University of Lisbon, 3Hospital Santa Maria, 4Faculty of Medicine, University of Lisbon, 5Faculty of Sciences, University of Lisbon

961 Western diet for 7 weeks in apolipoprotein-E-deficient mice induces non-alcoholic steatohepatitis with significant liver fibrosis and portal hypertension.
Robert Schierwagen1, Lara Maybüchen1, Sebastian Zimmer2, Kanishka Hittatiya3, Christer Baeck2, Sabine Klein1, Frank E. Uschner1, Winfried Reul1, Peter Boor5, 6, Georg Nickenig2, Christian P. Strassburg1, Christian Trautwein4, Jogchum Plat7, Dieter Luetjohann8, Frank Tacke4, Jonel Trebicka1, 9
1University Bonn, 2University Bonn, 3University Bonn, 4RWTH University of Aachen, 5RWTH University of Aachen, 6RWTH University of Aachen, 7University of Maastricht, 8University Bonn, 9University of Southern Denmark

962 TRPV4 deficiency enhances TLR4 recruitment to lipid rafts exhibiting exacerbated stellate cell activation and fibrosis in experimental nonalcoholic steatohepatitis
Suvarthi Das1, Ratanesh K. Seth1, Varun Chandrashekaran1, Firas Alhasson1, Diptadip Dattaroy1, Gregory A. Michelotti2, Prakash Nagarkatti3, Phillip D. Bell4, Wolfgang B. Liedtke2, Anna Mae Diehl2, Saurabh Chatterjee1, Mitzi Nagarkatti3
1University of South Carolina, 2Duke University , 3University of South Carolina, 4Medical University of South Carolina

963 ß7-Integrins and MAdCAM-1 have opposing functions in development and progression of Non-alcoholic steatohepatitis (NASH)
Hannah K. Drescher1, Angela Schippers2, Thomas Clahsen2, Hacer Sahin1, Norbert Wagner2, Christian Trautwein1, Konrad L. Streetz1, Daniela C. Kroy1
1University Hospital, RWTH Aachen, Germany, 2University Hospital RWTH Aachen

964 Association between nonalcoholic fatty liver disease and bone mineral density: a systematic review and meta-analysis
Sikarin Upala1, 3, Veeravich Jaruvongvanich4, 5, Karn Wijarnpreecha1, 2, Anawin Sanguankeo1, 3
1Bassett Medical Center and Columbia University College of Physicians and Surgeons, 2Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, 3Faculty of Medicine Siriraj Hospital, Mahidol University, 4University of Hawaii, 5Faculty of Medicine, Chulalongkorn University

965 Aliskiren reduces liver and epididymal fat steatosis and increases skeletal muscle insulin sensitivity in high-fat diet-fed mice
Kuei-Chuan Lee, Yun-Cheng Hsieh, Ying-Ying Yang, Che-Chang Chan, Yi-Hsiang Huang, Han-Chieh Lin
Taipei Veterans General hospital

966 A DPP-4 inhibitor, sitagliptin, can be preventative drug for the acceleration of the development in NAFLD caused by lipopolysaccharides through inhibiting expression of MyD88 and NF?B.
Keisuke Yokohama2, 1, Shinya Fukunishi1, Sanomura Makoto2, Akira Asai1, Yasuhiro Tsuds1, Kazuhide Higuchi1
1Osaka Medical College, 2Hokusetsu general hospital

967 DSS colitis has tumorinogenesis and fibrogenesis in choline-deficiency and high-fat diet induced NASH mouse model
Koichi Achiwa, Masatoshi Ishigami, Yoji Ishizu, Teiji Kuzuya, Takashi Honda, Kazuhiko Hayashi, Yoshiki Hirooka, Hidemi Goto
Nagoya Univercity Graduate School of Medicine

968 Inhibition of Mitophagy in Non-alcoholic Steatohepatitis lead to Apoptosis and Inflammation
Muhammad Sohail1, Seong-Jun Kim2, Aleem Siddiqui2
1university of California, 2University of California

969 NFkB inhibition by Andrographolide ameliorates inflammation and fibrogenesis through inflammasome substrate depletion in experimental Non-Alcoholic Steatohepatitis (NASH)
Daniel Cabrera1, 2, Alexander Wree3, Davide Povero3, Nancy Solis1, Margarita Pizarro1, Pamela Rojas de Santiago1, Javiera Torres7, Han Moshage5, Claudio Cabello-Verrugio4, Ariel E. Feldstein3, Enrique Brandan6, Marco Arrese1
1Facultad de Medicina Pontificia Universidad Católica de Chile , 2Universidad Bernardo O Higgins, 3University of California San Diego, 4Universidad Andres Bello, 5University of Groningen, 6Pontificia Universidad Católica de Chile, 7Pontificia Universidad Católica de Chile

970 Reduction of Hepatic 27-Hydroxycholesterol in Steatohepatitis Model Mice with Insulin Resistance
Sho-ichiro Yara1, Tadashi Ikegami1, Akira Honda1, 2, Teruo Miyazaki2, Masashi Murakami1, Junichi Iwamoto1, Yasushi Matsuzaki1
1Tokyo Medical University Ibaraki Medical Center, 2Tokyo Medical University Ibaraki Medical Center

971 Role of Fcgamma receptors in experimental Non-Alcoholic Steatohepatitis
Daniel Cabrera1, 3, Evelyn Jara2, Ricardo Cruz1, Natalia Muñoz-Durango2, Pamela Rojas de Santiago1, Alexis Kalergis2, Marco Arrese1
1Facultad de Medicina, Pontificia Universidad Católica de Chile , 2Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, 3Universidad Bernardo O Higgins

972 Regulation of Hepatocellular Fatty Acid Uptake in Mouse Models of Fatty Liver Disease With and Without Functional Leptin Signalling: Roles of NfKB and Srebp-1c.
Fengxia Ge, Jose L. Walewski, Paul D. Berk
Columbia University Medical Center

973 Role of the receptor tyrosine kinase Mer in the development of fibrosis in NAFLD
Giovanni Di Maira1, Salvatore Petta2, Andrea Cappon1, Elisa Vivoli1, Luca Valenti3, Paola Dongiovanni3, Elisabetta Bugianesi4, Vito Di Marco2, Fabio Marra1
1University of Florence, 2University of Palermo, 3University of Milan, 4University of Turin

974 GFT505 (ELAFIBRANOR) prevents nonalcoholic steatohepatitis (NASH), hepatic fibrosis and hepatocarcinoma in a new disease model
Benoit Noel1, Geraldine Rigou1, Nathalie Degallaix1, Valérie Daix1, Linda Cambula1, Alice Roudot1, Rémy Hanf1, Dean W. Hum1, Bart Staels2, Robert Walczak1
1Genfit SA, 2Institut Pasteur

975 Free fatty acid treatment reduces BMP6 signalling in AML12 hepatocytes
Nishreen Santrampurwala1, 2, Kim Bridle1, 2, Janske Reiling1, 3, Laurence J. Britton1, 2, Lesley-Anne Jaskowski1, 2, Nathan Subramaniam1, 4, Darrell H. Crawford1, 2
1The University of Queensland, 2Gallipoli Medical Research Foundation, 3Maastricht University, 4QIMR Berghofer Medical Research Institute

976 Increased sensitivity and compromised time-dependent adaptation to methoxamine in a rat model of severe steatosis.
Wilhelmus J. Kwanten1, Paul Fransen2, Joris G. De Man1, Benedicte Y. De Winter1, Peter P. Michielsen1, 3, Sven M. Francque1, 3, Denise Van Der Graaff1, Michiel Landen 1
1University of Antwerp, 2University of Antwerp, 3Antwerp University Hospital (UZA)

977 NorUDCA reduces liver injury and improves glucose sensitivity in a mouse model of obesity and steatosis.
Daniel Steinacher1, Thierry Claudel1, Tatjana Stojakovic2, Michael Trauner 1
1Medical University of Vienna, 2 Medical University of Graz

978 The obese insulin resistant Lepob/Lepob mouse as an accelerated diet-induced model of nonalcoholic steatohepatitis –tracking disease progression by liver biopsy
Michael Feigh, Sanne S. Veidal, Sanne M. Knudsen, Jacob Jelsing, Niels Vrang
Gubra

979 Inhibition of ß-hydroxybutyrate production and sensing increases alcoholic steatohepatitis
Yonglin Chen, Irma Garcia-Martinez, Xinshou Ouyang, Rafaz Hoque, Wajahat Z. Mehal
Yale University

HCV Virology and Pathogenesis

980 Interferon lambda 3 (IL28B) and interferon lambda 4 genotypes and resistance-associated variants in HCV genotype 1 and 3 infected patients
Kai-Henrik Peiffer, Lisa Sommer, Simone Susser, Julia Dietz, Dany Perner, Caterina Berkowski, Stefan Zeuzem, Christoph Sarrazin
J. W. Goethe University, Medizinische Klinik 1

981 MicroRNA-130a inhibit HCV production through regulating host immune responses and lipid metabolism
Xiaoqiong Duan1, Limin Chen1, 2
1Institute of Blood Transfusion,Chinese Academy of Medical Sciences (CAMS) /Peking Union Medical College (PUMC), 2Toronto General Research Institute,University of Toronto

982 Individualized DAA treatment duration for cure in patients with cirrhosis via modeling of early HCV kinetics
Martina Gambato3, Laetitia Canini1, 4, Sabela Lens3, Frederik Graw5, María-Carlota Londoño3, Susan L. Uprichard1, Zoe Mariño3, Enric Reverter Segura3, Concepció Bartres3, Patricia Gonzalez3, Scott Cotler1, Xavier Forns3, Harel Dahari1, 2
1Loyola University Medical Center, 2Los Alamos National Laboratory, 3IDIBAPS and CIBEREHD, 4University of Edinburgh, 5Heidelberg University

983 Kidney involvement in HCV Child-A cirrhosis
Gloria Taliani2, Donatella Palazzo2, Elisa Biliotti2, Francesca Tinti1, Alessandra Bachetoni3, Stefania Grieco2, Andrea Cappoli3, Raffaella Labriola3, Paola Perinelli2, Ilaria Umbro1, Paola Rucci4, Anna Paola Mitterhofer1
1Sapienza University or Rome, 2Clinic of Infectious and Tropical Diseases, Sapienza University of Rome, 3Laboratory of Clinical Pathology, Sapienza University of Rome, 4University of Bologna

984 Hepatitis C virus facilitates its persistent infection through ?Np63-miR-181a-SIRT1/ DUSP6 signaling pathways
Yun Zhou1, 2, Guangyu Li2, 3, Junping Ren2, 3, Ying Zhang1, Jianqi Lian1, Changxing Huang1, Shunbin Ning2, 3, Jonathan P. Moorman2, 3, Zhansheng Jia1, Zhi Q. Yao2, 3
1Tangdu Hospital, Fourth Military Medical University, 2James H. Quillen College of Medicine, East Tennessee State University, 3James H. Quillen College of Medicine, East Tennessee State University

985 Effects of Resistance Mutations of NS5A Inhibitor on Viral Production and Susceptibility to Anti-HCV Reagents in Recombinant Hepatitis C Viruses with NS5A of Genotype 1b
Sayuri Nitta1, 2, Yasuhiro Asahina1, Takaji Wakita2, Takanobu Kato2
1Tokyo Medical and Dental University, 2National Institute of Infectious Diseases

986 The impact of HLA-DQs and IFNL4 variant on hepatitis C virus-induced liver inflammation
Daiki Miki1, 2, Hidenori Ochi1, 2, C. Nelson Hayes1, 2, Hiromi Abe1, 2, Sakura Akamatsu1, 2, Atsushi Ono1, 2, Takashi Nakahara1, 2, Yizhou Zhang1, 2, Keiichi Masaki1, 2, Hatsue Fujino1, 2, Eisuke Miyaki1, 2, Hiromi Kan1, 2, Takuro Uchida1, 2, Nobuhiko Hiraga1, 2, Masataka Tsuge1, 2, Tomokazu Kawaoka1, 2, Michio Imamura1, 2, Yoshiiku Kawakami1, 2, Hiroshi Aikata1, 2, Kazuaki Chayama1, 2
1RIKEN Center for Integrative Medical Sciences, 2Hiroshima University Hospital

987 The Hepatitis C Virus modulates its replication and the degradation of its RNA through the subversion of KHSRP function.
Patrice Bruscella1, Camille Baudesson1, Hassan Danso1, Michele Trabucchi2, Jean-Michel Pawlotsky1, Cyrille Feray1
1INSERM, 2INSERM U 1065, C3M

988 Liver pDCs from HCV-Infected Patients Are Primed for Interferon-alpha Production
Erin H. Doyle1, Adeeb Rahman2, Arielle L. Klepper1, Sang Kim6, Brandy M. Haydel3, Sander S. Florman4, M. Isabel Fiel5, Thomas D. Schiano4, Andrea D. Branch1
1Icahn School of Medicine at Mount Sinai, 2Icahn School of Medicine at Mount Sinai, 3Icahn School of Medicine at Mount Sinai, 4The Mount Sinai Hospital, 5The Mount Sinai Hospital, 6The Mount Sinai Hospital

989 Establishment of A Novel Hepatocyte Cell Line for Hepatitis C Virus Replication
Quanfeng Wu, Liya Pi, David R. Nelson, Chen Liu
University of Florida

990 Selenoprotein P regulates the innate immune response through an RIG-I-mediated pathway
Kazuhisa Murai1, Masao Honda1, Tetsuro Shimakami1, Takayoshi Shirasaki1, Hirofumi Misu3, Toshinari Takamura3, Stanley M. Lemon 2, Seishi Murakami1, Shuichi Kaneko1
1Kanazawa University Graduate School of Medical Science, 2The University of North Carolina at Chapel Hill, 3Kanazawa University Graduate School of Medicine

991 Long noncoding RNAs regulate HCV replication and ISGs in a Jak-STAT independent manner
Xiao Liu, Jian Hong, Dachuan Cai, Sae Hwan Lee, Dahlene Fusco, Esperance A. Schaefer, Cynthia Brisac, Anna Lidofsky, Wenyu Lin, Raymond T. Chung
Massachusetts General Hospital, Harvard Medical School

992 Evaluatiin of protective and therapeutic strategies against hepatitis C virus in a syngenic transplantation mouse model
Matti Sällberg2, Sepideh Levander1, Fredrik Holmstom1, Gustaf Ahlén1, Lars Frelin1, Gang Long3, Daniel Rupp3, Ralf Bartenschlager3
1Karolinska Institutet, 2Karolinska Institutet, 3University of Heidelberg

993 Analysis of AL-516, a Novel Potent Nucleotide Analog, Combination Drug Interactions in the Hepatitis C Virus (HCV) Subgenomic Replicon System
Hua Tan, Kenneth Shaw, vivek Rajwanshi, Gary Wang, Leo Beigelman, David B. Smith, Lawrence M. Blatt, Julian A. Symons
Alios

994 Regulation of Hepatitis C Virus Infection by Long Non-Coding RNAs
Tetsuro Shimakami, Masao Honda, Takayoshi Shirasaki, Fanwei Liu, Masaya Funaki, Kazuhisa Murai, Shuichi Kaneko
Kanazawa University

995 Iron chelation restores mitophagy suppressed by hepatitis C virus
Yuichi Hara1, Sohji Nishina1, Tasuku Hirayama2, Hideko Nagasawa2, Keisuke Hino1
1Kawasaki Medical College, 2Gifu Pharmaceutical University

996 Cell-specific peripheral innate immune responses to immunomodulatory stimulation in chronic HCV
Jacinta A. Holmes1, 2, Narelle A. Skinner2, Mario Congiu2, Rosemary M. Millen2, Lijia Yu2, William Sievert3, Paul V. Desmond1, Kumar Visvanathan2, Alex J. Thompson1, 2
1St Vincent's Hospital, 2St Vincent's Hospital, 3Monash Health, Monash University

997 Role of very-low-density lipoprotein (VLDL) biogenesis in hepatitis C virus (HCV) production: a reassessment in primary human adult hepatocytes
Veronique Pene1, Maxime Villaret1, Matthieu Lemasson1, Lynda Aoudjehane2, 3, Jean-François Méritet1, 4, Filomena Conti3, 5, Yvon Calmus3, 5, Arielle R. Rosenberg1, 4
1Université Paris Descartes, 2Human HepCell, Hôpital Saint-Antoine, 3Inserm, 4AP-HP, Hôpital Cochin, 5AP-HP, Hôpital Pitié-Salpêtrière

998 A miR-122/miR-224-based model to identify severe fibrosis and cirrhosis in patients with chronic hepatitis C.
Kevin Appourchaux2, Emilie Estrabaud2, Matthieu Resche-Rigon3, 1, Martine Lapalus2, Michelle Martinot-Peignoux2, Nathalie Boyer4, Michel Vidaud5, Pierre Bedossa6, Patrick Marcellin2, Tarik Asselah2, 4
1INSERM, 2INSERM UMR1149, 3INSERM UMR1153, 4Beaujon Hospital, 5INSERM UMR745, 6Beaujon Hospital

999 Different HCV genotypes have different genetic barriers to resistance to N5A inhibitors, explaining different treatment outcomes
Slim Fourati1, 2, Stephane Chevaliez1, 2, Alexandre Soulier1, 2, Marion Lavert1, 2, Lila Poiteau1, 2, Jean-Michel Pawlotsky1, 2
1National Reference Center for Viral Hepatitis B, C and Delta,, 2INSERM U955, Université Paris-Est

1000 Establishment and Characterization of a New Permissive Cell Line for HCV Infection
Hitoshi Omura, Tetsuro Shimakami, Takayoshi Shirasaki, Kazuhisa Murai, Masaya Funaki, Fanwei Liu, Takehiro Hayashi, Taro Yamashita, Masao Honda, Shuichi Kaneko
Kanazawa university

1001 PD-1 blockade enhances cytopathic control of HCV by antiviral CD8 T cells in infectious HCV co-culture model
Keisuke Ojiro1, Xiaowang Qu1, 2, Jang-June Park1, Hyosun Cho1, 3, Kyong-Mi Chang1
1University of Pennsylvania, 2University of South China, 3Duksung Women's University

1002 HCV RNA and HCV core antigen are frequently detectable in stool of men chronically infected with HCV: Is feces a potential source of infection?
Benjamin Heidrich1, 3, Eike Steinmann4, Iris Plumeier2, Janina Kirschner1, Lisa Sollik1, Szilvia Ziegert1, Patrick Lehmann1, Michael Engelmann4, Tim Lankisch1, Michael P. Manns1, 3, Dietmar H. Pieper2, 3, Heiner Wedemeyer1, 3
1Hannover Medical School, 2Centre for Infection Research, 3German Center for Infection Research (DZIF), 4TWINCORE Centre for Experimental and Clinical Infection Research

1003 Essential Factors for Reconstitution of Entire Life Cycle of Hepatitis C Virus in Monkey Kidney Derived Cell Line
Asako Murayama, Nao Sugiyama, Takaji Wakita, Takanobu Kato
National Institute of Infectious Diseases

1004 Tim-3 Inhibits Monocyte Functions via T-bet during Hepatitis C Virus Infection
Ying Zhang1, Wenjing Yi1, Peixin Zhang1, Yan Liang1, Zhi Q. Yao2, Zhansheng Jia1
1Tangdu Hospital, Fourth Military Medical University, 2James H. Quillen College of Medicine, East Tennessee State University

1005 Downregulation of let-7 family miRs is strongly associated with increasing stages of hepatic fibrosis in chronic hepatitis C (HCV) Genotype 3a
Manish C. Choudhary1, Sadaf Dar1, Ekta Gupta2, Jaswinder S. Maras1, Syed N. Kazim3, Gayatri Ramakrishna1, Shiv K. Sarin1
1Institute of Liver and Biliary Science, 2Institute of Liver and Biliary Sciences, 3Jamia Milia Islamia

1006 Type III interferon responses contribute to hepatitis virus infection and depended on IFNL3-IFNL4 variant
Tsunamasa Watanabe2, 1, Susumu Tsutsumi2, Kentaro Matsuura3, Etsuko Iio3, Noboru Shinkai3, Kayoko Matsunami3, Fumio Itoh1, Yasuhito Tanaka2
1St. Marianna University School of Medicine, 2Nagoya City University Graduate School of Medical Sciences, 3Nagoya City University Hospital

1007 Altered frequencies and function of MAIT cells during treatment of patients with chronic HCV, HIV and HCV/HIV co-infections
Michelle Spaan2, Sebastiaan Hullegie1, Kim Kreefft2, Gertine van Oord2, Boris Beudeker2, Bart J. Rijnders1, Robert J. de Knegt2, Mark Claassen1, Andre Boonstra2
1 Erasmus MC, 2Erasmus MC

1008 Interferon-based treatment activates regulatory CD4+ T-cells to exert counteractive antiviral immunity
Bettina Langhans, Hans Dieter Nischalke, Philipp Lutz, Benjamin Krämer, Christian P. Strassburg, Jacob Nattermann, Ulrich Spengler
University of Bonn

1009 Hepatitis C Genotype 4r Resistance Associated Polymorphisms: The Achilles heel of the NS5A Inhibitors?
Philippe Halfon1, Sofiane Mohamed3, Guillaume Penaranda3, Carine Nicolas2, Armando Abergel2
1Europeen Hospital, 2CHU Estaing, 3Alphabio Laboratory

1010 LECT2 specifically induced by IL28B enhances the innate immune response and HCV replication
Takayoshi Shirasaki1, 2, Masao Honda1, 2, Tetsuro Shimakami1, Kazuhisa Murai1, 2, Hikari Okada1, Hirofumi Misu1, Toshinari Takamura1, Stanley M. Lemon 3, Seishi Murakami1, Shuichi Kaneko1
1Kanazawa University Graduate School of Medical Science, 2 Kanazawa University Graduate School of Medical Science, 3University of North Carolina

1011 MicroRNA 17 Host Gene Protein and its targets PTEN and NF-?B in Chronic Hepatitis C Virus Infection: Relation to Hepatic inflammation, fibrosis and steatosis.
Hoda El Aggan1, Sahah A. Mahmoud2, Nevine M. El Deeb3, Ehab M. Hassona1, Sally El Demiry1
1Faculty of Medicine, University of Alexandria, 2Faculty of Medicine, University of Alexandria, 3Faculty of Medicine, University of Alexandria

1012 The FGL2:Fc?RIIB Immunosuppressive Pathway Inhibits HCV Specific Antiviral T Cell Responses in Chronic Infection
Ramzi Khattar, Kaveh Farrokhi, Hassan Sadozai, Vanessa Rojas Luengas, Gary Levy, Nazia Selzner
University Health Network

1013 Novel effect of NS5A inhibition on Augmentation of HCV specific immunity and SVR
Shikha Shrivastava1, Anu Osinusi2, Shyam Kottilil1
1Institute of Human Virology, University of Maryland, Baltimore, 2Gilead Sciences Inc,

1014 Differential microRNA expression in the liver during the advanced stage of chronic hepatitis C
Rika Horii, Masao Honda, Takayoshi Shirasaki, Hikari Okada, Mikiko Nakamura, Shuichi Kaneko
Kanazawa University Graduate School of Medicine

1015 The tumor suppressor IQGAP2 plays an essential role in antiviral activity of Interferon alpha against HCV through the NF-?B pathway.
Cynthia Brisac, Shadi Salloum, Victor Yang, Stephane Chevaliez, Esperance A. Schaefer, Jian Hong, Charles Carlton-Smith, Nadia Alatrakchi, Anna Lidofsky, Dahlene Fusco, Xiao Liu, Dachuan Cai, Lee F. Peng, Wenyu Lin, Raymond T. Chung
MGH

1016 Single-strand RNA-induced monocyte differentiation generates pro-fibrogenic M2 macrophages in chronic hepatitis C Virus infection
Banishree Saha, Karen Kodys, Gyongyi Szabo
UMASS Med School

1017 Elucidating Mechanisms Underlying Development of Liver Disease in HIV/HCV Coinfection
Jinhee Hyun3, Masato Yoneda1, Eugene R. Schiff1, Emmanuel Thomas1, 2
1University of Miami Miller School of Medicine, 2Sylvester Comprehensive Cancer Center, 3University of Miami School of Medicine

1018 Expression of IFN?4 in liver is closely associated with non-response to antiviral therapy through the regulation of basal expression of ISGs in chronic hepatitis C patients but not in hepatitis B patients.
Miyako Murakawa1, 3, Yasuhiro Asahina1, Fukiko Kawai-Kitahata1, Hiroko Nagata1, Syun Kaneko1, Sayuri Nitta1, Takako Watanabe1, Yasuhiro Itsui1, 3, Mina Nakagawa1, Sei Kakinuma 1, Sayuki Iijima2, Yasuhito Tanaka2, Mamoru Watanabe1, Yujiro Tanaka3, 1
1Tokyo Medical and Dental University, 2Nagoya City University, 3Tokyo Medical and Dental University

1019 Lipid-Free apolipoprotein E signaling induces an ABCG1 driven cholesterol efflux that markedly decreases HCV replication
Emilie Crouchet1, 2, Mathieu Lefèvre1, 3, Eloi R. Verrier1, 2, Thomas F. Baumert1, 2, Catherine Schuster1, 2
1Inserm, 2Université de Strasbourg, 3CNRS UPR 9002

1020 Substitution in amino acid 70 of hepatitis C virus core protein changes the adipokine profile via toll-like receptor 2/4 signaling
Masahiko Tameda, Kazushi Sugimoto, Yoshiyuki Takei
Mie University

1021 Variability of the hepatitis delta virus quasispecies in chronic infection is high and similar to that of the hepatitis C virus quasispecies
Maria Homs1, 2, Josep Gregori3, Hadi Karimzadeh4, Damir G. Cehic3, Maria Blasi1, 2, Rosario Casillas3, David Tabernero1, 2, Josep Quer1, 3, Michael Roggendorf4, Mar Riveiro-Barciela5, Rafael Esteban1, 5, Francisco Rodriguez-Frias1, 2, Maria Buti1, 5
1CIBERehd, 2Hospital Vall d'Hebron, 3Research Institute Vall d'Hebron, 4Technische Universität München, 5Hospital Vall d'Hebron

1022 A methyl donor, S-adenosylmethionine (SAM) simultaneously decreases HCV expression, enhances glutathione biosynthesis, modulates antioxidant enzyme systems and switches mat2/mat1 turnover in hepatoma cells expressing HCV proteins
Sonia A. Lozano-Sepulveda, Eduardo Bautista-Osorio, Paula Cordero, Linda E. Muñoz, Ana Maria G. Rivas-Estilla
Universidad Autónoma de Nuevo León

1023 Pre-treatment levels of miR-29b are associated with response to treatment and stage of fibrosis in patients with chronic hepatitis C [CHC]
Hossein Sendi1, Marjan Mehrab-Mohseni2, Mark W. Russo2, Philippe J. Zamor2, Paul A. Schmeltzer2, Nury Steuerwald2, Judith Parsons2, Mark G. Clemens4, Keith Kaplan3, W. Carl Jacobs3, William A. Ahrens3, Herbert L. Bonkovsky1
1Wake Forest Baptist Medical Center, 2Carolinas Medical Center, 3Carolinas Medical Center, 4UNC Charlotte

1025 The roles of unphosphorylated-ISGF3 in HCV infection and interferon responsiveness
Pil Soo Sung1, HyeonJoo Cheon2, 3, Do Youn Park4, Hyung-Il Seo4, Su-Hyung Park1, Seung Kew Yoon5, George R. Stark2, 3, Eui-Cheol Shin1
1KAIST, 2Lerner Research Institute, 3Cleveland clinic, 4Pusan National University, 5The Catholic University of Korea

1026 The expression of Immune-miRs could contribute to the immunopathogenesis of HCV and be modified by 1(OH) vitamin D3 supplementation
Yasuteru Kondo1, Tatsuki Morosawa1, Masashi Ninomiya1, Yasuyuki Fujisaka1, Yasuhito Tanaka2, Takayuki Kogure1, Jun Inoue1, Teruyuki Umetsu1, Tooru Shimosegawa1
1Tohoku University Hospital, 2Nagoya City University

1027 Serial change of resistant associated variants during early phase of NS3/4A triple therapy and the final virological outcome: analyses by ultra-deep sequencing technology
Takako Watanabe1, Yasuhiro Asahina1, Mina Nakagawa1, Sei Kakinuma1, Yasuhiro Itsui1, Hiroko Nagata1, Miyako Murakawa1, Fukiko Kawai-Kitahata1, Mika Miura2, Shinya Maekawa1, Nobuyuki Enomoto1, Mamoru Watanabe1
1Tokyo medical dental univ, 2University of Yamanashi

1028 Analysis of genetic variation in the Aurora B kinase coding region of patients with chronic hepatitis C.
Irene Francisco-Recuero1, Ana Isabel Gil1, Antonio Madejon1, Aurora Sánchez-Pacheco4, Miriam Romero1, Araceli G. Sánchez1, Celia Perales2, 3, Javier García-Samaniego1
1CIBERehd. Hepatology Unit. Hospital Carlos III, 2CIBERehd/Centro de Biología Molecular "Severo Ochoa" (CBM-UAM), 3Liver Unit, Internal Medicine, Laboratory of Malalties Hepátiques, Vall dHebron (VHIR-HUVH), Universitat Autónoma de Barcelona, 4Departamento de Bioquímica, Facultad de Medina, Universidad Autónoma de Madrid (UAM)

1029 Transcriptomic analysis of CD4+CD25+CD127dim/- T regulatory in HCV-mono-infection and HCV/HIV-Co-infection
Shikha Shrivastava1, Eric G. Meissner2, Dan Sturdevant3, Bhawna Poonia1, Shyam Kottilil1
1Institute of Human Virology, University of Maryland, Baltimore, 2MUSC, 3NIAID, NIH

1030 The effect of sofosbuvir-based antiviral therapy on CD4+ T-cell counts in hepatitis C virus monoinfected cancer patients.
Andreas Kyvernitakis2, Parag Mahale2, Jagannadha Sastry1, Harrys A. Torres2
1The University of Texas MD Anderson Cancer Center, 2The University of Texas MD Anderson Cancer Center

1031 Persistence of HCV-specific Immune Complexes in Patients Who Cleared HCV Infection Spontaneously or Achieved Sustained Virologic Response to Antiviral Therapy
Ke-Qin Hu, Wei Cui
Division of GI/Hepatology, University of California, Irvine, School of Medicine

1032 Very low prevalence of Hepatitis C in HIV negative men who have sex with men in Tel Aviv: A prospective cohort analysis
Ella Veitsman1, 7, Adir Yanko2, Yuval Livnat3, 4, Margalit Lorber5, 6, Ziv Ben Ari1, 7
1sheba medical center, 2Israel LGBT organization, Levinsky clinic, 3Israel AIDS Task force, 4Tel Aviv University, 5Immunology Department, Rambam Health Care Campus, 6The Ruth and Bruce Rappaport School of medicine, Israel institute of Technology, 7Sackler School of medicine, Tel Aviv University

1033 The Antibody response to hepatitis B virus vaccination is not influenced by the hepatitis C virus viral load in patients with chronic hepatitis C
Roseane P. Medeiros, Marta Lopes, Daniel F. Mazo, Claudia P. Oliveira, Patricia M. Zitteli, João Renato R. Pinho, Flair J. Carrilho, Mario G. Pessoa
University of Sao Paulo School of Medicine

Hepatitis C: Therapeutics (Approved Agents)

1034 Approved All-oral Sofosbuvir Regimens are Safe and Highly Effective in Patients with Hereditary Bleeding Disorders
Christopher Walsh1, Kimberly Workowski2, Norah Terrault3, Paul Sax4, Alice Cohen5, Christopher L. Bowlus6, Arthur Y. Kim7, Robert H. Hyland8, Jing Wang8, Luisa M. Stamm8, Diana M. Brainard8, John G. McHutchison8, Annette Von Drygalski9, Frank S. Rhame10, Michael W. Fried11, Peter Kouides12, Gayle Balba13, K. Rajender Reddy14
1Mount Sinai Hospital, 2Emory University, 3University of California, San Francisco, 4Brigham and Women's Hospital, 5Newark Beth Israel Center - Barnabas Health, 6University of California, Davis, 7Massachusetts General Hospital, 8Gilead Sciences, Inc, 9University of California, San Diego, 10Abbott NW Infectious Disease Clinic, 11University of North Carolina at Chapel Hill, 12The Mary M Gooley Hemophilia Center, 13Georgetown University Hospital, 14University of Pennsylvania

1035 Sofosbuvir (SOF) and Ledipasvir (LDV) Improves Patient-Reported Outcomes (PROs) in Patients Co-infected with Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)
Zobair M. Younossi1, 2, Maria Stepanova3, Mark S. Sulkowski4, Susanna Naggie5, Linda Henry3, Sharon L. Hunt3
1Inova Fairfax Hospital, 2Inova Health System, 3Center for Outcomes Research in Liver Disease, 4John Hopkins University, 5Duke University Medical Center and Duke Clinical Research Inst

1036 Comparison of 8 vs. 12 weeks treatment durations in HCV-GT1 non-cirrhotic naïve patients receiving direct-acting antivirals with or without ribavirin: a meta-analysis
Vincent Di Martino1, Jean Paul Cervoni1, Carine Richou1, Delphine Weil1, Armand Abergel2, Tarik Asselah3, Thierry Thevenot1
1CHU Jean Minjoz, 2CHU Clermont-Ferrand, 3Hôpital Beaujon

1037 Sofosbuvir and Ledipasvir in attainment of SVR12 in sickle cell disease (SCD) sub-population with chronic hepatitis C (CHC). a single center prospective open label clinical pilot study - SLASH C Trial
Patrick Basu1, 2, Niraj J. Shah3, Nimy John2, M. Aloysius2, Robert Brown4
1Columbia University School of Physicians and Surgeons, 2King’s County Hospital Medical Center, NY, 3James J. Peters VA Medical Center, Icahn School of Medicine at Mount Sinai, NY , 4Weill Cornell Medical College

1038 Multicenter Experience using Sofosbuvir/Ledipasvir with or without Ribavirin to Treat Hepatitis C Genotype 1 Relapsers after Simeprevir and Sofosbuvir Treatment
Surakit Pungpapong1, 2, Michael D. Leise3, Kymberly D. Watt3, Hugo E. Vargas4, Andrew P. Keaveny1, 2, Bashar A. Aqel4
1Mayo Clinic, 2Mayo Clinic, 3Mayo Clinic, 4Mayo Clinic

1039 RUBY-I: Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir +/- Ribavirin in Non-cirrhotic HCV Genotype 1-infected Patients With Severe Renal Impairment or End-Stage Renal Disease
Paul J. Pockros1, K. Rajender Reddy2, Parvez S. Mantry3, Eric Cohen4, Michael Bennett5, Mark S. Sulkowski6, David Bernstein7, Thomas Podsadecki4, Daniel E. Cohen4, Nancy Shulman4, Deli Wang4, Amit Khatri4, Manal Abunimeh4, Eric Lawitz8
1Scripps Clinic, 2University of Pennsylvania, 3The Liver Institute at Methodist Dallas, 4AbbVie Inc., 5Medical Associates Research Group, 6Johns Hopkins University, 7North Shore University Hospital, 8The Texas Liver Institute, University of Texas Health Science Center

1040 Impact of baseline albumin levels in a Phase 3 study (OPTIMIST-2) of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis
Eric Lawitz1, Eric M. Yoshida2, Reem H. Ghalib3, Marcelo Kugelmas4, Ronald Kalmeijer5, Katrien Janssen6, Oliver Lenz6, Bart Fevery6, Guy De La Rosa7, Rekha Sinha5, James Witek5
1University of Texas Health Science Center, 2University of British Columbia, 3Texas Clinical Research Institute, 4South Denver Gastroenterology, PC, 5Janssen Research & Development, LLC, 6Janssen Infectious Diseases BVBA, 7Janssen Global Services, LLC

1041 Twelve Weeks of Sofosbuvir plus Ribavirin is Effective for Treatment of Genotype 2 HCV in Difficult to Treat U.S. Veterans with Cirrhosis – Results of the VALOR-HCV Study
Samuel B. Ho1, Alexander Monto2, Adam Peyton3, David E. Kaplan4, Sean Byrne5, Scott Moon5, Yanni Zhu5, Star Seyedkazemi5, Lorenzo Rossaro5, Diana M. Brainard5, William Guyer5, Obaid S. Shaikh6, Michael Fuchs7, Timothy R. Morgan8
1VA San Diego Healthcare System, 2UCSF/SFVAMC, 3Miami VA Healthcare System, 4Philadelphia VA Medical Center, 5Gilead Sciences, 6VA Pittsburgh Healthcare System, 7Richmond VA Medical Center, 8VA Long Beach Healthcare System

1042 Awareness Of Hepatitis C Status In HCV-Infected US Adults, 2003-2012Awareness Of Hepatitis C Status In HCV-Infected US Adults, 2003-2012
Mark T. Linthicum2, Timothy R. Juday1, Gigi Moreno2, Yuri Sanchez1, Darius Lakdawalla2, Steven Marx1, Brian R. Edlin3
1AbbVie, 2Precision Health Economics, 3SUNY Downstate Medical Center

1043 Sustained Virologic Response to Direct Acting Antiviral Therapy for Chronic Hepatitis C Infection is Associated with Improvement of Components of the Metabolic Syndrome
Mark Pedersen1, David W. Backstedt2, Bobby Kakati2, Myunghan Choi3, Anil B. Seetharam4, 5
1Banner University Medical Center, 2Banner University Medical Center, 3Arizona State University College of Nursing and Health Care Innovation , 4Banner Transplant and Advanced Liver Disease, 5University of Arizona College of Medicine Phoenix

1044 Global prevalence of pre-existing hepatitis C virus resistant-associated variants to direct-acting antiviral agents (DAA): mining of GenBank HCV genome data
Peng Hu, Zhi-wei Chen, Hu Li, Hong Ren
The Second Affiliated Hospital of Chongqing Medical University

1045 Effect of Different Immunosuppressant Regimens on Viral Kinetics and SVR12 in Liver Transplant Recipients Treated with LDV/SOF in the SOLAR Trials
Tania M. Welzel1, K. Rajender Reddy2, Michael P. Manns3, Steven L. Flamm4, David J. Mutimer5, Edward J. Gane6, Bernard E. Willems7, Christian Trautwein8, Robert H. Hyland9, Sarah Arterburn9, Phillip S. Pang9, John G. McHutchison9, Philip Wong10, Didier Samuel11, Michael R. Charlton12, Xavier Forns13, Gregory T. Everson14, Stefan Zeuzem1, Michael P. Curry15
1Johann Wolfgang Goethe University Medical Center, 2University of Pennsylvania School of Medicine, 3Hannover Medical School, 4Northwestern University Feinberg School of Medicine, 5Queen Elizabeth Hospital and University of Birmingham, 6University of Auckland, 7Centre hospitalier de l’université de Montréal, 8Uniklinik RWTH Aachen, 9Gilead Sciences, Inc, 10McGill University, 11Université Paris-Sud, 12Intermountain Medical Center, 13IDIBAPS and CIBEREHD Hospital Clinic, 14University of Colorado Denver, 15Beth Israel Deaconess Medical Center

1046 Effectiveness of 8 or 12 week LDV/SOF in treatment-naïve patients with non-cirrhotic, genotype 1 Hepatitis C: Real-world experience from the TRIO Network.
Michael P. Curry1, Bruce Bacon2, Steven L. Flamm3, Naoky CS C. Tsai4, Douglas Dieterich5, Scott Milligan6, Kris V. Kowdley7
1Beth Israel Deaconess Medical Center, 2Saint Louis University School of Medicine, 3Northwestern University Feinberg School of Medicine, 4Queens Medical Center, University of Hawaii, 5Icahn School of Medicine at Mount Sinai, 6Trio Health Analytics, 7Liver Care Network, Swedish Medical Center

1047 The effect of interferon-free Asunaprevir/Daclatasvir combination therapy on innate immune responses (NK cell activity and frequency of CD56dim and CD56bright NK cell subset in peripheral blood) in chronic hepatitis C patients
Ikuo Nakamura, Yoshihiro Furuichi, Katsutoshi Sugimoto, Yoshiyuki Kobayashi, Fuminori Moriyasu
Tokyo Medical University

1048 Demographic Predictors of Direct Acting Antiviral Receipt in Individuals with Hepatitis C Virus Infection
Fasiha Kanwal1, Jennifer R. Kramer1, Yumei Cao1, Thom Taylor2, Donna Smith1, Steven Asch2, Hashem B. El-Serag1
1Michael E DeBakey VA and Baylor College of Medicine, 2VA Palo Alto Health Care System

1049 High efficacy of ledipasvir/sofosbuvir with ribavirin in patients with decompensated cirrhosis or liver transplantation and HCV infection: combined efficacy from the SOLAR-1 and SOLAR-2 trials
Edward J. Gane2, Michael P. Manns3, Geoff McCaughan4, Michael P. Curry5, Markus Peck-Radosavljevic6, Hans Van Vlierberghe7, Jill M. Denning1, Sarah Arterburn1, Phillip S. Pang1, Diana M. Brainard1, John G. McHutchison1, Princy N. Kumar8, Eric M. Yoshida9, Massimo Colombo20, Bart van Hoek10, Jean-Francois Dufour11, Charles S. Landis12, Robert Brown13, David J. Mutimer14, Steven L. Flamm15, Michael R. Charlton16, K. Rajender Reddy17, Didier Samuel18, Gregory T. Everson21, Xavier Forns19
1Gilead Sciences, 2University of Auckland, 3Hannover Medical School, 4Royal Prince Alfred Hospital, University of Sydney, 5Beth Israel Deaconess Medical Center, 6Medical University of Vienna, 7Dienst Hepatologie en Gastroenterologie, 8Georgetown University, 9University of Milan, 10Leiden University, 11University of Berne, 12University of Washington/Harborview Medical Center, 13Weill Cornell Medical College, 14QE Hospital and University of Birmingham, 15Northwestern Feinberg School of Medicine, 16Intermountain Medical Center, 17University of Pennsylvania School of Medicine, 18Université Paris-Sud, 19Liver Unit, IDIBAPS, CIBEREHD Hospital Clinic, 20University of Milan, 21University of Colorado Denver

1050 Adherence and Discontinuation Rates of Sofosbuvir-Based Regimens: Modeling Real World Experience in a Large Managed Care Organization
Pravin S. Kamble2, David R. Walker1, Steven Marx1, Ray Harvey2, Claudia L. Uribe2, Suvapun Bunniran2, Jenna Collins2
1Abbvie, 2Comprehensive Health Insights

1051 Turquoise-III: 12-Week Ribavirin-Free Regimen Of Ombitasvir/Paritaprevir/R And Dasabuvir For Patients With HCV Genotype 1B And Cirrhosis
Fred Poordad1, Jordan J. Feld2, Roger Trinh3, Yves J. Horsmans4, Magdy Elkhashab5, Stefan Bourgeois6, Samuel S. Lee7, Christophe Moreno8, David Bernstein9, Ziad Younes10, Akshanth R. Polepally3, Kevin Howieson3, Bo Fu3, Greg Ball3, Nancy Shulman3, Edward Tam11
1The Texas Liver Institute/University of Texas Health Science Center, 2Toronto Centre for Liver Disease, University of Toronto, 3AbbVie, Inc., 4Université Catholique de Louvain, 5Toronto Liver Centre, 6ZNA Stuivenberg, 7University of Calgary, 8CUB Hôpital Erasme, Université Libre de Bruxelles, 9North Shore University Hospital, 10GastroOne, 11LAIR Centre

1052 High prevalence of co-morbidities and complex polypharmacy with drug-drug interaction (DDI) potential in patients with chronic Hepatitis C (CHC). Consistent findings from large primary care databases in the United Kingdom, Germany, and France
Fiona Marra1, 10, Werner Leber3, Stephen T. Barclay2, Stefan Christensen5, Denis Ouzan7, Valerie Oules8, Peter S. McMahon4, Karel Kostev6, Xavier Ansolabehere9
1NHS Greater Glasgow and Clyde, 2Walton Liver Clinic, 3Centre for Primary Care and Public Health, 4IMS Health UK, 5Center for Interdisciplinary Medicine (CIM) Infectious Diseases, 6IMS Health Germany, 7Institut Arnault Tzanck, 8Hôpital Saint Joseph, 9IMS Health France, 10University of Liverpool

1053 Real-Word Effectiveness of Ledipasvir (LDV)/Sofosbuvir (SOF)-Based Therapy for Hepatitis C Virus (HCV): Preliminary Analysis in a Large Integrated Health Care System.
Jennifer B. Lai2, 1, David J. Witt2
1Kaiser Permanente, 2Kaiser Permanente Medical Center

1054 Hepatitis C Cure Could Avoid Liver Transplant In Some Cirrhotic Patients On Dialysis Listed for Simultaneous Liver Kidney Transplantation
Frank Czul, David Roth, Rodrigo M. Vianna, Cynthia Levy, Paul Martin, Kalyan R. Bhamidimarri
University of Miami-Miller School of Medicine

1055 Association of polymorphisms in the hepatitis C virus NS5B polymerase with reduced virologic response to sofosbuvir-based treatment
Johannes Vermehren1, Simone Susser1, Christoph P. Berg2, Martin W. Welker1, Bernd Kronenberger1, Caterina Berkowski1, Stefan Zeuzem1, Christoph Sarrazin1
1Klinikum der J. W. Goethe-Universität, 2Universitätsklinikum Tübingen

1056 Hepatocellular carcinoma development in hepatitis C virus patients who achieved sustained viral response by interferon therapy: a large scale, long-term cohort study
Yuko Nagaoki, Hiroshi Aikata, Hiromi Kan, Hatsue Fujino, Tomoki Kobayashi, Takayuki Fukuhara, Keiichi Masaki, Takashi Nakahara, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatu, Michio Imamura, Yoshiiku Kawakami, Hidenori Ochi, Kazuaki Chayama
Hiroshima University

1057 Safety and Efficacy of Sofosbuvir and Ribavirin for the Treatment of HCV Genotype 2 and 3: Results of the HCV-TARGET Study
Tania M. Welzel1, David R. Nelson2, Giuseppe Morelli2, Adrian M. Di Bisceglie3, K. Rajender Reddy4, Alexander Kuo5, Joseph K. Lim6, Jama M. Darling7, Paul J. Pockros8, Joseph S. Galati9, Lynn M. Frazier10, Saleh Alqahtani11, Mark S. Sulkowski11, Michael W. Fried7, Stefan Zeuzem1
1JW Goethe University Hospital, 2University of Florida, 3Saint Louis University School of Medicine, 4University of Pennsylvania Hospital, 5University of California, San Diego, 6Yale University School of Medicine, 7University of North Carolina, 8Scripps Clinic, 9Research Specialists of Texas, 10Liver Wellness Center, 11Johns Hopkins

1058 Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of chronic HCV in patients coinfected with HIV: Interim results of a multicenter compassionate use program
Jürgen K. Rockstroh1, Tania M. Welzel2, Patrick Ingiliz3, Joerg Petersen4, Marc van der Valk5, Kerstin Herzer6, Peter Ferenci7, Michael Gschwantler8, Markus Cornberg9, Thomas Berg10, Ulrich Spengler11, Ola Weiland12, Hartwig Klinker13, Markus Peck-Radosavljevic7, Yue Zhao14, Maria Jesus Jimenez Exposito15, Stefan Zeuzem2
1Universitätsklinikum Bonn, 2Universitätsklinikum der Johann Wolfgang Goethe Universität, 3Praxis Driesener Strasse, 4IFI Institut für Interdisziplinäre Medizin, 5University of Amsterdam, 6Universitätsklinikum Essen (AöR), 7Medizinische Universität Wien, 8Wilhelminenspital, 9Medizinische Hochschule Hannover, 10Universitätsklinikum Leipzig, 11Universitätsklinikum Bonn, 12Karolinska University Hospital Huddinge, 13Universitätsklinikum Würzburg, 14Bristol-Myers Squibb, 15Bristol-Myers Squibb

1059 The Significance of Immunoallegic Adverse Events Developing during Dual Oral Therapy with Daclatasvir Plus Asunaprevir in Patients with Genotype 1b HCV Infection
Yohei Fujii, Yoshihito Uchida, Kayoko Sugawara, Mie Inao, Nobuaki Nakayama, Satoshi Mochida
SAITAMA MEDICAL UNIVERSITY

1060 Sofosbuvir-based treatments for patients with hepatitis C virus (HCV) mono-infection and human immunodeficiency virus (HIV)-HCV co-infection with genotype 3 in clinical practice – Results from the GErman hepatitis C COhort (GECCO)
Patrick Ingiliz1, Knud Schewe2, Thomas Lutz3, Christoph Boesecke4, Stefan Mauss5, Heiner W. Busch6, Axel Baumgarten1, Marcel Schuetze1, Guenther Schmutz5, Stefan Christensen6, Karl-Georg Simon7, Dietrich Hueppe8
1Medical Center for Infectious Diseases, 2ICH, 3Infektiologikum, 4University of Bonn, 5Center for HIV and Hepatogastroenterology , 6Center for Interdisciplinary Medicine, 7Practice for Gastroenterology Leverkusen,, 8Center for Gastroenterology

1061 A comparison of direct sequencing and PCR- invader assay for the detection of NS5A Y93H mutation and response to daclatasvir and asunaprevir therapy in patients with hepatitis C virus genotype 1b.
Kazuhiko Hayashi, Masatoshi Ishigami, Yoji Ishizu, Teiji Kuzuya, Takashi Honda, Yoshiki Hirooka, Hidemi Goto
Nagoya University

1062 Prediction for poor virological response and clinical utility of resistance-associated variant detection in combination therapy with direct-acting antivirals for HCV genotype 1
Norio Akuta, Fumitaka Suzuki, Yusuke Kawamura, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Satoshi Saitoh, Mariko Kobayashi, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada
Toranomon Hospital

1063 Adherence to All-Oral HCV Treatment in Patients with Substance and Alcohol Use Disorders
Donna M. Evon, Angela Edwards, Becky Straub, Christopher B. Hurt, Harsha Thirumurthy, David Wohl
University of North Carolina

1064 Frequent Emergences of Rare RAVs Showing Extreme Resistance to NS5A Inhibitors during Dual Oral Threpy with Daclatasvir Plus Asunaprevir in Patients Previously Receiving Triple Therapy with Simeprevir
Yoshihito Uchida, Nobuaki Nakayama, Jun-ichi Kouyama, Kayoko Naiki, Hayato Uemura, Kayoko Sugawara, Mie Inao, Satoshi Mochida
Saitama Medical University

1065 Preliminary Safety and Efficacy Results from TOPAZ-II: A Phase 3b Study Evaluating Long-Term Clinical Outcomes in HCV Genotype 1-infected Patients Receiving Ombitasvir/Paritaprevir/r and Dasabuvir +/-Ribavirin
Nancy Reau1, Fred Poordad2, Jeffrey Enejosa3, Asma Siddique4, Humberto I. Aguilar5, Jacob P. Lalezari6, Franco Felizarta7, Peter J. Ruane8, Peter Varunok9, David Bernstein10, Douglas Dieterich11, Gregory T. Everson12, Yiran Hu3, Greg Ball3, Tami Pilot-Matias3, Nancy Shulman3, Sanjeev Arora13
1University of Chicago Medical Center, 2The Texas Liver Institute/University of Texas Health Science Center, 3AbbVie Inc., 4Virginia Mason Medical Center, 5Louisiana Research Center, LLC, 6Quest Clinical Research, 7Private practice, 8Ruane Medical and Liver Health Institute, 9Premier Medical Group of the Hudson Valley, PC, 10North Shore University Hospital, 11Mount Sinai School of Medicine, Icahn School of Medicine, 12University of Colorado Denver School of Medicine, 13University of New Mexico

1066 Effect of Renal Function on the Pharmacokinetics of Ombitasvir/ Paritaprevir/Ritonavir, Dasabuvir and Ribavirin in Over 2000 Subjects with HCV GT1 Infection
Akshanth R. Polepally1, Prajakta Badri1, Doerthe Eckert2, Sven Mensing2, Rajeev Menon1
1AbbVie Inc.,, 2AbbVie Deutschland GmbH & Co.KG

1067 Clinical Management of Ribavirin Dosing in HCV-Infected Patients with Anemia-Related Events Receiving Ombitasvir/Paritaprevir/r and Dasabuvir
Jordan J. Feld2, David Bernstein3, Ziad Younes4, Hans Van Vlierberghe5, Greg Ball1, Ronald D'Amico1, Peter Ferenci6
1AbbVie, Inc., 2Toronto Centre for Liver Disease, University of Toronto, 3North Shore University Hospital, 4GastroOne, 5Ghent University Hospital, 6Medical University of Vienna

1068 The healthcare cost burden of HCV-infected baby boomers in the US
Ron Brookmeyer2, Timothy R. Juday1, Darius Lakdawalla3, 4, Steven Marx1, Gigi Moreno4, Yuri Sanchez1
1AbbVie, 2David Geffen School of Medicine at UCLA, 3USC, 4Precision Health Economics

1069 An Actuarial View of the Aging Hepatitis C Virus (HCV) Epidemic
Gabriela Dieguez2, Bruce Pyenson2, Ryan Cannon2, Steven Marx1, Yuri Sanchez1, Timothy R. Juday1
1AbbVie, 2Milliman

1070 Early and persistent increase of serum cholesterol and low-density lipoprotein in chronic hepatitis C patients during IFN-free treatment
Clarissa Freissmuth, Albert Stättermayer, Karin Kozbial, Sandra Beinhardt, Rafael Stern, Michael Eder, Petra E. Steindl-Munda, Michael Trauner , Peter Ferenci, Harald Hofer
Medical University of Vienna

1072 Simeprevir plus sofosbuvir for the treatment of hepatitis C genotype 1 and 4 in a French multicenter cohort in real life: ReaL-SimSof study
Eric Nguyen-Khac1, Alexandre Pariente3, Bruno Lesgourgues2, Remy Andre4, Brigitte Bernard-Chabert1, Thong Dao1, Isabelle Rosa1, Alexandre Pariente3, Patrick Delasalle1, Damien Lucidarme1, Christophe Renou1, Xavier Causse1, Christine Silvain1, Gilles Macaigne1, Thierry Fontanges 1, Matthieu Schnee1, Hortensia Lison2, Christophe Pilette1, Jean Pierre Arput1, Frédéric Heluwaert1, Francois Bourhis1, Alexandra Heurgué-Berlot1
1Amiens University Hospital, 2Montfermeil general hospital, 3Pau general hospital, 4Perpignan CH

1073 Safety And Efficacy Of The Combination Simeprevir-Sofosbuvir In HCV Genotype 1- And 4-Mono-Infected Patients From The French Observational Cohort Anrs Co22 Hepather*.
ANRS/AFEF HEPATHER CO22 study group
National Agency for Research on AIDS and Viral Hepatitis

1074 Sofosbuvir and Ledipasvir versus Sofosbuvir and Simeprevir combination therapy in the management of acute hepatitis C: A randomized open label prospective clinical pilot study. SLAM C study. Interim data.
Patrick Basu1, 2, Niraj J. Shah3, Nimy John2, M. Aloysius2, Robert Brown4
1Columbia University School of Physicians and Surgeons, 2King’s County Hospital Medical Center, NY, 3James J. Peters VA Medical Center, Icahn School of Medicine at Mount Sinai, NY , 4Weill Cornell Medical College

1075 Sofosbuvir, Ledipasvir in IBD treated patients with advanced biologics including Ribavirin eradicating Chronic Hepatitis C: SOLATAIRE C Trial. A multi-center clinical prospective pilot study
Patrick Basu1, 2, Niraj J. Shah3, Nimy John2, M. Aloysius2, Robert Brown4
1Columbia University School of Physicians and Surgeons, 2King’s County Hospital Medical Center, NY, 3James J. Peters VA Medical Center, Icahn School of Medicine at Mount Sinai, NY , 4Weill Cornell Medical College

1076 Sofosbuvir plus Ribavirin in the Treatment of Egyptian Patients with Chronic Genotype 4 HCV Infection
Wahid H. Doss1, Peter J. Ruane2, Gamal Shiha3, Dani Ain2, Reham Soliman3, Marwa Khairy4, Mohamad Hassany1, Joseph Riad2, Waleed Samir3, Rabab F. Omar4, Radi Hammad1, Raymond Meshrekey2, Mostafa Gamil4, Deyuan Jiang5, Benedetta Massetto5, Steven J. Knox5, Kathryn Kersey5, John G. McHutchison5, Gamal E. Esmat4
1National Hepatology and Tropical Medicine Research Institute, 2Ruane Medical and Liver Health Institute, 3Egyptian Liver Research Institute and Hospital, 4University of Cairo, 5Gilead Sciences, Inc.

1077 The TOSCAR Study: Sofosbuvir and Daclatasvir Therapy for Decompensated HCV Cirrhosis with MELD scores = 15: What is the point of no return?
Geoff McCaughan1, Stuart K. Roberts2, Simone I. Strasser1, Paul Gow3, Alan J. Wigg4, Caroline Tallis5, Gary P. Jeffrey6, Jacob George7, Alex J. Thompson8, Susan Mason9, Joanne Mitchell2, Peter W. Angus3
1Royal Prince Alfred Hospital/Univeristy of Sydney, 2Alfred Health, 3VLTU, 4SALTU, 5QLTU, 6WALTU, 7Westmead Hospital, 8St Vincent's Hospital, 9Royal Prince Alfred Hospital

1078 (THE SOFGER TRIAL) Sofosbuvir-based treatment under real life conditions in Germany
Peter Buggisch1, Christoph Sarrazin2, Stefan Mauss3, Holger Hinrichsen4, Karl-Georg Simon5, Dietrich Hueppe6, Johannes Vermehren2, Barbara Seegers4, Joerg Petersen1
1IFI, Liver Center Hamburg, 2Johann Wolfgang Goethe University Hospital, 3Zentrum für HIV und Hepatogastroenterologie, 4Gastroenterolgische Praxis , 5Gastroenterologisch-hepatologisches Zentrum , 6Gastroenterologische Gemeinschaftspraxis

1079 Quality-Adjusted Cost of Care for Treatment Naive (TN) Patients with Genotype 1 (GT1) Chronic Hepatitis C (CH-C): An Assessment of Innovation Cost of Drug Regimens versus the Value of Health Gains to the Society
Zobair M. Younossi1, 2, Haesuk Park3, Douglas Dieterich4, Sammy Saab5, Aijaz Ahmed6, Stuart C. Gordon7
1Inova Fairfax Hospital, 2Inova Health System, 3University of Florida, 4Mount Sinai Medical Center, 5University of California Los Angeles, 6Stanford University, 7Henry Ford Hospital

1080 Asian Patients with Chronic Genotype 2 HCV Infection Achieve 98% Sustained Virologic Response Following 12 Week administration of Sofosbuvir in Combination with Ribavirin: Integrated analysis of Phase 3 Multicenter Studies
Masao Omata1, Young-Suk Lim2, Wan-Long Chuang3, Jia-Horng Kao4, Bing Gao5, Shampa De-Oertel5, Jenny C. Yang5, Hongmei Mo5, Diana M. Brainard5, Steven J. Knox5, John G. McHutchison5, Masashi Mizokami6, Kwang-Hyub Han7
1Yamanashi Prefectural Hospital Organization, 2Asan Medical Center, University of Ulsan College of Medicine, 3Kaohsiung Medical University, 4National Taiwan University College of Medicine, 5Gilead Sciences, Inc, 6National Center for Global Health and Medicine, 7Yonsei University College of Medicine

1081 Sofosbuvir and ledipasvir for 8 weeks in patients with hepatitis C virus (HCV) mono-infection and human immunodeficiency virus (HIV)-HCV co-infection with genotype 1 and 4 in clinical practice – Results from the GErman hepatitis C COhort (GECCO)
Stefan Christensen1, Stefan Mauss2, Dietrich Hueppe3, Knud Schewe4, Thomas Lutz5, Jürgen K. Rockstroh6, Marcel Schuetze7, Guenther Schmutz2, Karl-Georg Simon8, Heiner W. Busch1, Patrick Ingiliz7, Axel Baumgarten7
1Center for interdisciplinary Medicine (CIM), 2Center for HIV and Hepatogastroenterology, 3Practice for Gastroenterology, 4Infektionsmedizinisches Centrum Hamburg, 5Infektiologikum, 6University of Bonn, 7Medizinisches Infektiologie Zentrum Berlin, 8Practice for Gastroenterology Leverkusen

1082 Hepatitis C virus NS5A L31V plus Y93H variants emerging after treatment failure with daclatasvir/asunaprevir are resistant to ledipasvir and sofosbuvir-like nucleotide polymerase inhibitor GS-558093 in human hepatocyte chimeric mice
Yugo Kai, Hayato Hikita, Tomohide Tatsumi, Kazuhiro Murai, Yuto Shiode, Yasutoshi Nozaki, Yuki Makino, Tasuku Nakabori, Yoshinobu Saito, Naoki Morishita, Satoshi Tanaka, Ryotaro Sakamori, Naoki Hiramatsu, Tetsuo Takehara
Osaka University Graduate School of Medicine

1083 Sofosbuvir and Ribavirin for Six Weeks Is Not Effective Among People with Acute and Recently Acquired HCV Infection: The DARE-C II Study
Marianne Martinello1, Edward J. Gane2, Margaret Hellard3, Joe Sasadeusz4, David Shaw5, Kathy Petoumenos1, Tanya L. Applegate1, Jason Grebely1, Laurence Maire1, Philippa Marks1, David Cooper1, Gregory Dore1, Gail Matthews1
1UNSW Australia, 2Auckland Hospital, 3Burnet Institute, 4Royal Melbourne Hospital, 5Royal Adelaide Hospital

1084 Ombitasvir/Paritaprevir/r and Dasabuvir with or without Ribavirin for HCV Patients with Post-Transplant Recurrence
Parvez S. Mantry1, Robert S. Brown2, Jeffrey Enejosa3, Marina Berenguer4, Paul Y. Kwo5, Kosh Agarwal6, Kimberly Ann Brown7, Norah Terrault8, Jacqueline G. O'Leary9, Michael P. Manns10, Geoff McCaughan11, Didier Samuel12, Prajakta Badri3, Wangang Xie3, Carolyn Setze3, Tami Pilot-Matias3, Nancy Shulman3, Xavier Forns13
1The Liver Institute at Methodist Dallas, 2Columbia University Medical Center, Center for Liver Disease and Transplantation, 3AbbVie, Inc., 4La Fe University Hospital and CIBERehd, 5Indiana University , 6Institute of Liver Studies, Kings College Hospital, 7Henry Ford Health System, 8University of California San Francisco, 9Baylor University, 10Medizinische Hochschule Hannover Klinik für Gastroenterologie, Hepatologie und Endokrinologie, 11AW Morrow Gastroenterology and Liver Centre Royal Prince Alfred Hospital, 12Hôpital Paul Brousse Centre Hépato-Biliaire, 13Liver Unit, Hospital Clinic, IDIBAPS, CIBEREHD

1085 Utilizing claims data to understand the relationships between diagnosing, prescribing, and dispensing patterns for HCV patients in the pre and post sofosbivir eras
Michel F. Denarie
IMS Health

1086 Long-Term Efficacy of Ombitasvir/Paritaprevir/r and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Patients With or Without Cirrhosis
Stefan Zeuzem2, Ira M. Jacobson3, Jordan J. Feld4, Heiner Wedemeyer5, Xavier Forns6, Pietro Andreone7, Massimo Colombo8, David Bernstein9, Fred Poordad10, Christophe Hezode11, Thomas Podsadecki1, Wangang Xie1, Tami Pilot-Matias1, Regis A. Vilchez1, John M. Vierling12
1AbbVie, 2J.W. Goethe University, 3Weill Cornell Medical College, 4Toronto Centre for Liver Disease, University of Toronto, 5Medizinische Hochschule Hannover, 6Liver Unit, Hospital Clinic, IDIBAPS and CIBEREHD, 7University of Bologna, 8Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, 9North Shore University Hospital, 10The Texas Liver Institute/University of Texas Health Science Center, 11Henri Mondor University Hospital, AP-HP, Universite Paris-Est, 12Baylor College of Medicine, St. Luke’s Advanced Liver Therapies

1087 Lifetime risks of liver morbidity and mortality in patients with chronic genotype (GT) 1 hepatitis C virus (HCV) and HIV coinfection treated with 3D±R (ombitasvir/ paritaprevir/ ritonavir, dasabuvir ± ribavirin) vs other standards of care in the US
Sammy Saab2, Suchin Virabhak3, Scott J. Johnson3, Hélène Parisé3, Yuri Sanchez1, Alice Wang1, Timothy R. Juday1
1AbbVie, 2Pfleger Liver Institute, UCLA, 3Medicus Economics Inc.

1088 Effect of Chronic Kidney Disease on the Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir in Subjects with HCV Genotype 1 Infection
Diana L. Shuster, Rajeev Menon, Daniel E. Cohen, Amit Khatri
AbbVie

1089 Health Outcomes and Cost Effectiveness of Treating Chronic Hepatitis C with the Abbvie 3D Regimen in Italy
Felicitas Kuehne1, Gaby Sroczynski1, Annette Conrads-Frank1, Jennifer C. Samp3, Derek A. Misurski3, Leonardo Perrone2, Alfredo Alberti4, Uwe Siebert1
1University for Health Sciences, Medical Informatics and Technology, 2Abbvie Italy, 3Abbvie Global, 4University of Padova

1090 Sofosbuvir in the Treatment of Acute HCV Infection in HIV-infected Men
Daniel S. Fierer1, Zachary Barbati1, Douglas Dieterich2, Andrew L. Foster1, 3, Tristan Morey1, 3, Samuel Turner1, 3
1Mount Sinai School of Medicine, 2Icahn School of Medicine at Mount Sinai, 3James Cook University

1091 Sofosbuvir in combination with simeprevir +/- ribavirin in genotype 4 hepatitis C patients with advanced fibrosis or cirrhosis: real-life experience from Belgium
Christophe Moreno1, Luc Lasser2, Jean Delwaide3, Peter Starkel4, Wim Laleman5, Philippe Langlet6, Hendrik Reynaert7, Stefan Bourgeois8, Sergio Negrin Dastis9, Thierry Gustot1, Sven M. Francque10, Anja M. Geerts11, Christophe Van Steenkiste12, Chantal de Galocsy13, Collins Assene13, Hans Orlent14, Marcel Nkuize15, Delphine Degré1
1CUB Hôpital Erasme, 2CHU Brugmann, 3CHU Sart Tilman, 4Cliniques Universitaires Saint-Luc, 5University Hospitals Leuven, 6CHIREC, 7UZ Brussel, 8ZNA , 9Grand hôpital de Charleroi, 10University Hospital Antwerp, 11Ghent University Hospital, 12AZ Maria-Middelares, 13Hôpitaux Iris Sud, 14AZ St Jan, 15CHU Saint-Pierre

1092 Efficacy and safety of IFN-free, DAA-based treatment-regimens in patients with HCV-recurrence after Liver Transplantation: Real-life experience from Austria
Sandra Beinhardt1, Ramona Al Zoairy2, Clarissa Freissmuth1, Karin Kozbial1, Stephanie Hametner3, Rafael Stern1, Rudolf E. Stauber5, Andreas Maieron3, Katharina Staufer4, Michael P. Strasser6, Heinz M. Zoller2, Ivo Graziadei7, Wolfgang Vogel8, Markus Peck-Radosavljevic1, Michael Trauner 2, Peter Ferenci1, Harald Hofer1
1Medical University of Vienna, 2Department of Internal Medicine II, 3Hosital Elisabethinen, 4Medical University of Vienna, 5Medical University of Graz, 6Paracelsus Medical University Salzburg, 7LKH Hall/Tirol, 8Medical University of Innsbruck

1093 Potential for drug-drug interactions between antiretrovirals and HCV direct acting antivirals in a large cohort of HIV/HCV coinfected patient
Isabelle Poizot-Martin3, 4, Alissa Naqvi5, Véronique Obry-Roguet3, Marc-Antoine Valantin6, 7, Lise Cuzin8, Eric Billaud9, Antoine Chéret10, David Rey11, Christine Jacomet12, Claudine C. Duvivier13, Pascal Pugliese5, Pierre Pradat14, Laurent Cotte1, 2
1HCL Hôpital de la Croix-Rousse, 2INSERM, 3APHM Hôpital Sainte-Marguerite, 4INSERM, 5CHU Nice, Hôpital l'Archet 1, 6UPMC Paris 6, 7APHP, Hôpital Pitié-Salpétrière, 8COREVIH Midi-Pyrénées-Limousin, 9CHU Nantes, Hôtel-Dieu, 10CH Tourcoing, 11Hôpitaux Universitaires de Strasbourg, 12Hôpital Gabriel Montpied, 13APHP Hôpital Necker, 14HCL Hôpital de la Croix-Rousse

1094 Sofosbuvir Plus Ribavirin Without Interferon For Treatment of Acute Hepatitis C Virus Infection in HIV-1 infected Individuals (SWIFT-C)
Susanna Naggie1, Kristen M. Marks2, Michael Hughes3, Daniel S. Fierer4, Arthur Y. Kim5, Kimberly Hollabaugh3, Jennifer Kiser6, Jhoanna Roa3, Bill Symonds7, Diana M. Brainard8, John G. McHutchison8, Marion G. Peters9, Raymond T. Chung5
1Duke University Medical Center, 2Weill Cornell, 3Harvard, 4Mount Sinai School of Medicine, 5Massachusetts General Hospital, 6University of Colorado, 7Roivant, 8Gilead Sciences, Inc, 9University of California, San Francisco

1095 Clinical- and Economic-performance of Ledipasvir and Sofosbuvir for HCV Genotype 1 in New York City: $100,000 per SVR12
Kian Bichoupan1, Daniel J. Waintraub2, Neal M. Patel1, Sweta Chekuri1, Joshua Hartman1, Alyson Harty1, David B. Motamed1, Alicia Stivala1, Viktoriya Khaitova1, Angela Woody1, Meena B. Bansal1, Priya Grewal1, Ritu Agarwal1, Charissa Y. Chang1, Jennifer Leong1, Gene Y. Im1, Lawrence Liu1, Joseph A. Odin1, Nancy Bach1, Scott L. Friedman1, Thomas D. Schiano1, Ponni V. Perumalswami1, Albert Min2, Lan S. Wang2, Jahnavi Naik2, Douglas Dieterich1, Andrea D. Branch1
1Icahn School of Medicine, 2Mount Sinai Beth Israel Medical Center

1096 IFN-? inhibits miR-122 transcription through a Stat3-HNF4a inflammatory feedback loop in an IFN-a resistant HCV cell culture system
Fatma Aboulnasr1, Sidhartha Hazari1, Partha K. Chandra1, Pauline Ferraris1, Rajesh Panigrahi1, Srinivas Chava1, Ramazan Kurt1, Kyoungsub Song1, Asha Dash1, Luis A. Balart2, Tong Wu1, Srikanta Dash1, 2
1Tulane University, 2Tulane University

1097 Efficacy of Daclatasvir/Asunaprevir According to Resistance Associated Variants in Chronic Hepatitis C Genotype1b
Etsuko Iio1, Noritomo Shimada2, Hiroshi Abe3, Masanori Atsukawa4, Kai Yoshiza5, Koichi Takaguchi6, Yuichiro Eguchi7, Hideyuki Nomura8, Tomoyuki Kuramitsu9, Jong-Hon Kang10, Takeshi Matsui10, Noboru Hirashima11, Atsunori Kusakabe12, Yasuhito Tanaka1
1Nagoya City University Graduate School of Medical Sciences, 2Ootakanomori Hospital, 3Jikei University School of Medicine Katsushika Medical Center, 4Nippon Medical School Chiba Hokusoh Hospital, 5Machida Municipal Hospital, 6Kagawa Prefectural Central Hospital, 7Saga University Hospital, 8Shin-Kokura Hospital, 9Kuramitsu Clinic, 10Teine Keijinkai Hospital, 11National Hospital Organization Nagoya Medical Center , 12Nagoya Red Cross Hospital

1098 Ribavirin levels at treatment weeks (TW) 4-6 can predict sustained viriological response (SVR12) in HCV cirrhotic patients treated with all oral direct–acting antiviral therapy (DAAs).
Suman Verma1, Ivana Carey1, Kate E. Childs1, Andrew Ayers1, Phillip Morgan1, Aisling B. Considine1, Kath Oakes1, Michael A. Heneghan1, Graham R. Foster2, Kosh Agarwal1
1Kings College Hospital, 2The Blizard Institute, Queen Marys University of London

1099 Frequency of Renal Impairment in Patients With Hepatitis C Infection Treated With Sofosbuvir-based Antiviral Regimens
Saeed Almarzooqi1, Jagpal S. Klair2, Joel G. Karkada1, Raoel Maan1, Orlando Cerocchi1, Matthew Kowgier1, Sherrie M. Harrell2, Kimberly Rhodes2, Harry L. Janssen1, Jordan J. Feld1, Andres Duarte-Rojo2
1Toronto Center for Liver Disease, 2University of Arkansas for Medical Sciences

1100 Prospective Study for The Efficacy of Sofosbuvir and Simeprevir ± Ribavirin in Hepatitis C Genotype 1 and 4 Compensated Cirrhotic Patients. Single Center Study and Real Life Experience.
Zeid Kayali1, 2, Cory Amador2, Andrew Lowe2, Besher Ashouri1, 2, Katherine Lam2, Warren N. Schmidt3
1Inland Empire Liver Foundation, 2Arrowhead Regional Medical Center, 3University of Iowa Hospital and Clinics

1101 Sofosbuvir + Ledispasvir Combination Therapy for Recurrent Hepatitis C in Liver Transplant Recipients: A Real-Life Multicenter Experience
Ryan M. Kwok1, Suzanne Robertazzi1, Helen S. Te2, Joshua Wiegel3, Joseph Ahn3, Janet Gripshover4, Darryn R. Potosky4, Amber Tierney5, Mohamed A. Hassan5, Rohit Satoskar1, Coleman I. Smith1
1Medstar Georgetown University Hospital, 2University of Chicago, 3Oregon Health and Science University, 4University of Maryland School of Medicine, 5University of Minnesota Medical School

1102 Hepatitis C treatment with Sofosbuvir and NS5A inhibitor in patients with an addiction
Jean-Baptiste Trabut5, Camille Barrault1, Hélène Charlot2, Damien Carmona3, Willy Kini-Matondo2, Franck Questel4, Christophe Hezode6
1CHIC, 2Hôpitaux Universitaires Henri Mondor, 3Centre Epice, 4Hôpital Fernand Widal, 5Hôpitaux Universitaires Henri Mondor, 6Hôpitaux Universitaires Henri Mondor

1103 Determination of on-treatment pharmacokinetics of sofosbuvir and ledipasvir in patients with decompensated cirrhosis - the need for real world PK studies
Omar El-Sherif1, 6, Diarmaid D. Houlihan2, Stephen Stewart3, Colm J. Bergin4, 6, Liam J. Fanning8, Susan McKiernan1, 6, Orla M. Crosbie7, Suzanne Norris1, 6, Saye H. Khoo5
1St. James's Hospital, 2St Vincents Hospital, 3Mater Hospital, 4St James's Hospital, 5University of Liverpool, 6Trinity College, 7Cork University Hospital, 8University College Cork

1104 Real Life Experience of Direct Acting Anti-Viral Therapy for Hepatitis C infection in North East of Scotland
Pauline Dundas, Shirley English, Lorna Bailey, Ashis Mukhopadhya, Balasubramaniam Vijayan, Andrew Fraser, Lindsay McLeman
Aberdeen Royal Infirmary

1105 Asian Patients with Genotype 1 HCV Infection Achieve 99% Sustained Virologic Response with 12 Weeks of Ledipasvir/Sofosbuvir Single Tablet Regimen: Integrated analysis of Phase 3 Multicenter Studies
Masashi Mizokami2, Wan-Long Chuang3, Kwang-Hyub Han4, Young-Suk Lim5, Jenny C. Yang1, Shampa De-Oertel1, Bing Gao1, Hongmei Mo1, Phillip S. Pang1, Steven J. Knox1, John G. McHutchison1, Masao Omata6, Jia-Horng Kao7
1Gilead Sciences, 2National Center for Global Health and Medicine, 3Kaohsiung Medical University, 4Yonsei University College of Medicine, 5Asan Medical Center, 6Yamanashi Prefectural Hospital Organization, 7National Taiwan University College of Medicine

1106 Efficacy, Change in MELD Score, and Safety by Baseline MELD Score in Patients With Compensated Cirrhosis Receiving Ombitasvir/Paritaprevir/r and Dasabuvir Plus Ribavirin in the Phase 3 TURQUOISE-II Trial
Ira M. Jacobson1, Tania M. Welzel2, Hugo E. Vargas3, Marcos C. Pedrosa4, Norah Terrault5, Douglas Dieterich6, Fredric D. Gordon7, Kris V. Kowdley8, Guy Neff4, Ran Liu4, Juan-Carlos Lopez-Talavera4, Stefan Zeuzem2
1Weill Cornell Medical College, 2J.W. Goethe University, 3Mayo Clinic Arizona, 4AbbVie Inc., 5University of California San Francisco, 6Mount Sinai School of Medicine, Icahn School of Medicine at Mount Sinai, 7Lahey Hospital & Medical Center, 8Liver Care Network, Swedish Medical Center

1107 Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir +/- ribavirin in HCV genotype 1-infected patients with a history of bleeding disorders: Results from phase 3 trials
Giustino Parruti1, Guilherme Macedo2, Axel Baumgarten3, Frederik Nevens4, Jordan J. Feld5, Christophe Hezode6, Lois M. Larsen7, Nancy Shulman7, Regis A. Vilchez7, Heiner Wedemeyer8
1Ospedale Civile Spirito Santo, 2Centro Hospitalar de São João, 3Medical Center for Infectious Diseases, 4University Hospitals KU, 5Toronto Centre for Liver Disease, University of Toronto, 6Henri Mondor University Hospital, AP-HP, Université Paris-Est, 7AbbVie Inc., 8Medizinische Hochschule Hannover

1108 Effectiveness of 12 or 24 week LDV/SOF and 12 week LDV/SOF + RBV in treatment-experienced patients with cirrhotic, genotype 1 Hepatitis C: Real-world experience from the TRIO Network.
Michael P. Curry1, Bruce Bacon2, Steven L. Flamm3, Kris V. Kowdley4, Douglas Dieterich5, Scott Milligan6, Naoky CS C. Tsai7
1Beth Israel Deaconess Medical Center, 2Saint Louis University School of Medicine, 3Northwestern Feinberg School of Medicine, 4Liver Care Network, Swedish Medical Center, 5Icahn School of Medicine, 6Trio Health Analytics, 7Queens Medical Center, University of Hawaii

1109 Lower 25-OH Vitamin D Levels are Associated With Advanced Fibrosis in Chronic Hepatitis C Infection but Pretreatment or Change in Level with Directing Acting Antiviral Therapy Do Not Predict Sustained Virologic Response
David W. Backstedt1, Mark Pedersen2, Bobby Kakati1, Myunghan Choi4, Anil B. Seetharam3
1Banner University Medical Center, 2Banner University Medical Center, 3Banner Transplant and Advanced Liver Disease Center, 4Arizona State University College of Nursing and Health Innovation

1110 Rapid virological response and other predictive factors of hepatitis C treatment outcomes with simeprevir and/or sofosbuvir use in veterans
Amanda A. Wong, Ivy Tonnu-Mihara
Veterans Affairs Long Beach Healthcare System

1111 Sofosbuvir and Ledipasvir for the Treatment of HCV GT-1, Cirrhotics and Non-Cirrhotics: Real-World Effectiveness
Kirat Gill, Garrett Fante, Shirin Nafisi, Ann Moore, Ashley Hepner, Justin A. Reynolds, Karen Arendt, Yvette Cummings, Robert Gish, Richard A. Manch, Anita Kohli
St. Joseph's Hospital and Medical Center, Creighton University School of Medicine

1112 Telaprevir in the Treatment of Acute HCV infection in HIV-infected Men: Final Results
Daniel S. Fierer2, Douglas Dieterich1, Michael P. Mullen2, Andrea D. Branch1, Alison J. Uriel1, 6, Damaris C. Carriero1, 7, Wouter van Seggelen2, 3, Rosanne M. Hijdra2, 3, David Cassagnol2, 5, Tristan Morey2, 4
1Icahn School of Medicine at Mount Sinai, 2Icahn School of Medicine at Mount Sinai, 3Amsterdam Medical Center, 4James Cook University, 5Weill Cornell Medical College, 6North Manchester General Hospital, 7Columbia University School of Medicine

1113 Transient renal dysfunction during INF-free therapy in decompensated HCV cirrhosis patients
Ivana Carey, Suman Verma, Anna Mrzljak, Aisling B. Considine, Sarah Knighton, Kath Oakes, Kate Childs, Matthew J. Bruce, Mary Horner, Abid Suddle, Kosh Agarwal
Kings College School of Medicine at King's College Hospital

1114 Patient Decision-Making: The Informational Needs of Patients Making Decisions about HCV Treatment
Donna M. Evon1, Carol E. Golin1, Rachel E. Jones1, Teodora Stoica1, Sarah Willis2, Michael W. Fried1
1University of North Carolina, 2University of North Carolina School of Public Health

1115 Resistance-associated variants in NS5A region of hepatitis C virus are susceptible to interferon-based therapy
Jun Itakura, Masayuki Kurosaki, Natsuko Nakakuki, Hitomi Takada, Nobuharu Tamaki, Yutaka Yasui, Shoko Suzuki, Kaoru Tsuchiya, Hiroyuki Nakanishi, Namiki Izumi
Musashino Red Cross Hospital

1116 Efficacy and safety of daclatasvir and asunaprevir in patients aged 70 years and older with genotype 1 chronic hepatitis C.
Shuhei Hige, Itaru Ozeki, Masakatsu Yamaguchi, Mutuumi Kimura, Tomohiro Arakawa, Tomoaki Nakajima, Yasuaki Kuwata, Takahiro Sato, Takumi Ohmura, Joji Toyota, Yoshiyasu Karino
Sapporo-Kosei General Hospital

1117 Differences in NK phenotype in Responders and Relapsers to Directly Acting Antivirals for HCV Infection
Kate E. Childs1, Elliot Merritt2, Suman Verma1, William M. Swanson1, Marc Martinez-Llordella2, Kosh Agarwal1, Ivana Carey1
1King's College hospital, 2King's College London

1118 Efficacy and Safety of Simeprevir based IFN- Free Therapy in Chronic HCV Genotype 4 Patients: Real Life Experience in Abu Dhabi
Mohamed Alzaabi2, Fatima Adem4, Asia Alharbi4, Eman Taleb1, Abdulla Alhassani3, Sultan Almazrouei3
1Sheikh Khalifa Medical City, 2Zayed Military Hospital, 3Zayed Military Hospital, 4Zayed Military Hospital

1119 Efficacy and Adverse Event Profile of Sofosbuvir Based Hepatitis C Virus (HCV) Treatment Regimens in the Elderly in a Community Based Setting
Beshoy T. Yanny, Amandeep K. Sahota
Kaiser Permanente Los Angeles Medical Center

1120 Sofosbuvir and Ledipasvir/Sofosbuvir for the Treatment of Patients with Chronic Genotype 6 Hepatitis C Virus Infection: Integrated Analysis of Phase 2 and Phase 3 Studies
Edward J. Gane1, Wan-Long Chuang2, Tarek I. Hassanein3, Kris V. Kowdley4, Eric Lawitz5, Bing Gao6, Hongmei Mo6, Robert H. Hyland6, Jenny C. Yang6, Shampa De-Oertel6, Diana M. Brainard6, Steven J. Knox6, John G. McHutchison6, Ching-Lung Lai7, Henry Lik-Yuen Chan8
1New Zealand Liver Transplant Unit, 2Kaohsiung Medical University, 3Southern California Liver Centers, 4Swedish Medical Center, 5The Texas Liver Institute, 6Gilead Sciences, Inc, 7Queen Mary Hospital, 8The Chinese University of Hong Kong

1121 Real Life Experience with Sofosbuvir and Ledipasvir Fixed Dose Regimen in the Multiethnic Cohort of Patients with Chronic Hepatitis C
Marina Roytman2, 1, Alister L. Tang1, Christina Wu1, Joy I. Piotrowski1, Leena K. Hong2, Ruby Trujillo2, Leslie Huddleston2, Isabel Hung Wan2, Peter Poerzgen2, Sumodh Kalathil2, Naoky CS C. Tsai2, 1
1University of Hawaii at Manoa, John A. Burns School of Medicine, 2Queen's Liver Center

1122 Treatment of Chronic Hepatitis C Infection in Kidney Transplant Recipients with Direct Acting Antiviral Medications – Initial Experience
Sushrut Trakroo1, Sirish Sanaka1, Hawah Musa1, Mohammed Eyad Yaseen Alsabbagh2, Mythili Ghanta1, Swati Rao1, Lee Peng2, Antonio Di Carlo1, Abdullah M. Al-Osaimi2, Kamran Qureshi2
1Temple University Hospital, 2Temple University School of Medicine

1123 Retreatment with sofosbuvir and simeprevir of patients who previously failed on an HCV NS5A inhibitor–containing regimen
Christophe Hezode1, 2, Stephane Chevaliez3, 2, Giovanna Scoazec1, Alexandre Soulier3, 2, Anne Varaut1, Magali Bouvier-Alias3, 2, Isaac Ruiz3, 2, Ariane Mallat1, 2, Cyrille Feray1, 2, Jean-Michel Pawlotsky3, 2
1Hospital Henri Mondor, 2INSERM U955, 3Virology, Henri Mondor Hospital

1124 Hepatitis C and HCC Outcomes Among Patients Listed for Liver Transplant with HCV-HCC who Received Direct Acting Antiviral Therapy
Ju Dong Yang1, Bashar A. Aqel2, Kymberly D. Watt1, Hugo E. Vargas2, Andrew P. Keaveny3, Surakit Pungpapong3, Gregory J. Gores1, Lewis R. Roberts3, Michael D. Leise1
1Mayo Clinic, 2Mayo Clinic College of Medicine, 3Mayo Clinic College of Medicine

1125 Combination therapy with daclatasvir and asunaprevir in cirrhotic patients with hepatitis C virus genotype 1b: On-treatment efficacy and adverse effects
Akihiro Tamori, Masaru Enomoto, Hoang Hai, Yuga Teranishi, Hiroyuki Motoyama, Ritsuzo Kozuka, Etsushi Kawamura, Atsushi Hagihara, Sawako K. Uchida, Hiroyasu Morikawa, Yoshiki Murakami, Norifumi Kawada
Osaka City University Graduate School of Medicine

1126 Safety and Efficacy of All-Oral Regimens for Hepatitis C in Cirrhotic Patients with Thalassemia
Emmanouil Sinakos1, Dimitrios Kountouras2, 3, Ioannis Koskinas4, Stylianos Karatapanis5, Alexandra Kourakli6, Efthimia Vlachaki7, Ioannis Goulis1, Antonios Kattamis8, Konstantinos Maragkos9, Fotini Petropoulou10, Barbara Toli3, Evangelos Akriviadis1, George V. Papatheodoridis2
1Aristotle University of Thessaloniki, 2University of Athens, 3Mitera Hospital, Athens, 4University of Athens, 5Hospital of Rhodes, 6Thalassemia Unit, Hospital of Patra, 7Aristotle University of Thessaloniki, 8University of Athens, 9Thalassemia Unit, Hippokratio Hospital, Athens, 10Thalassemia Unit, General Hospital, Athens

1127 NS3 Q80K Polymorphism in Viral Isolates from Liver Tissues and Serum Samples of Naïve HCV Genotype 1a Patients.
Deborah D'Aliberti2, Irene Cacciola2, Salvatore Benfatto1, Federica Mannino1, Roberto Filomia2, Concetta Beninati1, Giovanni Raimondo2, Teresa Pollicino1
1University Hospital of Messina, 2University Hospital of Messina

1128 Safety and Efficacy of Treatment with Daily Sofosbuvir 400 mg + Ribavirin 200 mg for 24 Weeks in Genotype 1 or 3 HCV-Infected Patients with Severe Renal Impairment
Paul Martin2, Edward J. Gane3, Grisell Ortiz-Lasanta4, Lin Liu1, Karim Sajwani1, Brian Kirby1, Jill M. Denning1, Luisa M. Stamm1, Diana M. Brainard1, John G. McHutchison1, Eric Lawitz5, Stuart C. Gordon6, Richard A. Robson7
1Gilead Sciences, 2University of Miami, FL, USA, 3University of Auckland, 4Fundcion de Investigacion, 5Texas Liver Institute, 6Henry Ford Health System, 7Christchurch Clinical Studies Trust, Ltd

1129 A Meta-Analysis of the Association Between Pre-Treatment Variables and SVR Amongst Genotype 1 Patients Treated with ABT-450/r–Ombitasvir and Dasabuvir (VIEKIRA PAK™) plus Ribavirin for 12 Weeks
Gregory J. Botwin2, Timothy R. Morgan1, 3
1VA Long Beach Healthcare System, 2VA Long Beach Healthcare System, 3University of California - Irvine

1130 On-treatment HCV RNA Decline in Pre-and Post-Liver Transplant Patients with Different Degrees of Fibrosis and Cirrhosis: a combined analysis of the SOLAR trials
Tania M. Welzel1, K. Rajender Reddy2, Michael P. Manns3, Steven L. Flamm4, David J. Mutimer5, Edward J. Gane6, Robert H. Hyland7, Ming Lin7, Phillip S. Pang7, John G. McHutchison7, Didier Samuel8, Michael R. Charlton9, Xavier Forns10, Gregory T. Everson11, Stefan Zeuzem1, Nezam H. Afdhal12
1Johann Wolfgang Goethe University Medical Center, 2University of Pennsylvania School of Medicine, 3Hannover Medical School, 4Northwestern University Feinberg School of Medicine, 5Queen Elizabeth Hospital and University of Birmingham, 6University of Auckland, 7Gilead Sciences, Inc, 8Université Paris-Sud, 9Intermountain Medical Center, 10IDIBAPS and CIBEREHD , 11University of Colorado Denver, 12Beth Israel Deaconess Medical Center

1131 Prevalence of drug-drug interactions with modern interferon free antiviral regimens against hepatitis C in a large real-world cohort
Benjamin Maasoumy1, Christoph Hoener zu Siederdissen1, Fiona Marra2, Kerstin Port1, Katja Deterding1, Michael P. Manns1, Markus Cornberg1, David J. Back2, Heiner Wedemeyer1
1Hannover Medical School, 2University of Liverpool

1132 Interferon Signaling and the Innate Immune Response: Still Relevant in the Age of Interferon Free Treatment
Kate E. Childs, Ivana Carey, William M. Swanson, Suman Verma, Kosh Agarwal
King's College Hospital

1133 Pharmacokinetic Analyses of Ledipasvir/Sofosbuvir and HIV Antiviral Regimens in Subjects with HCV/HIV Co-infection.
Polina German, Liyun Ni, Luisa M. Stamm, Jenny C. Yang, Maryanne Lenoci, John Ling, Anita Mathias
GIlead Sciences, Inc

1134 HCV genotype 3: Meta-analysis with current options
Javier Ampuero1, K. Rajender Reddy2, Manuel Romero-Gomez1
1Valme University Hospital, 2Hospital of the University of Pennsylvania

1135 Utilization and Effectiveness of Sofosbuvir Based HCV Regimens in a Community Based Setting
T. Craig Cheetham1, Sara Y. Tartof1, Zoe Bider-Canfield1, Vincent Louie3, Derenik Gharibian3, Amandeep K. Sahota2
1Kaiser Permanente Southern California, 2Southern California Permenente Medical Group, 3Kaiser Foundation Hospitals

1136 Evaluation of an Integrated HIV/HCV Care Model in an Urban, Low-Income, HIV/HCV Co-Infection Clinic
Angela Kapalko1, Linden Lalley-Chareczko1, Meghan F. Fibbi2, 3, Karam Mounzer1, 4
1Philadelphia FIGHT, 2University of Pennsylvania, 3Philadelphia College of Osteopathic Medicine, 4University of Pennsylvania

1137 What does Fibroscan® measure shortly after IFN-free DAA therapy?
Karin Kozbial, Albert Stättermayer, Clarissa Freissmuth, Rafael Stern, Sandra Beinhardt, Christian Rechling, Petra E. Steindl-Munda, Michael Trauner , Peter Ferenci, Harald Hofer
Medical University of Vienna

1138 Association between severe rash and HLA polymorphism in telaprevir-based triple therapy for chronic hepatitis C in a multi-centric study in Japan.
Yoko Yamagiwa1, Naohiko Masaki1, Nao Nishida1, Minae Kawashima2, Seik-Soon Khor2, Hiroko Miyadera1, Masaya Sugiyama1, Masaaki Korenaga1, Kazumoto Murata1, Tatsuya Kanto1, Yasuhito Tanaka3, Kazuhiko Koike4, Katsushi Tokunaga2, Masashi Mizokami1
1National Center for Global Health and Medicine, 2Graduate School of Medicine The University of Tokyo, 3Nagoya City University Graduate School of Medical Sciences, 4The University of Tokyo

1139 Patient Reasons for Initiating or Delaying Hepatitis C Virus (HCV) Treatment and Physician Reasons for Selecting an HCV Treatment: A Prospective Observational Study
Shelagh M. Szabo2, David R. Walker1, Timothy R. Juday1, Suzanne Lane2, Sammy Saab3
1Abbvie, 2Icon Health Economics, 3UCLA

1140 Co-morbidities and co-medications of patients with chronic hepatitis C (CHC) under specialist care in the UK - Challenges for scaling up HCV treatment?
Benjamin E. Hudson3, 8, William Irving4, 5, Stephen T. Barclay1, Fiona Marra2, 6, Alex J. Walker7
1Walton Liver Clinic, 2NHS Greater Glasgow and Clyde, 3HCV Research UK, 4NIHR Nottingham Digestive Diseases Biomedical Research Unit, 5School of Life Sciences, University of Nottingham, 6University of Liverpool, 7University of Nottingham, School of Life Sciences, 8Cambridge University Hospitals NHS trust

1141 Patterns of Care Since the Approval of New Therapies for Hepatitis C Virus (HCV) Infection: A 2013-2014 Real-World Analysis of US Community Specialty Practices
Paul J. Gaglio2, Tamar Sapir1, Jeffrey D. Carter1, Laurence Greene1, Erica Rusie1, Kathleen Moreo1
1PRIME Education, Inc., 2Montefiore Medical Center

1142 Treatment Outcomes of Veterans with Decompensated Cirrhosis Receiving All Oral Direct Acting Antiviral Hepatitis C Therapy
Abigail Rabatin1, Mohamed Hashem1, Mary L. Townsend1, William E. Bryan1, Cynthia A. Moylan1, 2, Steve S. Choi1, 2, Susanna Naggie1, 2
1Durham VA Medical Center, 2Duke University Medical Center

1143 Cost-effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir +/- ribavirin (3D±R) in patients with genotype (GT) 1 chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection compared with other standards of care in the US
Suchin Virabhak2, Scott J. Johnson2, Hélène Parisé2, Timothy R. Juday1, Alice Wang1, Yuri Sanchez1, Sammy Saab3
1AbbVie, 2Medicus Economics Inc., 3Pfleger Liver Institute, UCLA

1144 Lifetime risks of liver morbidity and mortality in patients with recurrent genotype 1 hepatitis C virus infection post-liver transplantation treated with ombitasvir/paritaprevir/ritonavir, dasabuvir and ribavirin (3D+R) vs former standards of care
Sammy Saab2, Caroline Huber3, Alice Wang1, Yuri Sanchez1, Timothy R. Juday1
1AbbVie, 2Pfleger Liver Institute, UCLA, 3Precision Health Economics

1145 Quantifying and Predicting Early Clinical Gains with Direct Acting Antiviral Therapy in Well Compensated HCV Cirrhosis: Is There an Unrecognized “Point of No MELD-based Return” Despite Sustained Virologic Response?
Meera Ramanathan1, David W. Backstedt2, Mark Pedersen1, Myunghan Choi4, Anil B. Seetharam3
1Banner University Medical Center, 2Banner University Medical Center, 3University of Arizona College of Medicine-Phoenix, 4Arizona State University

1146 Efficacy of Ledipasvir plus Sofosobuvir with or without ribavirin in hepatitis C genotype 1 patients who failed previous treatment with Simeprevir plus Sofosbuvir
Gabriel R. Gonzales3, Stevan A. Gonzalez1, Hector E. Nazario2, Manjushree Gautam1, Maisha Barnes2, Parvez S. Mantry2, Jeffrey S. Weinstein2, Milka Ndungu2, Olga Teachenor2, Apurva A. Modi1
1Liver Consultants of Texas, 2Liver Institute at Methodist-Dallas, 3University of North Texas HSC

1147 Safety And Efficacy Of Two IFN- Free Daas Regimens In Genotype 4 Chronic HCV Patients: First Real Clinical Practice Data In Gulf From Qatar HCV Registry
Moutaz F. Derbala1, Aliaa Amer2, Saad R. Alkaabi1, Yasser M. Kamel1, Khaleel H. Sultan1, Elham Elsayad3, Omer E. Hajelssedig1, Nazeeh Z. Dweik1, Mohammed T. Butt1, Mohammed E. Elbadri1
1Hamad Hospitaland Weill Cornell Medical College in Qatar,Consultant Gastroenterology & Hepatology HMC, 2Hamad Medical Corporation, 3Hamad Medical Corporation

1148 Preliminary Experience Of Direct Acting Antiviral Therapy In Hepatitis C Infected Kidney Transplant Recipients, Who Received Grafts From Hepatitis C Positive Or Negative Donors.
Kalyan R. Bhamidimarri, David Roth, Giselle Guerra, Cynthia Levy, Paul Martin
University of Miami-Miller School of Medicine

1149 IFNL4 ss469415590 Polymorphism Contributes to Treatment Decisions in Patients with Chronic Hepatitis C virus Genotype 1b but not 2a Infection
Ruihong Wu1, Xiumei Chi1, Haibo Sun1, Juan Lv1, Xiaomei Wang1, Xiuzhu Gao1, Ge Yu1, Fei Kong1, Peng Zhang2, Mo-li Wang3, Dongsheng Wang4, Tao Jiang4, Hongqin Xu1, Rui Hua1, Gerald Y. Minuk5, Jing Jiang6, Bing Sun7, Jin Zhong7, Yu Pan1, Junqi Niu1
1First hospital of JiLin University, 2First hospital of Jilin University, 3Fourth Hospital of Jilin University, 4Hospital of HepatologyBiliary of Jilin Province, 5University of Manitoba, 6First Hospital of Jilin University, 7Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences

1150 Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated hepatitis C virus in human hepatocyte chimeric mice
Hiromi Kan1, Michio Imamura1, Nobuhiko Hiraga1, Eisuke Miyaki1, Takuro Uchida1, Masataka Tsuge1, Hiromi Abe1, Nelson Hayes1, Hiroshi Aikata1, Chise Tateno2, Kazuaki Chayama1
1Hiroshima University , 2PhoenixBio Co., Ltd.

1151 HepCure: An Innovative web-based toolkit to train a new cohort of hepatitis C providers and increase patient engagement
Ponni V. Perumalswami1, Korin Parrella2, Jason Rogers3, Rahul Patel4, Brooke Wyatt1, Kian Bichoupan1, Andrea D. Branch1, Brian Kim1, Anna Patel1, Joseph Lawler1, Alicia Stivala2, Alyson Harty1, Donald Gardenier2, Michel Ng1, Catherine Amory2, Aaron M. Vanderhoff1, Douglas Dieterich1, Ashish Atreja3, Jeffrey J. Weiss2
1Icahn School of Medicine at Mount Sinai, 2Icahn School of Medicine at Mount Sinai, 3Icahn School of Medicine at Mount Sinai, 4Parsus Solutions, LLC

1152 Patient Expectations of the Impact on Quality of Life of Hepatitis C Treatment
Shelagh M. Szabo2, David R. Walker1, Timothy R. Juday1, Suzanne Lane2, Adrian Levy2, Sammy Saab3
1Abbvie, 2Icon Health Economics, 3UCLA

1153 Combination of IFNL4 polymorphisms and ALT reduction at 4 week of treatment with PEG IFN and Ribavirin is a new selection tool to optimize antiviral treatment allocation in HCV patients with low stage fibrosis.
Francesco Figorilli1, 5, Simona Onali1, Stefania Catone2, Claudio Argentini2, Stefania Casu1, Cinzia Balestrieri3, Maria Conti3, Giancarlo Serra3, Michele Casale1, Maria Cristina Pasetto1, Laura Matta1, Lucia Barca1, Rosetta Scioscia1, Irene Canini4, Maria Giovanna Quaranta2, Domenico Genovese2, Stefano Vella2, Luchino Chessa1, 3
1University of Cagliari, 2Istituto Superiore di Sanità, 3AOU Cagliari, 4Istituto Superiore di Sanità, 5liver failure group, UCL Institute for Liver and Digestive Health

1154 Real Life Treatment Outcomes with 8 week Course Treatment for Hepatitis C without Cirrhosis Confirmed by Transient Elastography
Vanessa Marshall2, 3, Kelsey Rife1, Amy Hirsch1, 3, Marina G. Silveira2, 3, Anita Compan2, Anita L. Moreland2, Yngve Falck-Ytter2, 3
1Louis Stokes Cleveland VA Medical Center, 2Louis Stokes Cleveland VA Medical Center, 3Case Western Reserve University

1155 Effectiveness of Treatment of Chronic Hepatitis C in Patients Being Treated for Hepatocellular Cancer: A Single Center Experience
Shruti Mony2, Shirin Nafisi1, Justin A. Reynolds1, Ann Moore1, Ashley Hepner1, Karen Arendt1, Yvette Cummings1, Robert Gish1, Richard A. Manch1, Anita Kohli1
1St. Joseph's Hospital and Medical Center, 2St. Joseph's Hospital and Medical Center

1156 Sofosbuvir-based treatments for patients with hepatitis C virus (HCV) mono-infection and human immunodeficiency virus (HIV)-HCV co-infection with genotype 1 and 4 in clinical practice – Results from the GErman hepatitis C COhort (GECCO)
Stefan Mauss1, Knud Schewe2, Jürgen K. Rockstroh3, Dietrich Hueppe4, Axel Baumgarten5, Guenther Schmutz1, Karl-Georg Simon6, Thomas Lutz8, Heiner W. Busch7, Patrick Ingiliz5, Stefan Christensen7
1Center for HIV and Hepatogastroenterology, 2ICH, 3Department I University Hospital Bonn, 4Center for Gastroenerology, 5MIB, 6Practice for Gastroenterology, 7CIM, 8Infektiologikum

1157 Efficacy of combination therapy Daclatasvir and Asunaorevir for elderly patients with HCV genotype 1 infection in Japan
Kenta Motomura1, Masayoshi Yada1, Taiji Mutsuki1, Masayuki Miyazaki1, Takeshi Senju1, Motoyuki Kohjima2, Makoto Nakamuta2, Akihide Masumoto1
1Iizuka Hospital, 2Kyushu medical center

1158 Sofosbuvir-based antiviral therapy in HCV patients with severe renal failure
Jérôme Dumortier1, François Bailly2, Georges-Philippe Pageaux3, Anaïs Vallet-Pichard4, Sylvie Radenne2, François Habersetzer5, Marie-Claude Gagnieu1, Jean Didier Grange6, Anne Minello7, Nassim Kamar8, Laurent Alric9, Vincent Leroy10
1Hôpital Edouard Herriot, 2Croix-Rousse Hospital, 3Saint Eloi University Hospital, 4Cochin Hospital, 5University Hospital of Strasbourg, 6Tenon Hospital, 7Dijon University Hospital, 8Rangueil University Hospital, 9Purpan University Hospital, 10CHU A Michallon

1159 Therapeutic effect of dual oral therapy with Daclatasvir and Asunaprevir
Motoyuki Kohjima1, 2, Kenta Motomura1, Toshimasa Koyanagi1, Seiya Tada1, Takeaki Satoh1, Naoki Yamashita1, Masaki Yokota1, Rie Sugimoto1, Syoji Nagase1, Syusuke Morizono1, Nobito Higuchi1, Tsuyoshi Yoshimoto1, Shigeki Tashiro1, Yuki Tanaka1, Kunitaka Fukuizumi1, Kazuhiro Kotoh1, Makoto Nakamuta1
1Fukuoka Kanzo Treatment research (FKT) group , 2Kyushu Medical Center, National Hospital Organization

1160 Concomitant use of chemotherapy and antivirals in hepatitis C virus infected cancer patients.
Parag Mahale1, Andreas Kyvernitakis1, Hagop Kantarjian2, Aung Naing3, Francesco Turturro4, Ahmed O. Kaseb5, Harrys A. Torres1
1The University of Texas MD Anderson Cancer Center, 2The University of Texas MD Anderson Cancer Center, 3The University of Texas MD Anderson Cancer Center, 4The University of Texas MD Anderson Cancer Center, 5The University of Texas MD Anderson Cancer Center

1161 Ombitasvir/Paritaprevir/r and Dasabuvir +/- Ribavirin is Better Tolerated Than Telaprevir + Peginterferon/Ribavirin With Less Frequent and Less Severe Anemia in the MALACHITE-I and MALACHITE-II Trials
Brian Conway1, Yan Luo2, Victoria Arama3, Wayne Ghesquiere4, Joe Sasadeusz5, Richard Skoien6, Alejandro Soza7, Malgorzata Inglot8, Danielle Sullivan2, Thomas Podsadecki2, Gregory Dore9
1Vancouver Infectious Diseases Centre, 2AbbVie Inc., 3Carol Davila University of Medicine and Pharmacy, National Institute for Infectious Diseases "Prof. Dr. Matei Bals”, 4Island Health Authority, Section of Infectious Diseases, 5Royal Melbourne Hospital, 6Royal Brisbane and Women’s Hospital, 7Department of Gastroenterology, Pontificia Universidad Católica de Chile, 8Wroclaw Medical University, 9Kirby Institute, UNSW Australia, and St. Vincent's Hospital

1162 Early dose adjustment of RBV in HCV patients treated with peginterferon and RBV is efficient and safe in the population underexposed to the drug. Multicentric French Study (Ribajuste)
Veronique Loustaud-Ratti1, Marianne Maynard-Muet10, Sylvie Thevenon2, Pierre Pradat2, Annick Rousseau3, Marie-Claude Gagnieu4, Sophie Alain5, Paul Deny8, Françoise Lunel-Fabiani9, Nicolas Picard6, Irène Zublena7, Pierre Marquet6, Christian Trepo10
1CHU de Limoges, 2Hôpital de la Croix Rousse, 3Université de Limoges, 4Hôpital Edouard Herriot, 5CHU Dupuytren, 6Université de Limoges, 7CHU de Lyon, 8INSERM, 9CHU Angers, 10Hôpital de la Croix Rousse

1163 Treatment of Hepatitis C Genotype 4 patients with Simeprevir and Sofosbuvir: Preliminary Results from a Phase IIa, Partially Randomised, Open-label Trial conducted in Egypt (OSIRIS)
Maissa El Raziky4, Mohamed Gamil2, Radi Hammad3, Mohammed Saad Hashem5, Marwa Khairy2, Aisha Elsharkawy2, Asmaa Gomaa5, Sofia Keim6, Gino Van Dooren1, Robert Ryan7, Ralph DeMasi7, Isabelle Londjon-Domanec8, Mohamad Hassany3, Wahid H. Doss3, Imam Waked5
1Janssen Infectious Diseases BVBA, 2Cairo University, 3National Hepatology and Tropical Medicine Research Institute, 4Cairo University, 5National Liver Institute, 6Janssen-Cilag Portugal, 7Janssen Research & Development LLC, 8Janssen-Cilag

1164 Limited Effectiveness of Sofosbuvir and Ribavirin for the Treatment of HCV GT-3 in Patients with Cirrhosis: A Real-World GT-3 HCV Treatment Experience
Shirin Nafisi, Garrett Fante, Ann Moore, Ashley Hepner, Justin A. Reynolds, Karen Arendt, Yvette Cummings, Robert Gish, Richard A. Manch, Anita Kohli
St. Joseph's Hospital and Medical Center

1165 Efficacy and Safety of Sofosbuvir-based Regimens in Asian-Americans With Chronic Hepatitis C Virus (HCV) Mono-Infection: A Multi-Center Study in the United States
Calvin Q. Pan1, Elsa Ouyang2, Myron Tong3, Albert Min4, Ke-Qin Hu5, James Park1
1NYU Langone Medical Center, NYU School of Medicine, 2Columbia University , 3 David Geffen School of Medicine at UCLA , 4Mount Sinai Beth Israel, Mount Sinai School of Medicine, 5UC Irvine Medical Center

1166 The number needed to treat with interferon-free therapy to prevent one cirrhosis-related complication for individual HCV-infected patients with advanced fibrosis
Adriaan J. van der Meer1, Raoel Maan1, Jordan J. Feld2, Heiner Wedemeyer3, Giovanna Fattovich4, Jean-Francois Dufour5, Frank Lammert6, Andres Duarte-Rojo2, Michael P. Manns3, Stefan Zeuzem7, Wolf P. Hofmann7, Donatella Ieluzzi8, Robert J. de Knegt1, Bart J. Veldt1, Bettina E. Hansen1, Harry L. Janssen2, 1
1Erasmus MC, 2Toronto Western Hospital, University Health Network, 3Medical School Hannover, 4University of Verona, 5University of Bern, 6Saarland University Medical Center, 7Klinikum der Johann Wolfgang Goethe-Universität, 8University of Verona

1167 Early response and efficacy of dual oral therapy with asunaprevir and daclatasvir for elderly patients with hepatitis C
Takashi Honda, Masatoshi Ishigami, Yoji Ishizu, Teiji Kuzuya, Kazuhiko Hayashi, Yoshiki Hirooka, Hidemi Goto
Nagoya University Graduate School of Medicine

1168 Resistance Analyses of Phase 3 Studies in Korean and Taiwanese Patients with Chronic Hepatitis C Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens
Kwang-Hyub Han2, Brian Doehle1, Hadas Dvory-Sobol1, Evguenia S. Svarovskaia1, Ramakrishna K. Chodavarapu1, Jenny C. Yang1, Steven J. Knox1, Michael D. Miller1, Hongmei Mo1, Wan-Long Chuang3
1Gilead Sciences, 2Severance Hospital, 3Kaohsiung Medical University Hospital

1169 Sustained Virologic Response (SVR) of Liver Transplant Recipients (OLT) with Advanced Hepatitis C Recurrence (HCVR), All Genotype 1, after Combination Antiviral Therapy (Rx) with either Telaprevir(TVR) or Sofosbuvir/Simeprevir (SOF/SIM): A Single Center Experience.
Carlos Fasola, Parvez S. Mantry, Jeffrey S. Weinstein, Hector E. Nazario, Adil Habib, Maisha Barnes, Alejandro Mejia, Edward A. Dominguez, Richard Dickerman, Stephen Cheng
Methodist Dallas Medical Center

1170 Treatment of Chronic HCV Genotype 1 (G1) Infection with Boceprevir: Frequency, Severity, Predictability and Management of Anemia in German Real-Life
Gerlinde Teuber1, Peter Buggisch2, Hanns F. Loehr3, Hermann Steffens4, Michael R. R. Kraus5, Peter R. Geyer6, Bernd Weber7, Thomas Witthoeft8, Uwe Naumann9, Elmar Zehnter10, Dagmar Hartmann11, Bernd Dreher11, Manfred Bilzer11
1Gastroenterological Practice, 2IFI Liver Center Hamburg, 3Gastroenterological Practice, 4Practice of Internal Medicine, 5Klinikum Burghausen, 6Gastroenterological Practice, 7Competence Center Addiction, 8Gastroenterological Practice, 9Center of Medicine, 10Gastroenterological Practice, 11MSD Pharma GmbH

1171 Virological efficacy of new oral direct acting antivirals in hepatitis C patients with mixed cryoglobulinemia
Rasham Mittal, T. Craig Cheetham, Zoe Bider-Canfield, Amandeep K. Sahota
Kaiser Permanente Los Angeles Medical Center

1172 The Time and Cost Investment Required to Obtain and Initiate Direct Acting Antiviral Therapy
Veronica Loy, Tamara Benyashvili, Megan OMahony, Douglas Pavkov, William Adams, Robin Todus, Michelle Watts, Natasha Von Roenn, Scott Cotler
Loyola Medical Center

1173 Health resource usage in peri-transplant patients during 12 weeks of therapy with sofosbuvir (SOF), with or without ribavirin (RBV) and an NS5A inhibitor.
Suman Verma1, Graham R. Foster2, William Irving4, John McLauchlan6, Michelle C. Cheung2, Benjamin E. Hudson5, Ivana Carey1, Kosh Agarwal1
1Kings College Hospital, 2The Blizard Institute, Queen Marys University of London , 4University of Nottingham, 5University of Nottingham, 6MRC University of Glasgow

1174 Outcomes of ribavirin free regimens for treatment of recurrent hepatitis C (genotype1) infection post liver transplant
Mohamed G. Shoreibah1, DeAnn Jones2, Sarah Baggett2, Brendan M. McGuire1, Omar Massoud1
1University of Alabama at Birmingham, 2University of Alabama at Birmingham

1175 Predictors of Treatment Adherence and Discontinuation in Department of Defense (DoD) Health Care Beneficiaries Treated for Chronic Hepatitis C 2004-2013
Dana Y. Teltsch2, David R. Walker1, Beth L. Nordstrom2, Kathy Fraeman2, Karl Kronmann3, Kristina St Clair3
1Abbvie, 2Evidera, 3Naval Medical Center Portsmouth

1176 Real-world effectiveness and cost per SVR of ledipasvir/sofosbuvir chronic hepatitis C treatment
Peter Buggisch1, Karsten Wursthorn1, Albrecht Stoehr1, Aline Gauthier2, Petar K. Atanasov2, Joerg Petersen1
1IFI Institut für Interdisziplinäre Medizin , 2Amaris Consulting

1177 Hope and Hopelessness in HCV patients in the era of DAA therapy
Sophie K. Afdhal1, Michael Penn1, Zobair M. Younossi2, Michael P. Curry3
1Franklin & Marshall College, 2Inova Fairfax Hospital, 3Beth Israel Deaconess Medical Center

1178 Sofosbuvir is well tolerated and effective in chronic hepatitis C patients with advanced renal disease and/or on hemodialysis
Geoffrey Kitzman1, Eric Davis1, Jesus Monico2, Evelyn Arendale1, Brian B. Borg1
1University of Mississippi Medical Center, 2University of Mississippi Medical Center

1179 High efficacy of a 12-week simeprevir plus peginterferon alfa 2a/ribavirin regimen in treatment-naïve patients with chronic HCV genotype 4 infection and mild-to-moderate fibrosis
Tarik Asselah1, Christophe Moreno2, Christoph Sarrazin3, Michael Gschwantler4, Graham R. Foster5, Antonio Craxi6, Peter Buggisch7, Faisal M. Sanai8, Robert Ryan9, Oliver Lenz10, Gino Van Dooren10, Isabelle Londjon-Domanec11, Catherine Nalpas11, Michael Schlag12, Maria Buti13
1University of Paris , 2Université Libre de Bruxelles, 3Johann Wolfgang Goethe University Hospital, 4Wilhelminenspital, 5Queen Mary Hospital, University of London, Barts Health, 6University of Palermo, 7Institute for Interdisciplinary Medicine, 8King Abdulaziz Medical City, 9Janssen Research & Development, 10Janssen Infectious Diseases BVBA, 11Janssen Pharmaceuticals, 12Janssen-Cilag, 13Hospital Valle Hebron and Ciberehd del Institut Carlos III

1180 Rapid drop in serum glucose and hypoglycemia in chronic hepatitis C patients with diabetes during oral HCV therapy
Laura M. Benítez-Gutiérrez1, Vincent Soriano2, Isabella Esposito1, Pablo Barreiro2, Ana Maria Duca1, Silvia Requena1, Isolina Baños1, Ana Treviño1, Valentin Cuervas-Mons1, Carmen de Mendoza1
1Hospital Universitario Puerta de Hierro Majadahonda, 2La Paz University Hospital & IdiPAZ

1181 Treatment of recurrent Hepatitis C with sofosbuvir and simeprevir in post transplant patients in an academic liver center
Nikolaos Pyrsopoulos, Nneoma O. Okoronkwo, George Protopopas , Kiran V. Rao, Vivek A. Lingiah, Maliha Ahmad, Lizza Bojito-Marrero, Kathleen Ruping, Raja G. Reddy Edula
Rutgers New Jersey Medical School

1182 Similar Tolerability and Effectiveness with SMV+SOF Therapy in Asians and Non-Asians with Chronic Hepatitis C Genotype 1 (CHC-1) but Anemia and Fatigue were Common with SOF+RBV in Both Groups
Christine Y. Chang1, Nghia H. Nguyen2, 1, Changqing Zhao1, 3, Glen A. Lutchman1, Aijaz Ahmed1, Tami Daugherty 1, Gabriel Garcia1, Radhka Kumari1, W. Ray Kim1, Huy N. Trinh4, Vinh D. Vu1, Winston Ku1, My T. Nguyen4, Andrew Huynh4, Mindie H. Nguyen1
1Stanford University Medical Center, 2University of California, San Diego, 3Department of Cirrhosis, 4San Jose Gastroenterology

1183 “Real-life”-Experience with Sofosbuvir-based Direct Acting Antiviral Treatment in HCV Patients (n=187)
Christoph R. Werner, Daniel P. Egetemeyr, Nisar P. Malek, Ulrich M. Lauer, Christoph P. Berg
University Hospital Tübingen

1184 Sofosbuvir Combination Therapy and Chronic Hepatitis C Infection: Is Cultural Background a Predictor of Sustained Virologic Response?
Amber Tierney, John R. Lake, Amar Mahgoub, Carolyn Schmitt, Qi Wang, Mohamed A. Hassan
University of Minnesota

1185 Hepatic Decompensation and Serious Adverse Events in Liver Transplant Recipients Treated with Sofosbuvir-containing Regimens for Recurrent HCV Infection
Neal M. Patel, Kian Bichoupan, Lawrence Ku, Rachana Yalamanchili, Alyson Harty, Donald Gardenier, Michel Ng, David B. Motamed, Viktoriya Khaitova, Nancy Bach, Charissa Y. Chang, Priya Grewal, Meena B. Bansal, Ritu Agarwal, Lawrence Liu, Gene Y. Im, Jennifer Leong, Leona Kim-Schluger, Joseph A. Odin, Jawad Ahmad, Scott L. Friedman, Douglas Dieterich, Thomas D. Schiano, Ponni V. Perumalswami, Andrea D. Branch
Icahn School of Medicine at Mount Sinai

1186 Treatment of Hepatitis C Virus with Direct Acting Antivirals (DAA) and Ribavirin (RBV) is Associated with Changes in Serum Apolipoprotein and TNF-alpha Levels
Pegah Golabi2, Mehmet Sayiner2, Michael J. Estep2, Elzafir Elsheikh2, Brian P. Lam2, Huong T. Pham2, Maria Stepanova2, Zobair M. Younossi2, 1
1Inova Fairfax Hospital, 2Inova Health System

1187 Is ribavirin actually useful for Genotype 1 cirrhotic patients who receive DAAs combination? An updated meta-analysis of randomized controlled trials
Vincent Di Martino1, Carine Richou1, Jean Paul Cervoni1, Delphine Weil1, Claire Vanlemmens1, Thong Dao2, Anne Minello3, Veronique Loustaud-Ratti4, Odile Goria5, Eric Nguyen-Khac6, Christine Silvain7, Thierry Thevenot1
1CHU Jean Minjoz, 2CHU Caen, 3CHU de Dijon, 4CHU de Limoges, 5Charles Nicolle Hospital, 6CHU d'Amiens, 7CHU Poitiers

1188 Real World Effectiveness Of Sofosbuvir Based Therapy In Chronic HCV Infected Patients: The Results From Data Anlaysis Of 167 Patients In Qatar
Moutaz F. Derbala1, Aliaa Amer2, Saad R. Alkaabi1, Nazeeh Z. Dweik1, Khaleel H. Sultan1, Yasser M. Kamel1, Khalid Al-Ejji1, Hamid Wani1, Fuad I. Pasic1
1Hamad Hospitaland Weill Cornell Medical College in Qatar,Consultant Gastroenterology & Hepatology HMC, 2Hamad Medical Corporation

1189 IFN and/or RBV-Free Therapy (Rx) with Simeprevir+Sofosbuvir (SMV+SOF) was Well-Tolerated and Effective for Chronic Hepatitis C Genotype 1 (CHC-1) Including Post-Liver Transplant (LT) and Decompensated Non-Liver Transplant (Non-LT) Patients: A Single-Center Experience
Glen A. Lutchman1, Nghia H. Nguyen1, 3, Christine Y. Chang1, Aijaz Ahmed1, Tami Daugherty 1, Gabriel Garcia1, Radhka Kumari1, W. Ray Kim1, Soumi Gupta4, Dilesh Doshi2, Mindie H. Nguyen1
1Stanford University Medical Center, 2Janssen Scientific Affairs, 3University of California, San Diego, 4Janssen Scientific Affairs

1190 Virological and Clinical Response in Patients with HCV-Related Mixed Cryoglobulinemia Treated with Interferon-Free Regimens: Preliminary Results of a Prospective Pilot Study.
Laura Gragnani, Alessia Piluso, Teresa Urraro, Alessio Fabbrizzi, Elisa Fognani, Luisa Petraccia, Monica Monti, Anna Linda Zignego
University of Florence

1191 Evaluation of the efficacy and safety to dual oral therapy with daclatasvir and asunaprevir in Japanese real-life settings
Hitomi Sezaki1, Fumitaka Suzuki1, Tetsuya Hosaka1, Shunichiro Fujiyama1, Hideo Kunimoto1, Yushi Sorin1, Yusuke Kawamura1, Norio Akuta1, Masahiro Kobayashi1, Yoshiyuki Suzuki1, Satoshi Saitoh1, Yasuji Arase1, Kenji Ikeda1, Mariko Kobayashi2, Hiromitsu Kumada1
1Toranomon Hospital, 2Toranomon Hospital

1192 Simeprevir, pegylated-interferon and ribavirin therapy revealed high rate of SVR in patients with favorable IL28B genotype: Real life data from nationwide multicenter study by Japanese Red Cross Liver Study Group.
Masayuki Kurosaki, Shoko Suzuki, Jun Itakura, Namiki Izumi
Musashino Red Cross Hospital

1193 ITPA polymorphisms are predictors of anemia but no contribution to outcomes in chronic hepatitis C patients who treated with interferon plus ribavirin
Xiumei Chi1, Mo-li Wang3, Yu Pan1, Jing Jiang2, Hongqing Yan1, Ruihong Wu1, Xiaomei Wang1, Junqi Niu1
1The first hospital of Jilin University, 2The first hospital of Jilin University, 3The fourth hospital of Jilin University

1194 Cardiac arrhythmia in patients with chronic hepatitis C virus infection treated with sofosbuvir-including regimen
Hélène Fontaine1, 2, Arnaud Lazarus3, 4, Caroline Pecriaux5, François Bagate3, Philippe Sultanik1, 2, Estelle Boueyre1, 2, Marion Corouge1, 2, Vincent Mallet1, 2, Anaïs Vallet-Pichard1, 2, Philippe Sogni1, 2, Denis Duboc3, Stanislas Pol1, 2
1Cochin Hospital, 2INSERM USM20, Institut Pasteur et Assistance Pubique - Hôpitaux de Paris, 3Hôpital Cochin, Assistance Publique -Hôpitaux de Paris, 4Clinique Ambroise Paré, 5Hôpital Cochin, Assistance Publique - Hôpitaux de Paris

1195 Utility of acoustic radiation force impulse (ARFI) for predicting treatment response of patients with chronic hepatitis C receiving triple therapy with protease inhibitor plus pegylated interferon and ribavirin
Ryoko Yamada1, Naoki Hiramatsu1, Tsugiko Oze1, Ayako Urabe1, Yuki Tahata1, Naoki Morishita1, Takayuki Yakushijin1, Yuichi Yoshida1, Tomohide Tatsumi1, Yasuharu Imai2, Tetsuo Takehara1
1Osaka University Graduate School of Medicine, 2Ikeda Municipal Hospital

1196 Ribavirin Levels and Transporters in the Early Phase of Hepatitis C Therapy
Ludi Koning, Bettina E. Hansen, Andre Boonstra, Robert J. de Knegt
Erasmus MC University Medical Center

1197 Resistant-associated variants analyzed by deep sequence of retreatment with simeprevir-based triple therapy after failure of telaprevir-based triple therapy in patients with genotype 1 hepatitis C virus infection
Naoki Morishita1, Naoki Hiramatsu1, Tsugiko Oze1, Yuki Tahata1, Ryoko Yamada1, Takayuki Yakushijin1, Akira Yamada8, Eiji Mita2, Toshihiko Nagase3, Yukinori Yamada10, Toshifumi Ito4, Masahiko Tsujii5, Masami Inada6, Yasuharu Imai7, Hayato Hikita1, Ryotaro Sakamori1, Yuichi Yoshida1, Tomohide Tatsumi1, Norio Hayashi9, Tetsuo Takehara1
1Osaka University Graduate School of Medicine, 2National Hospital Organization Osaka National Hospital, 3Suita Municipal Hospital, 4JCHO osaka hospital, 5Osaka Rousai Hospital, 6Toyonaka Municipal Hospital, 7Ikeda Municipal Hospital, 8Sumitomo Hospital, 9Kansai Rosai Hospital, 10Kaizuka City Hospital

1198 Better Work Productivity and Activity in Patients on Ombitasvir/ Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin (3D+RBV or 3D) in Treatment-Naïve Adults with Genotype 1(GT1) Chronic Hepatitis C
Yan Liu1, Yan Luo1, Xuan Liu1, Danielle Sullivan1, Timothy R. Juday1, Brian Conway2
1Abbvie Inc, 2Vancouver Infectious Diseases Centre

1199 Effect of Proton pump inhibitor co-administration on virological response in hepatitis C genotype 1 patients treated with Sofosbuvir plus Ledipsavir
Jamil S. Alsahhar2, Hector E. Nazario4, Manjushree Gautam1, Stevan A. Gonzalez1, Ruben Ramirez-Vega5, Mohammad Ashfaq1, Milka Ndungu4, Olga Teachenor4, Gabriel R. Gonzales3, Apurva A. Modi1
1Liver Consultants of Texas, 2Baylor University Medical Center, 3UNTHSC, 4Liver Institute Methodist Dallas, 5Gastroenterology Specialists

1200 Pre-Existing Co-Morbidities and Co-Medications of Patients Undergoing Treatment of Chronic HCV G1 Infection in German Real-Life
Peter Buggisch1, Hanns F. Loehr2, Gerlinde Teuber3, Hermann Steffens4, Michael R. R. Kraus5, Peter R. Geyer6, Bernd Weber7, Thomas Witthoeft8, Uwe Naumann9, Elmar Zehnter10, Dagmar Hartmann11, Bernd Dreher11, Manfred Bilzer11
1IFI Liver Center Hamburg, 2Gastroenterological Practice, 3Gastroenterological Practice, 4Practice of Internal Medicine, 5Klinikum Burghausen, 6Gastroenterological Practice, 7Competence Center Addiction, 8Gastroenterological Practice, 9Center of Medicine, 10Gastroenterological Practice, 11MSD Pharma GmbH

1201 High ribavirin dose and extended treatment can raise sustained virologic response in chronic hepatitis C genotype 1 patients treated with simeprevir, pegylated interferon plus ribavirin.
Yuki Tahata1, Naoki Hiramatsu1, Tsugiko Oze1, Ayako Urabe1, Naoki Morishita1, Ryoko Yamada1, Takayuki Yakushijin1, Yukiko Saji2, Yoshinori Doi3, Hideki Hagiwara4, Akira Kaneko5, Hiroyuki Fukui6, Masami Inada7, Kazuhiro Katayama8, Atsuo Inoue9, Yuichi Yoshida1, Tomohide Tatsumi1, Norio Hayashi4, Tetsuo Takehara1
1Osaka University Graduate School of Medicine, 2Itami City Hospital, 3Otemae Hospital, 4Kansai Rosai Hospital, 5NTT West Osaka Hospital, 6Yao Municipal Hospital, 7Toyonaka Municipal Hospital, 8Osaka Medical Center for Cancer and Cardiovascular Diseases, 9Osaka General Medical Center

1202 Hepatitis C Cure Results in a Modest, but Durable, Decrease in Liver Stiffness
Sweta Chekuri, Kian Bichoupan, Sanders Chang, Neal M. Patel, Ponni V. Perumalswami, David P. Del Bello, Rachana Yalamanchili, Alyson Harty, Douglas Dieterich, Andrea D. Branch
Mount Sinai

1203 Clinical Significance of Blood Asunaprevir Concentrations Levels during Combined Daclatasvir and Asunaprevir Therapy
Itaru Ozeki
Department of Gastroenterology, Sapporo Kosei General Hospital

1204 IFN-free DAA regimens improve on-treatment quality of life in patients with HIV/HCV coinfection in contrast to previously used PEGIFN/RBV regimens
Bernhard Scheiner1, Philipp Schwabl1, Mattias Mandorfer1, Sebastian Steiner1, David Chromy1, Theresa Bucsics1, Berit A. Payer1, Maximilian C. Aichelburg2, Armin Rieger2, Katharina Grabmeier-Pfistershammer2, Michael Trauner 1, Markus Peck-Radosavljevic1, Thomas Reiberger1
1Medical University of Vienna, 2Medical University of Vienna

1205 Real-world effectiveness of ledipasvir/sofosbuvir 8 weeks chronic hepatitis C treatment
Peter Buggisch1, Karsten Wursthorn1, Albrecht Stoehr1, Aline Gauthier2, Petar K. Atanasov2, Joerg Petersen1
1IFI Institut für Interdisziplinäre Medizin, 2Amaris Consulting

1206 Efficacy of Sofosbuvir and Simeprevir (COSMOS Regimen) in Hepatitis C Genotype 1 in Decompensated Cirrhosis: A tertiary-center Experience
Eduardo A. Rodriguez1, Cynthia Levy2, Paul Martin2, Kalyan R. Bhamidimarri2
1University of Miami Miller School of Medicine, 2University of Miami Miller School of Medicine

1207 Assessment of serum hepatitis C virus RNA 24 weeks after the end of treatment using TaqMan PCR is more relevant than after 12 weeks for predicting sustained virological response by simeprevir- versus telaprevir-based triple therapy
Tatsuo Kanda, Shingo Nakamoto, Reina Sasaki, Yuki Haga, Masato Nakamura, Shin Yasui, Makoto Arai, Fumio Imazeki, Osamu Yokosuka
Chiba University, Graduate School of Medicine

Immunosuppression, Outcomes, and Complications in Transplant

1208 Reduced Survival in Elderly Liver Transplant Recipients: How Old is Too Old?
Nae-Yun Heo1, 2, Ajitha Mannalithara1, Prowpanga Udompap1, Donghee Kim1, Waldo Concepcion3, Carlos O. Esquivel3, W. Ray Kim1
1Stanford University School of Medicine, 2Inje University College of Medicine, 3Stanford University School of Medicine

1209 The Small Molecule TLR9 Antagonist COV08-0064 Protects from Warm Ischemia Reperfusion Injury of the Liver
Mohamed E. Shaker1, 2, Bobby N. Trawick3, Wajahat Z. Mehal1
1Yale School of Medicine, 2Faculty of Pharmacy, Mansoura University, 3Mallinckrodt Pharmaceuticals

1210 Primary Biliary Cirrhosis: Natural history and recurrence after liver transplantation
Prashanth Francis, Robert S. Rahimi, Giovanna Saracino, Sumeet K. Asrani
Baylor University Medical Center

1211 Aging of liver transplant registrants and recipients: trends and impact on waiting list and post-transplantation outcomes
Feng Su1, Lei Yu1, Kristin Berry2, Iris W. Liou1, Charles S. Landis1, Jorge Reyes1, Stephen C. Rayhill1, George N. Ioannou2, 1
1University of Washington, 2Veterans Affairs Puget Sound Healthcare System

1212 Outcomes of acute-on-chronic liver failure in liver transplant recipients based on EASL-CLIF consortium definition
Anuj Sharma1, William J. Goldkamp1, Satheesh Nair2, 1, Jason Vanatta2, 1, James Eason2, 1, Sanjaya K. Satapathy2, 1
1University of Tennessee Health Science Center, 2Methodist Transplant Institute

1213 Prediction of Posthepatectomy Liver Failure based on Preoperative Liver Fibrosis Assessment: Comparison of Mac-2 Binding Protein Glycosylation Isomer and Liver Stiffness Measurement
Takahiro Nishio, Kojiro Taura, Kazutaka Tanabe, Gen Yamamoto, Yukihiro Okuda, Yoshinobu Ikeno, Satoru Seo, Kentaro Yasuchika, Etsuro Hatano, Hideaki Okajima, Toshimi Kaido, Shinji Uemoto
Department of Surgery, Graduate School of Medicine, Kyoto University

1214 Two-Year Results of a Pilot Program in Early Liver Transplantation for Severe Alcoholic Hepatitis
Brian P. Lee1, Po-Hung Chen1, Ruben Hernaez1, Ahmet Gurakar1, Benjamin Philosophe2, Zhiping Li1
1Johns Hopkins University School of Medicine, 2Johns Hopkins University School of Medicine

1215 Early Liver Transplantation in Severe Alcoholic Hepatitis: A Multi-Center, Retrospective, Cohort Study
Brian P. Lee1, David W. Victor2, Darryn R. Potosky3, Ibrahim A. Hanouneh4, Mary E. Rinella5, Michael D. Voigt6, Sheila L. Eswaran7, Howard P. Monsour2, R. Mark Ghobrial2, Jessica A. Keppel7, Zhiping Li1
1Johns Hopkins University School of Medicine, 2Houston Methodist Hospital , 3University of Maryland School of Medicine, 4Cleveland Clinic, 5Northwestern University Feinberg School of Medicine, 6University of Iowa Carver College of Medicine, 7Rush Medical College

1216 Liver Transplantation for Portopulmonary Hypertension (PoPH): Multi-centre UK experience over twenty years.
Suman Verma1, Fiona M. Hand2, Matthew J. Armstrong3, Marie de Vos4, Douglas Thorburn4, Terry Pan6, John R. Klinck6, Rachel Westbrook1, Georg Auzinger1, Andrew Bathgate5, Steven Masson7, Andrew Holt3, Diarmaid D. Houlihan2, James W. Ferguson3
1Kings College Hospital, 2St. Vincent's Hopsital, 3University Birmingham Hospital Trust, 4Royal Free Hospital, 5Scottish Transplant Unit, 6Addenbrooke's Hospital, 7Freeman Hospital

1217 Sublingual administration of tacrolimus is a feasible route and requires a lower dose to achieve similar drug exposition in adult liver transplant recipients.
Sandra Solari2, Alejandra Cancino1, Blanca M. Norero1, Rodrigo Wolff1, Francisco Barrera1, Alejandro Soza1, Marco Arrese1, Juan Francisco Guerra3, Nicolás Jarufe3, Jorge A. Martínez3, Carlos E. Benítez1
1Pontificia Universidad Católica de Chile, 2Pontificia Universidad Católica de Chile, 3Pontificia Universidad Católica de Chile

1218 Pre-transplant echocardiographic parameters as a tool to evaluate post-transplant survival and cardiac outcomes in liver transplant recipients.
Daniel W. Bushyhead1, James N. Kirkpatrick2, David S. Goldberg3
1Hospital of the University of Pennsylvania, 2Hospital of the University of Pennsylvania, 3Hospital of the University of Pennsylvania

1219 Reporting Physical Function in UNOS: The Weakness of the Karnofsky Performance Status Scale
Connie W. Wang, John P. Roberts, Jennifer C. Lai
University of California, San Francisco

1220 Acute Kidney Injury among Patients Listed for Liver Transplantation
Paul S. Fitzmorris1, Kirk B. Russ1, Donny Kakati1, Toni Seay2, Ashwani Singal2
1University of Alabama at Birmingham, 2University of Alabama at Birmingham

1221 Renal Recovery Outcomes after Liver Transplantation in Patients Requiring Pre-operative Renal Replacement Therapy.
Rex Cheng1, Kimberly Muczynski2, Lena Sibulesky3, Renuka Bhattacharya1
1University of Washington, 2University of Washington, 3University of Washington

1222 Coffee consumption promotes survival and protects against hepatocellular carcinoma recurrence following liver transplantation: putative mechanisms involve modulation of adenosinergic signalling
Georg Wiltberger1, Ruoyu Miao2, Undine G. Lange1, Rudi Ascherl1, Hans-Michael Hau1, Felix Krenzien1, Georgi Atanasov1, Christian Benzing1, Elliot B. Tapper2, Linda Feldbrügge2, Johannes Broschewitz1, Michael Bartels1, Sven Jonas3, Johann Pratschke4, Yan Wu2, Simon C. Robson2, Moritz Schmelzle4
1Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital Leipzig, Leipzig, Germany, 2Liver Center and The Transplant Institute, Div. of Gastroenterology, 3310Klinik, Nürnberg , 4Charité - Universitätsmedizin Berlin, Campus Virchow Klinikum

1223 Recipient obesity is an independent risk factor for unplanned reoperations and prolonged operative time in orthotopic liver transplant
Eric S. Wise1, Malena Outhay2, Michael Maggart2, Saad Rehman2, Sir Norman T. Melancon2, James Leathers2, Kristina Jacomino2, Michelle Izmaylov2, Amol Utrankar2, Kyle M. Hocking1, Sunil K. Geevarghese1, 3
1Vanderbilt, 2Vanderbilt, 3Vanderbilt

1224 Ursodeoxycholic Acid as Adjunctive Therapy to Endoscopic Management of Non Anastomotic Biliary Lesions after Liver Transplant: Effectiveness Depends on Etiology
Mark Pedersen1, David W. Backstedt2, Bobby Kakati2, Myunghan Choi3, Anil B. Seetharam4
1University of Arizona College of Medicine-Phoenix, 2University of Arizona College of Medicine-Phoenix, 3Arizona State University College of Nursing and Health Innovation, 4University of Arizona College of Medicine

1225 Quantiferon-CMV testing after cessation of antiviral therapy predicts late CMV reactivation after Liver Transplantation
Siddharth Sood2, 1, Craig Haifer1, Lijia Yu3, Julie Pavlovic1, Paul Gow1, Robert M. Jones1, Kumar Visvanathan3, Peter W. Angus1, Adam Testro1
1Austin Health, 2Royal Melbourne Hospital, 3University of Melbourne

1226 Everolimus is Associated with Lower Weight Gain Two Years Following Liver Transplantation – Results of a Randomized Multicenter Study
Michael R. Charlton1, Mary E. Rinella2, Julie Heimbach3
1Intermountain Medical Center, 2Northwestern University, 3Mayo Clinic

1227 Glycine is graft protective and preserves kidney function after liver transplantation: Data of the HEGPOL-Trial [ISRCTN69350312]
Peter Schemmer1, Arash Nickkholgh1, Georgios Polychronidis1, Steffen P. Luntz2, Ertan Mayatepek3, MarkusW. Buechler1, Ernst Klar4
1Ruprecht-Karls University of Heidelberg, 2Ruprecht-Karls University of Heidelberg, 3Heinrich-Heine-University, , 4University of Rostock

1228 The Combination of Strongly (+) C4d Staining and High Titer Donor Specific Antibody (DSA) Suggests that Plasma Cell Hepatitis is a Result of Antibody-Mediated Rejection
M. Isabel Fiel1, Sander S. Florman2, Thomas D. Schiano2
1Icahn School of Medicine at Mount Sinai, 2Icahn School of Medicine

1229 The coming of age of the graft in pediatric orthotropic liver transplant (OLT) recipients
Shewit Giovanni, J. Michael Millis, Andrew I. Aronsohn, John F. Renz, Ruba K. Azzam, Pamela Boone, Kathleen Dasgupta, Helen S. Te
University of Chicago Medicine

1230 Lack of effect of CMV reactivation in the outcome of HCV-infected liver transplant(LT)patients
Victoria Aguilera1, 2, Tommaso Di Maira1, Isabel Conde3, Angel Rubin1, 2, Carmen Vinaixa1, 2, Salvador Benlloch1, 2, Martin Prieto1, 2, Marina Berenguer4, 2
1Hospital Universitari La Fe, 2Instituto de Salud Carlos III, Grant PI13/01770, 3Instituto de Investigación Sanitaria Hospital Universitari La Fe, 4Universidad de Valencia

1231 Blood Phosphatidyl ethanol identifies alcohol use among liver transplant recipients
Michael F. Fleming2, Jenny Vue1, Michael R. Lucey1
1Univ. of Wisconsin School of Medicine and Public Health, 2Northwestern University

1232 A New Score based on explant pathology allows an individualized prediction of HCC-recurrence after liver transplantation
Charlotte E. Costentin1, Giuliana Amaddeo1, Christophe Duvoux1, Julien Calderaro2, Alexis Laurent3, Ariane Mallat1, Françoise Roudot-Thoraval4
1Hôpital Henri Mondor, 2Henri Mondor Hospital, 3Henri Mondor Hospital, 4Henri Mondor Hospital

1233 Comparative analysis of renal dysfunction in recipients with NASH compared to controls with alcoholic liver disease after liver transplantation
Cheri Ogwo1, Satheesh Nair2, 1, Jason Vanatta2, 1, Vinaya Rao2, 1, Chibuzor Iwelu1, James Eason2, 1, Sanjaya K. Satapathy2, 1
1University of Tennessee Health Sciences Center, 2Methodist University Hospital

1234 Long-Term Outcome of Extrahepatic Biliary Atresia into adult life
Javaid Sadiq1, Aditi Kumar4, Hifsa Sohail3, Carla Lloyd3, James W. Ferguson4, Darius Mirza2, Khalid Sharif1, Gideon Hirschfield4, Deirdre A. Kelly3
1Birmingham Children's Hospital Birmingham UK, 2University Hospital Birmingham, 3Birmingham Children's Hospital, 4University Hospital Birmingham

1235 Assessment of Energy Metabolism in Liver Transplant Recipients
Ajay Singhvi1, H. Steven Sadowsky2, Ayelet Cohen1, Alysen Demzik1, Mary E. Rinella1, Lisa B. VanWagner1, Josh Levitsky1
1Northwestern Memorial Hospital, 2Feinberg School of Medicine

1236 Retained HLA Class II Donor Specific Antibody after Liver Transplantation Increases Risk of Acute Cellular Rejection: A Case Control Study
Mohamed Elfeki1, 3, Mahmoud El-Bendary3, Petrina V. Genco2, Raghda Farag3, Youssef Mosaad4, Justin H. Nguyen1, Denise M. Harnois1, Surakit Pungpapong1
1Mayo Clinic, 2Mayo Clinic, 3Mansoura University, Faculty of Medicine, 4Mansoura University, Faculty of Medicine

1237 Renal function at month 1 and 6 post-transplant predicts longterm kidney function and patient outcome.
Faouzi Saliba, Noémie Minczeles, Valérie Delvart, Teresa Maria Antonini, Rodolphe Sobesky, Philippe Ichai, Audrey Coilly, Bruno Roche, Marc Boudon, Eric Vibert, Rene Adam, Denis X. Castaing, Daniel Cherqui, Gilles Pelletier, Jean-Charles Duclos-Vallee, Didier Samuel
Hopital Paul Brousse

1238 Value of Magnetic Resonance Cholangiography in Assessment of Non-Anastomotic Biliary Strictures after Liver Transplantation
A. Claire den Dulk1, Martin N.J.M. Wasser2, Francois Willemssen3, Melanie A. Monraats2, Marianne de Vries3, Rivka van den Boom2, Jan Ringers4, Hein W. Verspaget1, Herold J. Metselaar5, Bart van Hoek1
1Leiden University Medical Center, 2Leiden University Medical Center, 3Erasmus Medical Center , 4Leiden University Medical Center, 5Erasmus Medical Center

1239 Are cirrhotic patients awaiting liver transplantation protected against vaccine preventable diseases?
Mazzola Alessandra1, 2, Margherita Tran Minh1, 3, Raluca Pais1, Pascal Lebray1, Denis Bernard4, Claire Goumard5, Yvon Calmus1, Filomena Conti1
1APHP, Hôpital Pitié Salpétrière, 2University of Palermo, 3Università del Piemonte Orientale, 4APHP, Hôpital Pitié Salpétrière, 5APHP, Hôpital Pitié Salpétrière

1240 Increase in Red Cell Distribution Width Post Liver Transplant is Associated with Patient Mortality
Thure Caire1, Kirbylee K. Nelson2, R. Todd Stravitz 4, Ambuj Kumar2, Nyingi M. Kemmer3
1USF, 2USF, 3Tampa General Medical Group, 4VCU

1241 Reevaluating Risk Factors for Hepatic Artery Thrombosis in an Era of Increasing Intra-Arterial Therapy for Hepatocellular Cancer Prior to Liver Transplant
Mark Pedersen2, Meera Ramanathan2, Myunghan Choi3, Anil B. Seetharam1
1University of Arizona College of Medicine, 2University of Arizona College of Medicine-Phoenix, 3Arizona State University College of Nursing and Health Innovation

1242 The Association of Pre-Transplant Sarcopenia and Cirrhotic Cardiomyopathy with Postoperative Complications after Liver Transplant.
Tripti Gupta1, 2, Ryan M. Durel1, Qingyang Luo1, Daniel Devun1, John Seal1, Emily Ahmed1, David S. Bruce1, Trevor W. Reichman1, Shobha Joshi1, Natalie H. Bzowej1, Nigel Girgrah1, Humberto E. Bohorquez1, Ari J. Cohen1, Ian C. Carmody1, George E. Loss1, George Therapondos1
1Ochsner Clinic Foundation, 2University of Queensland

1243 Outcomes Post-Liver Transplant for Primary Sclerosing Cholangitis: Colitis Activity and Malignancy
Astrid-Jane Greenup1, Gokulan Pavendranathan1, 2, Mathew J. Keegan1, Sean Griffin1, David Bowen1, 4, Warwick Selby1, 3, Nicholas A. Shackel1, 4, Simone I. Strasser1, 3, Geoff McCaughan1, 4, David J. Koorey1, 3
1Royal Prince Alfred Hospital, 2University of New South Wales, 3University of Sydney, 4Centenary Institute of Cancer Medicine & Cell Biology

1244 The Gap Between Assessed Physical Capacity And Actual Activity In Advanced Cirrhosis
Michael A. Dunn1, 2, Deborah A. Josbeno3, Amy R. Schmotzer1, Doug Landsittel1, 2, Anthony Delitto3
1University of Pittsburgh, 2Thomas E Starzl Transplantation Institute, University of Pittsburgh, 3University of Pittsburgh

1245 Liver Transplantation in Older Recipients
Denise M. Harnois, Kaitlyn R. Musto, Bhupendra Rawal, Justin H. Nguyen
Mayo Clinic

1246 IgG4 status in explanted livers may affect the outcome of Primary sclerosing cholangitis (PSC) after liver transplantation
Mansour G. Alghanem1, Bandar Al-Judaibi2, Paul Marotta2, Subrata Chakrabari3, Chaturika Herath3
1university of western ontario, 2Western university, 3Western university

1247 Conversion from Sirolimus to Everolimus in the Maintenance Treatment of Liver Transplant Recipients: Preliminary Results of a 1-Year Study
Ilker Turan1, Suna Yapali2, Zeki Karasu1, Murat Sozbilen3, Ulus S. Akarca1, Galip Ersoz1, Omer Ozutemiz1, Fulya Gunsar1
1Ege University Faculty of Medicine, 2Acibadem University Faculty of Medicine, 3Ege University Faculty of Medicine

1248 Physical activity measured by accelerometer in transplant candidates reveals a large need for intervention
Eric R. Kallwitz1, Lara R. Dugas2, Jamie Berkes1, Thomas J. Layden1, Scott Cotler1
1Loyola University Medical Center, 2Loyola University Chicago

1249 MELD Based Outcomes of Simultaneous Liver Kidney Transplants among Patients with Diabetes Mellitus and/or Hypertension
Mohsen Hasanin1, 2, Russell H. Wiesner3, Yong-Fang Kuo4, Ashwani Singal5
1UAB Montgomery, 2University of Missouri, 3Mayo clinic, 4UTMB, 5UAB

1250 Liver Transplantation For Alcoholic Hepatitis: A Survey of Liver Transplant Centers
Mohsen Hasanin1, 2, Derek Dubay3, Brendan M. McGuire4, Thomas D. Schiano5, Ashwani Singal4
1UAB Montgomery, 2University of Missouri, 3UAB, 4UAB, 5Mount Sinai School of Medicine

1251 15 first-days over-immunosuppression (IS) is NOT associated with immune-outcome measures post-liver transplantation (LT)
Tommaso Di Maira, Victoria Aguilera, Angel Rubin, Carmen Vinaixa, Maria Garcia, Salvador Benlloch, Eva Montalva, Angel Moya, Fernando San Juan, Rafae Lopez-Andujar, Martin Prieto, Marina Berenguer
La Fe University Hospital

1252 Females, Hispanics, and Nonalcoholic Steatohepatitis Patients Have the Highest Rates of Waitlist Drop-Off Due to Death or Being Too Ill for Liver Transplantation
Maria Aguilar2, Edward W. Holt3, Taft Bhuket1, Benny Liu1, Zobair M. Younossi4, Aijaz Ahmed5, Robert J. Wong1
1Alameda Health System - Highland Hospital, 2Alameda Health System - Highland Hospital, 3California Pacific Medical Center, 4Inova Fairfax Hospital, 5Stanford University Medical Center

1253 Renal Function Recovery and Outcomes after Liver Transplantation Alone among Patients with Pre-Transplant Acute Kidney Injury
Paul S. Fitzmorris1, Kirk B. Russ1, Donny Kakati1, Ashwani Singal2
1University of Alabama at Birmingham, 2University of Alabama at Birmingham

1254 Impact of Positive Crossmatch on Outcomes in Living Donor Liver Transplantation
Sandeep Walia1, Alexander Weick2, Sharon Skorupski3, Atsushi Yoshida4, Omar Fagoaga3, George Divine5, Dilip Moonka1
1Henry Ford Health System, 2Henry Ford Health System, 3Henry Ford Health System, 4Henry Ford Health System, 5Henry Ford Health System

1255 Role of Coronary Artery Calcium (CAC) Score in Identifying Patients at Risk for Cardiac Events Within the 30 Day Postoperative Period Following Deceased Donor Liver Transplantation
Theodore W. James1, Joban Vaishnav1, Mohammad U. Malik2, Aliaksei Pustavoitau3, Andrew M. Cameron4, Stuart D. Russell1, Ahmet Gurakar1
1Johns Hopkins Hospital, 2Conemaugh Memorial Medical Center, 3Johns Hopkins Hospital, 4Johns Hopkins Hospital

1256 Neurological Syndrome de novo in Familial Amyloidotic Polineuropathy after Liver Transplant
Elia S. Mateus, Ana Morbey, Julio M. Veloso, Rui Perdigoto, Helena Gloria, Joao Machado, Ines Mega, Americo Martins, Eduardo Barroso
Hospital Curry Cabral

1257 Echocardiography for Liver Transplant Evaluation: Optimal Cut-off for Right Heart Catheterization and Impact on Transplant Listing
Natalie Mitchell, Fakhar U. Islam, Nicholas Piazza, Danisa M. Clarett, Ashwani Singal
University of Alabama at Birmingham

1258 Pre-transplant portal vein thrombosis is an independent risk factor for graft loss due to hepatic artery thrombosis in liver transplant recipients
Jonathan G. Stine1, Shawn Pelletier4, Timothy Schmitt2, Robert J. Porte3, Patrick Northup1
1University of Virginia, 2University of Kansas, 3University of Groningen, 4University of Virginia

1259 Liver Transplant (LT) Candidates with Alcoholic Cirrhosis (ALC) are at Lower Risk of Wait-list Removal than Patients with Other Etiologies of Cirrhosis
Jeanne-Marie Giard, Norah Terrault
University of California San Francisco

1260 Rotational Thromboelastometry (ROTEM) versus Conventional Coagulation Tests during Orthotopic Liver Transplantation: Comparison of Intra-operative Blood Loss, Transfusion Requirements, and Cost
Laura Smart1, Danielle T. Scharpf2, Nicole O'Bleness Gray1, Daniel Traetow2, Sylvester Black3, Anthony Michaels1, Elmahdi Elkhammas3, Robert B. Kirkpatrick1, Khalid Mumtaz1, A. James Hanje1
1The Ohio State University Medical Center, 2The Ohio State University Medical Center, 3The Ohio State University Medical Center

1261 Systolic Dysfunction Post-Liver Transplantation is associated with Increased All-Cause Mortality
Michael Cheung2, She-Yan Wong1, Arun Mathew3, Dina Halegoua-De Marzio1
1Thomas Jefferson University, 2Lankenau Medical Center, 3Thomas Jefferson University Hospital

1262 Downstaging or Bridging Therapy of Hepatocellular Cancer Does Not Increase Incidence of Biliary Complications after Liver Transplantation
Meera Ramanathan2, Mark Pedersen2, Myunghan Choi3, Anil B. Seetharam1
1University of Arizona College of Medicine-Phoenix, 2University of Arizona College of Medicine-Phoenix, 3Arizona State University College of Nursing and Health Innovation

1263 Outcomes of Patients with Familial Transthyretin Amyloidosis after Liver Transplantation
Dipti Banerjee1, Lindsey Roeker3, John J. Poterucha2, Julie Heimbach2, Martha Grogan2, Angela Dispenzieri2
1Mayo Medical School, 2Mayo Clinic, 3Brigham and Women's Hospital

1264 Severity and Predictive Factors of Chronic Renal Dysfunction after Liver Transplantation
Yi Huang1, 2, Leon A. Adams1, 2, Oscar Arauz2, Peter W. Angus3, Marie Sinclair3, Graeme A. Macdonald4, Uthayanan Chelvaratnam4, Alan J. Wigg6, Sze Pheh Yeap6, Nicholas A. Shackel5, Linda I. Lin5, Spiro C. Raftopoulos2, Geoff McCaughan5, Gary P. Jeffrey2, 1
1The University of Western Australia, 2Sir Charles Gairdner Hospital, 3The Austin Hospital, 4Princess Alexandria Hospital, Brisbane, 5Royal Prince Alfred Hospital, 6Flinders Medical Centre

1265 Ohio Solid Organ Transplantation Consortium (OSOTC) criteria for liver transplantation in patients with alcoholic liver disease
Kaveh Hajifathalian1, Zubin Arora2, Annette Humberson2, David S. Barnes2, Arthur J. McCullough2, Nizar N. Zein2, Bijan Eghtesad2, Ibrahim A. Hanouneh2
1Cleveland Clinic Foundation, 2Cleveland Clinic Foundation

1266 Recipient Risk Factors for Acute Cellular Rejection After Orthotopic Liver Transplant in Patients with Average MELD More Than 25
Mengyuan Liu1, Kelly Galen1, Grace Guzman2, Hoonbae Jeon3, Costica Aloman1
1University of Illinois at Chicago, 2University of Illinois at Chicago, 3University of Illinois at Chicago

1267 Pre-Transplant Sarcopenia Does Not Reverse After Successful Liver Transplantation
Trushar Patel, Valery Vilchez, Roberto Gedaly, Rashmi T. Nair, Anna Christina Dela Cruz, Terrence Barrett
University of Kentucky

1268 Early Cytomegalovirus infection in living-donor related liver transplant recipients in high seropositive population: does pre-transplant CMV immunity have any role?
Ekta Gupta1, Viniyendra Pamecha2, Nadeem Hasnain1, Yogita Verma1, Ajeet S. Bhadoria3, Niteen Kumar2, Shiv K. Sarin4
1Institute of Liver and Biliary Sciences, 2Institute of Liver and Biliary Sciences, 3Institute of Liver and Biliary Sciences, 4Institute of Liver and Biliary Sciences

1269 Good results of liver transplantation for decompensated cirrhosis with multi-organ failure in ICU: a retrospective study in two French centers
Florent Artru1, Alexandre Louvet1, Isaac Ruiz2, Julien Labreuche3, Eric Levesque2, Philippe Ichai2, Sebastien Dharancy1, Guillaume Lassailly1, Emmanuel Boleslawski4, Gilles Lebuffe5, Audrey Coilly2, Eric Vibert6, Philippe Mathurin1, Didier Samuel2, Faouzi Saliba2
1CHRU Lille, 2Hepatology, Hopital Paul Brousse, 3Biostatistics Unit, CHRU Lille , 4Surgery Transplant Unit, CHRU Lille, 5Anaesthesiology Department, CHRU Lille, 6Surgery Transplant Unit, Hopital Paul Brousse

1270 Metabolic Syndrome and Insulin Resistance After Liver Transplantation: a Prospective Single Centre Study
Veronica Pepe1, Giacomo Germani1, Alberto Ferrarese1, Alberto Zanetto1, Elena Nadal1, Ilaria Bortoluzzi1, Francesco P. Russo1, Marco Senzolo1, Umberto Cillo2, Patrizia Burra1
1Multivisceral Transplant Unit, Padua University Hospital, 2Hepatobiliary Surgery and Liver Transplant Unit, Padua University Hospital

1271 How intra-operative factors affect kidney recovery after simultaneous liver-kidney transplantation (SLK)
Mario Spaggiari1, Mohamed Shaaban2, Galal El-Gazzaz1, Lisa Louwers1, Emmanouil Palaios1, Cristiano Quintini1, Federico N. Aucejo1, Koji Hashimoto1, Teresa Diago1, Masato Fujiki1, Bijan Eghtesad1, Charles M. Miller1, Mauricio Perilla2, Dympna Kelly1
1Cleveland Clinic, 2Department of Anesthesia, Cleveland Clinic Foundation

1272 Effective Systems of Care Improve Outcomes in Liver Transplantation, Regardless of Patient-Level Risk Factors
David J. Taber, Kenneth D. Chavin, Charles F. Bratton, John W. McGillicuddy, Satish Nadig, Prabhakar Baliga
Medical University of South Carolina

1273 Morbid Obesity and Diabetes (DM) are Associated with Increased Risk of Death on the Liver Transplant (LT) Waiting List
Ani A. Kardashian1, Jennifer L. Dodge2, John P. Roberts2, Danielle Brandman1
1University of California, San Francisco, 2University of California, San Francisco

1274 Intrahepatic Cholangiocarcinoma in the Liver Explant after Liver Transplantation: What to Do Next?
Kazuhiro Takahashi, David A. Bruno, Marwan Kazimi, Atsushi Yoshida, Marwan S. Abouljoud, Gabriel Schnickel
Henry Ford Hospital

1275 Post-Transplant Lymphoproliferative Disease is more common in primary sclerosing cholangitis patients after liver transplant
Ahmed Abu Shanab1, 2, Yasser Gayed1, Naeem Ullah1, Diarmaid D. Houlihan1, Aiden McCormick1
1St-Vincent University Hospital, 2Menofiya University

1276 Sarcopenia is a Risk Factor for Left Ventricular Systolic Dysfunction Post-Liver Transplantation
Arun Mathew2, She-Yan Wong1, Michael Cheung3, Flavius Guglielmo4, Cataldo Doria5, David A. Sass1, Dina Halegoua-De Marzio1
1Thomas Jefferson University, 2Thomas Jefferson University Hospital, 3Lankenau Medical Center, 4Thomas Jefferson University, 5Thomas Jefferson University

1277 Risk Stratification for Optimal Timing of Liver Transplantation Following Repeated Locoregional Therapies in Patients With Hepatitis B-Related Hepatocellular Carcinoma
Hwi Young Kim1, Won Kim1, Yong Jin Jung1, Hyeyoung Kim2, Nam-Joon Yi2, Kwang-Woong Lee2, Hae Won Lee3, Kyung-Suk Suh2
1Seoul National University Boramae Medical Center, 2Seoul National University Hospital, 3Seoul National University Boramae Medical Center

1278 Synergistic anticancer effect of metformin in combination with immunosuppressant on hepatocellular carcinoma cell lines
Suk-Won Suh1, Kwang-Woong Lee2, Yoo-Shin Choi1
1Chung-Ang University College of Medicine, 2Seoul National University College of Medicine

1279 Evaluation of risk indices to determine 1 year graft survival after liver transplantation using the UNOS database
Shahzad Ahmed, Vinay Sundaram
Cedars-Sinai Medical Center

1280 Outcomes of Transjugular Intrahepatic Porto-Systemic Shunt (TIPSS) in patients waiting and after liver transplantation: Study based on the UNOS database.
Sherif N. Metwally1, A. James Hanje2, Anthony Michaels2, Robert B. Kirkpatrick2, Douglas M. Levin2, Mitchel Henry5, Elmahdi Elkhammas3, Don Hayes4, Sylvester Black3, Khalid Mumtaz2
1Ohio State University, 2Ohio State University, 3The Ohio State University Wexner Medical Center, 4The Ohio State University Wexner Medical Center, 5The Ohio State University Wexner Medical Center

1281 Renal Function Improvement in Early Conversion to Sirolimus with Similar Patient Survival and Metabolic Side Effects of Continued CNI Immunosuppression
Ana Silvera1, Concepcion Sanchez2, Miguel Escobedo3, Gabriela Alarcon-Galvan4, Paula Cordero1, Homero A. Zapata3, Edelmiro Perez-Rodriguez3, Asdrubal Guevara3, Marco A. Hernandez-Guedea3, Linda E. Muñoz1
1Universidad Autonoma de Nuevo Leon, 2Universidad Autonoma de Nuevo Leon, 3Universidad Autonoma de Nuevo Leon, 4Universidad Autonoma de Nuevo Leon